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“As far as the laws of mathematics  
refer to reality, they are not certain,  
as far as they are certain, they do  
not refer to reality.” 
 
Albert Einstein (1879-1955) 
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1 Introduction 
Drug delivery is a challenging part in pharmaceutical sciences. Especially, 
delivery of proteins is of interest, since these molecules are high potential 
therapeutics for e.g. cancer, contraception, diabetes and vaccination. Proteins 
are used for local and systemic therapy and administration could be oral, nasal, 
transdermal, rectal, ocular, bucal or parenteral (Sinha et al.; 2003). When given 
e.g. orally, proteins are often poorly bioavailable, due to rapid degradation, 
deactivation at acidic pH values and poor adsorption in the gastrointestinal tract. 
Therefore, the most convenient way for drug delivery to achieve high 
bioavailability is the parenteral route (Ranade et al.; 2003). Therapeutic 
effectiveness can be achieved by multiple injections, resulting in a problem of 
compliance, or by providing controlled or sustained release devices which 
release drugs in well-defined pharmacokinetic profiles (Sinha et al.; 2003). This 
second approach was even practiced before the word “pharmacy” existed. 
Aztecs, Mayans, Incas and people in Mesopotamia, Egypt and China  
developed macroscopic delivery systems containing polymers, commonly 
waxes, to extend the action mechanism of drugs and to improve features such 
as site specificity (Mainardes et al.; 2004). In 1937, Deanesly et al. presented 
the first controlled drug delivery system for hormonal implantation, containing 
pure crystalline estrogen pellets (Dash et al.; 1998). Nowadays, one of the most 
important features of drug delivery, going beyond release kinetics, is to enhance 
patient compliance by improving therapeutic efficacy and reducing toxic side 
effects. This can be achieved by providing implantable controlled release drug 
delivery systems (DDS). Drug release is either controlled by a polymer or 
polymeric membrane (polymeric DDS) or by mechanical ways like in pumps 
(mechanical DDS) (Danckwerts et al.; 1991). A major application field of pumps 
is diabetes (Ranade et al.; 2003). A certain insulin level is needed at all times 
which otherwise can be maintained only by multiple injections per day 
(circulation half live of insulin < 25min; (Siegel et al.; 1984)). Different types of 
pumps are used, e.g. infusion pumps or mircopumps (Dash et al.; 1998). 
1 Introduction 2 
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Another type of pump which attracted attention, is an osmotic based system 
developed from Alza Corporation (Alzet®). It is approved in the US for the 
treatment of prostate cancer by delivery of leuprolide acetate (Viadur®). 
However, an unrestricted use is limited by high costs and the eventual need of 
surgical removal (Weadock; 1986). Polymeric DDS are either monolithic or 
reservoir-type devices which are prepared from biodegradable or non-
biodegradable polymers (Dash et al.; 1998). These DDS are used for local and 
systemic therapy.  
1.1 Classification of Polymers for Controlled Drug Release 
Devices  
A wide range of polymers for parenteral drug delivery are available (see Table 
1-1) (Pillai et al.; 2001; Saltzman; 2001). Due to this overwhelming variety, 
many approaches for classification were taken. One main feature is 
biodegradability.  
A classification of degradable and non-degradable polymers can be made by 
applying the Deborah number (Göpferich; 1997a). Degradable polymers have 
small Deborah numbers with values approaching zero (time of degradation is 
much shorter than human lifetime), whereas non-degradable polymers have 
large values (time of degradation can exceed human lifetime). Another definition 
for degradable materials can be based on the degradation of the material during 
application or immediately afterwards (Göpferich; 1996).    
 
Table 1-1 Representative list of polymers used in drug delivery (modified from (Mohl; 2004; 
Pillai et al.; 2001; Saltzman; 2001; Shastri; 2003)) 
Classification Examples  
NATURAL POLYMERS 
Proteins  albumin, collagen, gelatin 
Polysaccharides  agarose, alginate, carrageenan, cellulose, chitin, chitosan, 
cyclodextrin, dextran, hyaluronic acid, starch  
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Lipids cholesterol, triglycerides 
SYNTHETIC POLYMERS 
Biodegradable 
Polyesters  poly(lactic acid), poly(glycolic acid), copolymers of 
lactide/glycolide, poly(ε-caprolactone), poly(β-hydroxy 
butyrate), poly(β-malic acid), poly(dioxanone) 
Polyanhydrides  poly(sebacic acid), poly(adipic acid), poly(terephthalic acid) 
and various copolymers 
Polyamides  poly(imino carbonate), poly(amino acid) 
Phosphorous-based 
polymers  
poly(phosphazene), poly(phosphate), poly(phosphonate)  
Others  poly(orthoester), poly(urethane), poly(cyanoacrylate), 
poly(ethylene gylcol), poly(dihydropyran), poly(acetal)  
Non-biodegradable 
Cellulose derivatives  carboxymethyl cellulose, cellulose acetate, cellulose acetate 
propionate, ethyl cellulose, hydroxypropyl methyl cellulose 
Silicones  poly(dimethylsiloxane), colloidal silica 
Acrylic polymers  poly(methacrylate), poly(methylmethacrylate), 
poly(hydroxy(ethylmethylacrylate)) 
Others  poly(ethylene-co-(vinyl acetate)), poloxamer, 
poly(vinylpyrrolidone), poloxamine, poly(propylene) 
 
 
One of the first implants, prepared by Folkman and Long in 1964, was a 
poly(dimethylsiloxane) tubing loaded with isoproterenol (Heller; 1984). This 
polymer was tolerated well during implantation in dogs, but a severe limitation 
was its non biodegradability. At the end of therapy, the depleted implant matrix 
remains inside the body or has to be removed surgically and non-biodegradable 
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potentially toxic fragments could stay behind (Ranade et al.; 2003). Hence, 
these polymers are suitable for implants when the removal is easy, such as 
ocular or vaginal implants or for artificial replacement of failing body parts in 
which long term resistance and excellent mechanical properties are desired 
(Shastri; 2003). Beyond this, for special applications, e.g. contraception 
(Implanon®), non-biodegradable polymers are used as drug delivery systems as 
well. Another limitation is the mechanism of drug release. Since most of the 
drug is released by diffusion, controlled release of molecules with molecular 
weights over 7.5kDa and/or poor solubility in the polymer can be difficult (Sinha 
et al.; 2003). This problem was overcome by Langer and Folkman in 1976 who 
achieved a reproducible three month delivery of macromolecules up to 2x106Da 
from so-called “sandwich” pellets. These pellets consist of a polymer-drug core 
which is coated with the pure polymer e.g. poly(ethylene-co-(vinyl acetate) 
(EVAc)) to retard drug diffusion (Langer et al.; 1978). 
Consequently, development of biodegradable polymer drug matrices has 
become increasingly important over the last 30 years (Pillai et al.; 2001). The 
first documented study was performed by Yolles et al. in 1970, who investigated 
the drug release of cyclazocine from a poly(lactic acid) (PLA) implant. The 
polymer is degraded to lactic acid, its natural metabolite, and disappears from 
the implant site without surgical removal (Heller; 1984).  
Before going into details on biodegradable polymers, some terms have to be 
defined. Biodegradable or bioerodible reactions involve biological systems 
(Siepmann et al.; 2001). Biodegradable polymers are defined as polymers 
which are eroded in vivo, either enzymatically or non-enyzmatically, into 
biocompatible, non-toxic products which are subsequently removed via normal 
metabolic pathways from the implant site (Ranade et al.; 2003; Sinha et al.; 
2003). Often biocompatibility is defined by the degradation products and not 
necessarily by the polymer itself (Uhrich et al.; 1999). Biodegradable polymers 
can be subdivided by their material source (see 1.2.1) or by their mechanism of 
erosion (see 1.2.3). Erosion is considered as a physical phenomenon related to 
dissolution and diffusion processes (Mainardes et al.; 2004), in which the 
polymer bulk looses material, such as mono- or oligomers or parts of the 
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polymer backbone or bulk. In contrast, degradation is a chemical process that is 
restricted to the scission of the polymer chain resulting in mono- or oligomers. 
Consequently, degradation is a necessary condition for erosion (Göpferich; 
1997a).  
1.2 Classifications of Biodegradable Polymers  
1.2.1 Origin of Polymer – Collagen: a Natural Polymer 
Besides natural polymers, many synthetic biodegradable polymers, such as 
poly(esters), poly(amides), poly(anhydrides), poly(orthoesters) and 
poly(cyanoacrylates) are used as biodegradable matrices (see Table 1-1, Table 
1-2).  
 
Table 1-2 Functional groups of biodegradable polymers (Göpferich; 1997a)  
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Their advantage is, that large quantities with predictable and reproducible 
physicochemical properties, adapted to distinct applications, can be produced 
and purified (Cleland; 1997; Ranade et al.; 2003). On the other hand, for 
production organic solvents and high temperatures may be necessary (Cleland; 
1997), and polymerization by-products, like non-reacted monomers or organic 
solvents, can have negative effects on drug release and biocompatibility. 
The most extensively investigated subgroup are poly(esters), especially 
aliphatic poly(esters), like poly(lactic acid), poly(glycolic acid) and copolymers of 
lactic and glycolic acid. Consequently, the current “gold standard” of 
biodegradable polymers is poly(lactic acid-co-glycolic acid) (PLGA) (Pillai et al.; 
2001). The advantages of these polymers are their good biocompatibility, 
because degradation products are natural metabolites, e.g. lactic and glycolic 
acid, and easy manufacturing. A wide variety of modifications by using racemic 
or optical active monomers for preparation of homo- and copolymers can be 
easily achieved (Uhrich et al.; 1999). Poly(esters) are used as rate controlling 
membranes or monolithic devices for delivery of narcotic antagonists, 
contraceptives, anticancer and antimalarial drugs (Sinha et al.; 2003). However, 
the release rate is difficult to predict because non-enzymatic bulk hydrolysis of 
ester linkages takes place. Additionally, an initial burst release and another 
burst after complete matrix erosion can occur. Consequently, a release 
mechanism with different stages is proposed for PLA and/or PLGA 
microspheres (Sinha et al.; 2003). To improve release kinetics, PLGA devices 
can be coated with pure polymer, stabilizing buffer salts can be added or the 
polymer itself can be modified (Sinha et al.; 2003). Apart from this complex 
release mechanism, PLGA has some further limitations for protein delivery. For 
the manufacturing of PLGA devices either organic solvents or elevated 
temperatures are needed which may cause harm to the incorporated proteins 
(Cleland; 1997). Furthermore, proteins can become unstable during release due 
to a change in environmental conditions (e.g. fast hydration of the matrix or 
decrease in pH caused by acidic erosion products) (Mohl; 2004).  
Natural polymers, also named biopolymers, can be divided into polysaccharides 
(e.g. alginate, cellulose, chitosan, hyaluronic acid and starch), proteins (e.g. 
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albumin, collagen, gelatin) and lipids (e.g. triglycerides) (see Table 1-1). They 
are attractive as drug delivery materials because commercial quantities are 
available and the possibility of performing a variety of chemical modifications. 
As given by their name, they are natural products with good biocompatibility. On 
the other hand, because of their natural origin, batch to batch variations in 
polymer composition and difficulties in purification can occur (Pillai et al.; 2001). 
A frequently used biopolymer is collagen. Its attractiveness is its natural source, 
more precisely it is found in vertebrates to a great extent. Hence, in general it is 
well tolerated, biodegradable, biocompatible, non-toxic and shows low 
immunogenicity and antigenicity. Wound repair and cellular penetration are 
enhanced and degradation leads to well tolerated physiological compounds with 
haemostatic properties (Frieß; 1999; Gorham; 1991). Beyond this, its structural, 
chemical, physical and immunological properties are well documented (Sinha et 
al.; 2003).  
1.2.1.1 Structure of Collagen 
Collagen is the major structural protein in vertebrates, accounting approximately 
30% of complete body protein (Frieß; 1999), and is predominantly located in the 
extracellular matrix (Brinckmann et al.; 2005). Different collagen types are 
necessary to meet the demands of different kinds of connective tissue. 
Currently, 27 collagen types have been isolated (Brinckmann et al.; 2005). Of 
those, 21 types are characterized in detail and divided into eight subgroups 
(Gelse et al.; 2003). Type I collagen is predominant in higher order animals and 
is found e.g. in bone, skin and tendon.  
Due to these special requirements, collagen shows a very characteristic triple-
helical structure with unusual strength and stability (Frieß; 1999). The sequence 
of amino acids is characterized by a repetitive unit: Gly-X-Y. The absence of a 
side chain in glycine, results in the formation of a typical left-handed triple helix 
as closest packing with glycine orientated into the core. The X- and Y-positions 
can be any amino acid, however, the X-position is occupied almost exclusively 
by proline, whereas hydroxyproline is found predominantly in the Y-position 
(Gorham; 1991). The stabilization of the triple helix is attributed to a limited 
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rotation along the backbone, based on the heterocyclic structure of the imino 
acids, intramolecular van der Waals interactions between imino acids and on 
the inductive effect of the OH-group of hydroxyproline (Brinckmann et al.; 2005). 
Three triple helical polypeptides, named α-chains, form a rope-like right-handed 
supercoil with a length of approximately 300nm and a diameter of 1.5nm. The 
supercoil is stabilized by hydrogen bonds between glycine and proline located 
in neighboring chains and by an extensive water network which can form 
hydrogen bonds between several carbonyl and hydroxyl peptide residues 
(Brinckmann et al.; 2005). Furthermore, amino acids in the X- and Y-positions 
are able to participate in intermolecular stabilization, e.g. by hydrophobic 
interactions or interactions between charged residues (Brinckmann et al.; 2005). 
This helical part is flanked by short non-helical domains (9-26 amino acids), the 
so called telopeptides, which play an important role in fibril formation and 
natural cross-linking. Instead of the repeating unit Gly-X-Y, a high variation in 
amino acids is available which is responsible for most of the immunological 
responses (Piez; 1985). At this level, the collagen supercoil is known as 
tropocollagen. Type I collagen is composed of two α1 (I) and one α2 (I) chains, 
containing approximately 1050 amino acids each. New data show that besides 
the telopeptides, tropocollagens still contain the N- and C-terminal propeptide 
sequences, also called non-collagenous domains (Brinckmann et al.; 2005). 
These domains are responsible for correct chain alignment and triple helix 
formation. The propeptides are removed before fibril formation and regulate the 
fibril formation process. Tropocollagens are staggered longitudinally and 
bilaterally by inter- and intramolecular cross-links into microfibrils (4 to 8 
tropocollagens) and further into fibrils. This periodic arrangement is 
characterized by a gap of 40nm between succeeding collagen molecules and 
by a displacement of 67nm. The fibrils organize into fibers which in turn can 
form large fiber bundles (see Figure 1-1). Fibers and fiber bundles are stabilized 
by intermolecular cross-links (Frieß; 1998). 
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Figure 1-1 Structure of collagen (modified from (Junqueira et al.; 1996)) 
 
1.2.1.2 Cross-linking of Collagen 
Collagen is predominantly isolated and purified from skin or tendon, even 
though it is ubiquitously present in vertebrates. For DDSs either soluble or 
insoluble collagen can be used. The choice of collagen has a great influence on 
the matrix durability in vivo (Frieß; 1999). During collagen biosynthesis (see 
1.2.1.1), natural cross-links are created at the stage of fibril formation. After 
enzymatic transformation of lysine and hydroxylysine into their aldehydes, 
telopeptides are linked intrachainly by aldol condensation. Intermolecular bonds 
between telopeptides and the helical region of another collagen molecule are 
formed by aldimine formation between aldehydes and the ε-amino groups of 
lysine and hydroxylysine residues and subsequent stabilization by amadori 
rearrangement. These intermolecular linkages are still reactive and can develop 
additional cross-links with histidine, lysine and hydroxylysine (Frieß; 1998).  
Insoluble collagen is more appropriate to enhance the resistance of collagenous 
DDSs, because the original primary to tertiary structures with intact collagen 
fibers and telopeptides are still present, whereas (parts of the) telopeptides are 
gap overlap 
gap overlap 
microfibril 
fiber fibril 
fiber bundle 
tropocollagen 
40 nm 
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removed by enzymatic, acidic or alkali treatment in soluble collagen materials 
(Ruszczak et al.; 2003).  
 
Table 1-3 Overview over cross-linking methods for collagen material 
Chemical cross-linking 
Aldehydes 
e.g. glutaraldehyde (GTA) 
Charulatha et al.; 2003, Cheung et al. ; 1984, Frieß; 
1999, Geiger; 2001, Gilbert; 1988b, Gorham; 1991, 
Jayakrishnan et al.; 1996, Khor; 1997, Olde Damink et 
al.; 1995, Weadock et al.; 1984 
Acyl azide Charulatha et al.; 2003, Frieß; 1999, Gorham; 1991, 
Khor; 1997, Petite et al.; 1990  
Carbodiimides 
e.g.1-ethyl-3-(3-dimethylamino-  
propyl)carbodiimide (EDC) 
Frieß; 1999, Geiger; 2001, Gorham; 1991, Khor; 1997, 
Olde Damink et al.; 1996, Park et al.; 2002, Pieper et al.; 
1999, Weadock et al.; 1984, Zeeman et al.; 1999 
Hexamethylene diisocyanate Frieß; 1999, Geiger; 2001, Gorham; 1991, Khor; 1997 
Poly-epoxy-compounds  Frieß; 1999, Khor; 1997, Tang et al.; 1995, Zeeman et 
al.; 1999  
Physical cross-linking 
Dehydrothermal treatment (DHT) Frieß; 1999, Geiger; 2001, Gilbert; 1988b, Gorham; 
1991, Gorham et al.; 1992, Pieper et al.; 1999, Wang et 
al.; 1994, Weadock et al.; 1984, Weadock et al.; 1995, 
Weadock et al.; 1996  
UV irradiation Frieß; 1999, Gilbert; 1988b, Weadock et al.; 1984, 
Weadock et al.; 1995, Weadock et al.; 1996  
 
 
Further increase in mechanical and chemical stability and in consequence 
reduced biodegradability and swelling can be achieved by additional exogenous 
cross-linking. This kind of cross-linking mainly takes place in the helical parts of 
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collagen because most commonly carboxyl groups of aspartic and glutamic 
acids and ε-amino groups of lysine and hydroxylysine residues are involved 
which are hardly found in the telopeptides (Zeeman et al.; 1999). Different ways 
of cross-linking, either chemical or physical, have been carried out and often the 
method is prescribed by the target application (see Table 1-3) (Frieß; 1999; 
Gorham; 1991; Hendriks et al.; 1998).  
Chemical cross-linking is based on the additional formation of ionic or covalent 
bonds (Gorham; 1991). Aldehydes have a long tradition as cross-linking 
reagents. Especially treatment with GTA is intensively used. Besides its good 
efficiency, this cross-linking method is fast, inexpensive and mechanical 
properties are enhanced (Frieß; 1999; Jayakrishnan et al.; 1996). But due to 
polymerization of GTA, cross-linking is sometimes restricted to the surface of 
the device and a heterogeneous cross-linking structure can occur (Cheung et 
al.; 1984). Additionally, GTA is incorporated into the new linkage and non-
reacted GTA can cause local incompatibility, inflammation, encapsulation and 
calcification, going along with limited cell ingrowth (Jayakrishnan et al.; 1996; 
Weadock et al.; 1984). Hence, non-toxic, water soluble substances which only 
facilitate the reaction, without becoming part of the new linkage, are needed. 
Such reagents are acyl azides and carbodiimides. Carbodiimides, e.g. EDC, 
couple carboxyl groups of glutamic or aspartic acid with amino groups of lysine 
or hydroxylysine residues. Reaction efficacy is increased by addition of N-
hydroxysuccinimde (NHS) which prevents side reactions of the intermediate 
(Frieß; 1999; Gorham; 1991; Olde Damink et al.; 1996b). Because EDC can 
only couple groups within a distance of 1nm, this treatment enhances intra- and 
interhelical linkages, but no intermicrofibrillar cross-links (Zeeman et al.; 1999). 
EDC cross-linked collagens show reduced calcification, no cytotoxicity and slow 
enzymatic degradation (Khor; 1997; Pieper et al.; 1999; van Wachem et al.; 
1994b). 
Apart from chemical treatments, physical procedures have been developed 
(Frieß; 1999). Optimized DHT cross-linking of collagenous material is performed 
under vacuum at 110°C for 5d (Wang et al.; 1994). If the water content is below 
0.1% (w/w) (Gilbert; 1988b), interchain amide formation or esterification occur 
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as a consequence of condensation of amino acid side chains (Weadock et al.; 
1984). However, partial denaturation, detectable by trypsin digestion, 
accompanies this treatment (Weadock et al.; 1996). To minimize denaturation 
effects, DHT cross-linking has to be performed after removal of residual 
moisture. Distances between neighboring molecules are reduced after cross-
linking, which is reflected in lower flexibility, less swelling, slower degradation 
and higher mechanical stability (Wang et al.; 1994). Advantages of this method 
are the absence of substances with toxic potential, the reduction of the 
microbiological burden (Geiger; 2001) and the preservation of the three 
dimensional matrix structure (Weadock; 1986). On the other hand partial 
denaturation may cause a faster degradation in vivo and if cross-linking is 
performed on the final product, incorporated drugs may loose their activity due 
to thermal instability or temperature induced reactions with collagen (Frieß; 
1999; Gorham; 1991). 
1.2.1.3 Collagen as a Biomaterial 
Collagen was first employed as a biomaterial in medical surgery in the late 19th 
century (Burke et al.; 1983; Silver et al.; 1997). Subsequently, it was used in 
many other medical applications, e.g. as wound dressings, hemostats or in 
cardiovascular, plastic or neurosurgery (see Table 1-4). Most commonly, 
collagen type I is used in medical devices (Silver et al.; 1997). Device 
production is uncomplicated and is performed in water without applying high 
temperatures resulting in a variety of matrix forms, such as coatings, fibers, 
films, fleeces, implants, injectable solutions and dispersions, membranes, 
meshes, powders, sheets, sponges, tapes and tubes. Additionally, its properties 
can be adapted to the desired requirements by additional cross-linking (Frieß; 
1999; Gorham; 1991; Silver et al.; 1997). However, shape instability due to 
swelling, poor mechanical strength and low elasticity in vivo may limit its 
unrestricted usage. Further limitations are possible antigenic responses, tissue 
irritations and variations in release kinetics (Sinha et al.; 2003).   
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Table 1-4 Some medical applications of collagen (modified from (Frieß; 1999; Fujioka et al.; 
1998; Gilbert; 1988b; Gorham; 1991; Pachence et al.; 1987; Silver et al.; 1997; 
Weadock; 1986)) 
Specialty Applications 
Cardiology heart valves 
Dermatology soft tissue augmentation 
Surgery hemostatic agent 
plasma expander 
suture 
wound dressing and repair 
skin replacement (artificial skin) 
nerve repair and conduits 
blood vessel prostheses 
Orthopaedic born, tendon and ligament repair  
cartilage reconstruction 
Ophthalmology corneal graft, vitreous implants 
artificial tears 
tape and retinal reattachment 
contact lenses 
Urology dialysis membrane 
sphincter repair 
Vascular vascular graft, Vessel replacement 
angioplasty 
Others biocoatings 
cell culture 
organ replacement 
skin test 
 
 
Nevertheless, collagen is used as a drug delivery matrix in cancer treatment, 
contraception, ophthalmology, orthopedics, periodontology, tissue repair and for 
the delivery of proteins (see Table 1-5). Except for protein delivery, these 
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applications are all used for local drug delivery (Frieß; 1998). Comprehensive 
reviews of collagen applications are given in (Frieß; 1998; Gorham; 1991). 
 
Table 1-5 Drug delivery from collagen devices (modified from (Frieß; 1999; Fujioka et al.; 1998; 
Silver et al.; 1997; Weadock; 1986)) 
Application Field Drug 
Ophthalmology amphothericin B, antibiotics, cyclosporine, 5-fluorouracil, non-
steroidal anti-inflammatory drugs, pilocarpine, steroids 
Parenteral antibiotics, antineoplastic agents, bone morphogenetic 
proteins, contraceptives, growth factors, insulin, interferons, 
interleukins, medroxyprogesterone   
Dermal antibiotics, cosmetics, local anesthetics, retinol, tretinoin 
 
 
1.2.2 Mechanism of Degradation  
In general, erosion can be divided into four steps: hydration, loss of mechanical 
strength, loss of integrity and finally mass loss (Ranade et al.; 2003). The critical 
step therein is hydration, or more precisely degradation. Biodegradation is 
affected by properties of the polymer, like the type of the chemical bond, 
crystallinity, molecular weight and the ability of water uptake, and environmental 
factors, e.g. pH (Göpferich; 1997a). The polymer degradation mechanisms were 
classified by several investigators (see Figure 1-2) (Gombotz et al.; 1995; 
Heller; 1984; Kamath et al.; 1993). Heller distinguished between three types of 
degradation mechanisms (Heller; 1984). Type I occurs in water soluble 
polymers which have been made insolube by covalent cross-linking. 
Consequently, water penetration into the device leads to swelling which is 
limited by the degree of cross-linking. The active agent must be only slightly 
water soluble or a macromolecule if drug release should be erosion controlled. 
Otherwise, drugs would be released by diffusion (see also 1.2.3). 
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Figure 1-2 Mechanism of polymer degradation (modified from (Gombotz et al.; 1995; Heller; 
1984) 
 
Type I degradation can be subdivided into two groups. Either it takes place by 
cleaving the cross-links (type Ia) or by digestion of the polymer backbone (type 
Ib) (see Figure 1-2). Type Ia results in fragments which have to be further 
degraded, whereas cleavage products of type Ib have relatively low molecular 
weight. Gombotz et al. mentioned these two degradation pathways as well 
(Gombotz et al.; 1995). Polymers with unstable linkages in the water insoluble 
polymer backbone are equal to Heller’s type Ib polymers. After either chemical 
or enzymatic cleavage, the resulting fragments are water soluble and have a 
lower molecular weight. Type Ia was defined by Gombotz et al. as degradation 
of a network of covalently or ionically cross-linked monomers. After digestion of 
unstable linkages, water soluble fragments are released. Their molecular weight 
depends on the density of cleavable bonds. Cross-linked collagen or gelatin are 
degraded by this mechanism (Gombotz et al.; 1995).  
Degradation type II refers to polymers that are initially water insoluble. 
Hydrolysis, ionization or protonation of a pendant group is necessary before 
these polymers become water soluble (Heller; 1984). If solely type II 
degradation occurs, materials are only suitable for topical applications due to 
Type Ia 
Type II 
Type III 
Type Ib 
Solubilization 
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high molecular weight degradation products. However, often a combination of 
type II and III degradation takes place, resulting in smaller fragments because 
of additional cleavage in the backbone (= type III) and polymers are appropriate 
for implants (Heller; 1984). Normally, combinations, e.g. of type Ia with type III 
occur with an initial cleavage of cross-links and subsequent backbone digestion. 
Such combined degradation mechanism occur in aliphatic poly(esters), 
poly(amides), poly(cyanoacrylates), poly(anhydrides), poly(acetals) and 
poly(orthoesters) (Heller; 1984).   
Besides these degradation mechanisms, polymers, like non cross-linked 
gelatin, hyaluronic acid or polysaccharides, can be degraded by solubilization 
(Gombotz et al.; 1995). The polymer itself does not disintegrate and its 
molecular weight remains constant. The simplest form of solubilization is water 
diffusion into the polymer which leads to swelling and finally dissolution (Kamath 
et al.; 1993). 
1.2.2.1 In vitro Degradation of Collagen 
As described above, degradation of collagen requires water and enzyme 
penetration and digestion of linkages. Collagen swells to a certain extent by 
exposure to water. But due to its special sterical arrangement, native collagen 
can only be digested completely when collagenases participate. These 
enzymes are unique because they are able to cleave collagen in its 
undenatured helical regions at physiological pH and temperature (Harrington; 
1996). If this general definition is used, collagenases which cleave one time 
across all three chains, like tissue collagenases, as well as collagenases 
making multiple scissions per chain, like collagenase from Clostridium 
histolyticum (CHC), are included (Seifter et al.; 1971). Non-specific proteinases, 
like pepsin, can only attack the telopeptides or denatured helical regions of 
collagen (Weiss; 1976). Hence, these enzymes are responsible for further 
degradation down to amino acids. 
For in vitro experiments CHC is often used, because this enzyme was the only 
one available in adequate purified quantities for a long time (Seifter et al.; 1971) 
due to lower costs in production compared to tissue collagenases. These types 
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of collagenase are only present in tissue at very low levels and tightly bound to 
collagen (Woessner; 1991). Furthermore, CHC is easier to handle because no 
activation step is required and it has a broader spectrum than tissue 
collagenases, cleaving all types of collagen with no preference for a special 
collagen substrate (Welgus et al.; 1983). Last but not least, despite different 
cleavage sites (Mallya et al.; 1992), its specificity is quite similar to that of 
human neutrophil and fibroblast collagenase, which is important for in vivo / in 
vitro - correlation (Mookhtiar et al.; 1992). Scission occurs between Y and 
glycine at a –P-Y-Gly-P- sequence within the helical apolar regions, with P 
representing proline or hydroxyproline. Depending on the collagen type about 
150-200 cleaves per chain can be made (Seifter et al.; 1971). 
Up to now, seven forms of CHC are known (Mookhtiar et al.; 1992). All seven 
enzymes contain zinc and calcium and consist of one polypeptide chain with 
one active site. The zinc (II) atom is located in the active site and is therefore 
essential for catalysis, whereas the calcium (II) atoms are required to stabilize 
the enzyme conformation and consequently the enzymatic activity (Bond et al.; 
1984). On the basis of their primary and secondary structure, their substrate 
specifity and their way of attack, CHCs can be divided into two classes. Class I 
contains α-, β-, γ-, and η-collagenase and firstly attacks the collagen triple helix 
near the ends. After cleavage at the C-terminal end, a cut near the N-terminus 
follows, before collagen is successively degraded into smaller fragments (see 
Figure 1-3a). Class II consists of δ-, ε- and ζ- collagenase and cleaves the 
tropocollagen in its center to produce two fragments. Further digestion of the 
bigger fragment follows (see Figure 1-3b) (French et al.; 1992; Mookhtiar et al.; 
1992). Consequently, class II CHC better resembles tissue collagenases, which 
cleave collagen in a TCA and a TCB fragment (Seifter et al.; 1971; Welgus et al.; 
1980). 
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Figure 1-3 Schematic illustration of collagen cleavage by class I (a) and class II (b) CHC; 
numbers denote the molecular weight of resulting fragments (modified from (French 
et al.; 1992)) 
 
Moving along the polypeptide chain, collagenase recognizes its specific binding 
sites (see Figure 1-4). Thereby, the calcium (II) atoms of collagenase and the 
structural arrangement of collagen play a fundamental role. If collagenase binds 
to collagen, calcium ions interact with collagen residues, the conformation of the 
enzyme changes and positions in vicinity of the zinc atom become available to 
bind collagen amino acids. Due to the typical helical form of collagen, the 
cleavage sequence –P-Y-Gly-P- forms a pocket with Y and glycine at the 
bottom. The zinc (II) atom of the enzymatic active site is thought to form a 
linkage with glycine and digestion can occur (Seifter et al.; 1971; Seifter et al.; 
1970). Fields et al. detected enriched imino acids at the specific binding site for 
tissue collagenases, resulting in a stiff and thermally stable collagen region. 
This section is followed by a less thermally stable helical part which is more 
mobile due to depletion of imino acids. The helix can be unwound easily and the 
enzyme gains access to the cleavage site (Fields et al.; 1992). A similar 
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observation was made by Federman et al., who detected substantial unwinding 
of the triple helix during gelatin degradation by gelatinase A and B (Federman et 
al.; 2002). However, not all cleavage sites of CHC have a deficiency in imino 
acids. This suggests that digestion sites for bacterial collagenases exhibit not 
simply local disorder, but rather can adopt non-helical conformations and that 
local conformations at the cleavage site are more important than the amino acid 
sequence (French et al.; 1992). After scission, CHC can move on along the 
same collagen chain up to the next cleavage site (see Figure 1-4) (Gaspers et 
al.; 1994), whereas tissue collagenases have to switch to the next triple helix. 
Degradation by collagenases does not result in complete digestion down to 
individual amino acids (Mandl et al.; 1953). This subsequent digestion is 
catalyzed by non-specific proteinases.  
 
 
Figure 1-4 Schematic illustration of the proposed mechanism of the action of bacterial 
collagenase (Paige et al.; 2002) 
 
Collagen fibrils are degraded in a non-specific manner, with no preferential 
cleavage site in the interior or at the ends of fibrils (see Figure 1-4) (Paige et al.; 
2002). Paige et al. observed that fibril diameter and length decreases uniformly. 
It was concluded that collagenase is too large to penetrate into the fibrils and 
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that digestion can only occur at the fibril surface (Okada et al.; 1992a; Paige et 
al.; 2002). Hence, degradation rate is directly correlated to substrate molecules 
available on the surface. If collagen forms fibers and fiber bundles, 
tropocollagens within get inaccessible and degradation rate is even more 
reduced (Steven; 1976).     
1.2.2.2 In vivo Degradation of Collagen 
In vivo, degradation of collagen is more complex than in vitro. Collagen implants 
are infiltrated by various inflammatory cells, e.g. fibroblasts, macrophages or 
neutrophils, which cause contraction of the implant and secret collagen 
degrading enzymes. Infiltration depends on properties of the implant, such as 
shape, porosity and degree of cross-linking, implantation site and individual 
enzyme levels (Gorham; 1991). Connective tissue, for example, is digested by 
the interplay of four different classes of proteinases which are either stored 
within cells or released when required. Cystein and aspartic proteinases 
degrade connective tissue intracellularly at acidic pH values, whereas serine 
and matrix metalloproteinases (MMP) act extracellularly at neutral pH values 
(Shingleton et al.; 1996). Furthermore, non-enzymatic degradation 
mechanisms, e.g. hydrolysis, participate in collagen breakdown (Okada et al.; 
1992a). For degradation of the extracellular matrix, mainly MMPs are 
responsible. These enzymes represent a family of structurally and functionally 
related zinc-containing endopeptidases which degrade almost all extracellular 
matrix and basement membrane proteins (Wall et al.; 2002). Especially their 
catalytic domains are characterized by high sequence and structural homology 
(Overall; 1991). Up to now, 24 different MMPs and four tissue inhibitors of 
metalloproteinases (TIMP) are characterized (Yoshizaki et al.; 2002). According 
to their primary structure and substrate specifity, MMPs are divided into five 
sub-classes (see Table 1-6). 
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Table 1-6 MMP family (modified from (Yoshizaki et al.; 2002)) 
Group MMP Substrates 
Collagenases 
Collagenase-1 
(interstitial)  
MMP-1 collagen types I, II, III, VII, X, casein 
Collagenase-2 
(neutrophil)  
MMP-8 collagen types I, II, III, VII, X, casein 
Collagenase-3  MMP-13 collagen types I, II, III, VII, X, casein 
Collagenase-4 
(Xenopus)  
MMP-18 not known 
Gelatinases 
Gelatinase A  MMP-2 collagen types I, IV, V, VII, IX, gelatin types I, IV, V, 
X, elastin, fibronectin, laminin V 
Gelatinase B  MMP-9 collagen types I, III, IV, V, VII, gelatin types I, IV, V, 
X, elastin, laminin V 
Stromelysins 
Stromelysin-1  MMP-3 collagen types I, III, IV, IX, X, gelatin, pro-MMP-1, 
fibronectin, laminin, proteoglycan 
Matrilysin  MMP-7 gelatin, fibronectin, pro-MMP-1, transferrin 
Stromelysin-2  MMP-10 collagen types III, IV, IX, X, gelatin, pro-MMP-1, 
elastin, laminin, proteoglycan 
Stromelysin-3  MMP-11 collagen types II, IV, V, gelatin, elastin, fibronectin, α-
1-antiproteinase 
Metalloelastase  MMP-12 elastin 
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Membrane-type MMPs 
MT1-MMP  MMP-14 pro-MMP-2, gelatin and collagens 
MT2-MMP  MMP-15 pro-MMP-2 
MT3-MMP  MMP-16 pro-MMP-2 
MT4-MMP  MMP-17 not known 
Non-classified MMPs 
No trivial name  MMP-19 not known 
Enamelysin  MMP-20 not known 
XMMP (Xenopus)  MMP-21 not known 
CMMP (Chicken)  MMP-22 not known 
No trivial name  MMP-23 not known 
No trivial name  MMP-24 not known 
 
 
In human, five major MMPs have been identified, namely MMP-1, 2, 3, 8 and 9 
(Netzel-Arnett et al.; 1991). Besides MMP-8, which is stored in specific granules 
of neutrophils, and membrane-type MMPs (MT-MMP), which are integral 
membrane cell (glyco)proteins, all other MMPs are synthesized if required (Imai 
et al.; 1998).  
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Figure 1-5 Control of MMP-1 activity (  activation;  inhibition; modified from (Birkedal-Hansen et 
al.; 1993; He et al.; 1989; Shingleton et al.; 1996) 
 
MMP expression is induced by various cytokines, e.g. interleukin-1, and growth 
factors (see Figure 1-5) (Shingleton et al.; 1996). MMPs are secreted as latent 
inactive pro-enzmyes (= zymogens) which have to be activated before they 
have complete proteolytic activity (Overall; 1991). Four amino acids (three 
histidines and one cysteine) are coordinated to the zinc atom in the active 
center of zymogens (Birkedal-Hansen et al.; 1993). For activation, a “cysteine 
switch model” is proposed (see Figure 1-6). The linkage to the cysteine residue 
is thought to be cleaved and a water molecule, which must be the fourth 
substituent in the active enzyme, can bind (Nagase et al.; 1999; Woessner; 
1991). In vivo, zymogens are activated by removal of a pro-peptide by 
proteinases, like plasmin or stromelysin, followed by a second activation step 
provoked by proteinases or autocatalysis (Shingleton et al.; 1996). Additionally, 
activation is controlled by TIMPs, which can prevent activation of zymogens 
and/or action of activated MMPs (see Figure 1-5). In vitro, trypsin and 
organomercurials can be used for activation as well (Overall; 1991). Physical 
agents unfold the structure, the zinc-cysteine contact breaks and the pro-
peptide is cleaved autocatalytically (Woessner; 1991).  
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Figure 1-6 Cysteine switch model (modified from (Birkedal-Hansen et al.; 1993; Woessner; 
1991)) 
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Tissue collagenases cleave tropocollagen at one single site, producing TCA and 
TCB fragments about three-quarters and one-quarter of the original molecule 
size. After that initial cleavage, the helical fragments spontaneously denature at 
body temperature and are subsequently further digested by other proteinases 
(Mallya et al.; 1992). This secondary degradation can take place extracellularly 
or intracellularly after phagocytosis (Harris, Jr. et al.; 1974). Apart from 
collagenases, gelatinases play an important role in collagen degradation. 
Besides further degradation of initially cleaved collagen, gelatinases can 
degrade native collagen type I, IV, V and VII (Aimes et al.; 1995; Okada et al.; 
1995; Overall; 1991). Furthermore, levels of gelatinases are considered to be a 
good index whether inflammation is present or not, because high concentrations 
are only available when a normal remodeling process is disrupted (Trengove et 
al.; 1999; Wysocki et al.; 1993).  
1.2.3 Mechanism of Drug Release 
Looking more closely at the drug release mechanism, one has to focus first of 
all on the structure of the device. For parenteral depot delivery systems, either 
implants or microparticles are used. The active agent can be surrounded by a 
rate-controlling biodegradable membrane, e.g. in microcapsules, or uniformly 
distributed throughout the biodegradable polymer giving monolithic devices 
(Heller; 1984) such as microspheres, cylinders, films or beads. In the first case, 
drug release is predictable whenever the membrane erodes after complete drug 
delivery. Nevertheless, if the polymer is degraded before the complete drug is 
liberated, a dramatic change in release profile occurs (dose dumping). Drug 
release from monolithic devices is based on diffusion, swelling, matrix erosion 
or combinations (see Figure 1-7) (Göpferich; 1997a).  
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Figure 1-7 Possible drug release mechanism from degradable polymer devices (modified from 
(Winzenburg et al.; 2004)) 
 
For example PLGA microspheres combine different drug release mechanism. 
Initially, the release is controlled by desorption of the drug from the device 
surface, followed by drug diffusion through porous channels. The formation of 
these channels is influenced by the swelling rate of the microspheres. 
Afterwards, drug release is governed by diffusion through the intact and water 
swollen polymer barriers. This release phase is strongly dependent on the 
polymer properties, such as hydrophilicity and crystallinity. Finally, degradation 
and erosion of the polymer affect the drug delivery by formation of additional 
pores. Beyond this, the release mechanism can be influenced by physical 
properties of the polymer which further complicates the release kinetics 
(Gombotz et al.; 1995; Sinha et al.; 2003).  
If drug release is diffusion controlled, delivery is described for monolithic 
devices by either Fick’s second law (drug loading is lower than drug solubility in 
the polymer) or by the Higuchi equation (drug loading is higher than drug 
solubility in the polymer) (Kanjickal et al.; 2004).  
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1.2.3.1 Erosion Controlled Drug Release 
When erosion is faster than drug diffusion, drug release is controlled by erosion. 
Distinction between two erosion mechanisms can be made. Erosion can take 
place throughout the whole matrix, referred as homogeneous or bulk erosion, or 
can be restricted to the device surface, named heterogeneous or surface 
erosion (see Figure 1-8). Mathematical models for drug delivery are discussed 
in more detail in section 1.3.2. 
 
Figure 1-8 Principles of surface (left) and bulk (right) erosion (modified from (von Burkersroda 
et al.; 2002)) 
 
Bulk erosion is very complex because water uptake is much faster than polymer 
degradation. The entire device is rapidly hydrated and digestion can take place 
throughout the complete matrix. This results in simultaneous drug diffusion and 
matrix erosion (Siepmann et al.; 2001). Consequently, the molecular weight of 
the matrix decreases steadily and the permeability of the device increases over 
time. However, the device retains its original shape and mass, until up to 
approximately 90% is degraded. Then solubilization and mass loss starts (Sinha 
et al.; 2003). The release rate is difficult to predict, especially if the matrix 
disintegrates before drug is released completely (Heller; 1984).  
If surface erosion occurs, water penetration is slow compared to the polymer 
degradation rate. Degradation takes place only at the matrix boundaries and not 
in the core of the polymer (Siepmann et al.; 2001). Thus, except for the 
boundaries, the chemical integrity of the device is preserved and a consistent 
degradation rate of the polymer is the result (Heller; 1984). In general, the 
active agent is entangled within the matrix. Since only minimal diffusion occurs, 
degree of 
degradation 
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prediction of release rate is easier because drug is released by zero-order 
kinetics. Therefore, surface erosion is considered as the preferable erosion 
mechanism in many cases, because it is highly reproducible, the degradation 
rate can be manipulated by just changing the surface area and water labile 
drugs are protected within the device (Uhrich et al.; 1999).  
For most biodegradable drug systems, especially for hydrophilic matrices, both 
erosion mechanisms occur together (Gilbert; 1988b). The relative extent 
depends on the chemical backbone of the polymer (Mainardes et al.; 2004). 
Polymers which contain reactive functional groups, e.g. poly(anhydrides) or 
poly(orthoesters), tend towards fast degradation, i.e. surface erosion, whereas 
polymers with less reactive functional groups, e.g. PLGA or 
poly(cyanoacrylates), commonly show bulk erosion (Siepmann et al.; 2001). 
However, von Burkersroda et al. showed that this general assumption is not 
applicable without restrictions. For example, depending on device dimensions, 
bulk eroding materials can undergo surface erosion if the critical dimensions are 
exceeded (von Burkersroda et al.; 2002). The other extremes are formulations 
of nano- and microparticles in which similar degradation processes occur 
irrespectively of the type of polymer (Uhrich et al.; 1999). 
1.2.3.2 Drug Release from Collagen Devices  
Hydrogels, like non cross-linked collagen or gelatin, hyaluronic acid or 
polysaccharide systems, show a combination of swelling and erosion controlled 
drug release. The initial release rate is controlled by diffusion through water 
filled channels which depends on the swelling rate of the polymer. If 
degradation occurs, the release rate becomes additionally erosion dependent 
(Gombotz et al.; 1995). Drug liberation of hydrophilic drugs from collagen films, 
gels and dense DDSs is mainly diffusion and erosion controlled (see Figure 
1-9). Due to swelling of collagen matrices, high water contents up to 
approximately 90% (w/w) are found in the swollen systems (Frieß; 1999) and 
diffusion through water filled channels can occur (Gilbert et al.; 1988a; Maeda et 
al.; 1999). 
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Figure 1-9 Schematic illustration of drug release from collagen minirods (  drug release) 
 
After a short lag time, resulting from swelling, the first part of release is 
characterized by a Higuchi dependent release kinetic (Frieß et al.; 1996b; 
Gilbert et al.; 1990; Maeda et al.; 1999). When drugs are bound to collagen or 
when macromolecules are incorporated into the delivery system, release may 
be additionally dependent on matrix degradation. However, swelling and 
diffusional release have the greater impact on release (Radu et al.; 2002). 
Different strategies in order to reduce diffusion controlled release were 
developed (Frieß; 1998). In general, drying a collagen-drug-mixture shows 
better sustained release properties than a collagen matrix which is soaked with 
the drug solution. Increasing the concentration of collagen results in an increase 
in viscosity of the swollen devices and reduces drug diffusion (Fujioka et al.; 
1995). By changing the mesh size of fibrillar collagen gels, diffusional drug 
release of macromolecules can be controlled, since diffusion becomes hindered 
when the mesh size of the gel approaches the drug size (Rosenblatt et al.; 
1989). The same result is obtained by increasing the cross-linking density: drug 
release by diffusion is restrained and delivery controlled by erosion becomes 
more important since tortuosity increases (Frieß et al.; 1996b; Gilbert et al.; 
1988a). For drugs with smaller molecular weight, diffusional release from gels 
can be controlled by the extent of non-fibrillar collagen, because of a lower 
effective pore size of these gels compared to fibrillar gels (Wallace et al.; 2003). 
swelling and diffusion  
controlled drug release 
erosion controlled drug release 
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Charge interactions between drug and collagen have a great influence on 
diffusional drug liberation as well. Diffusion is slowed down by electrostatic 
interactions (Singh; 1994). The extent is dependent on the type of collagen, due 
to different amino acid compositions, the collagen preparation, e.g. use of 
succinylated collagen, and the incorporated drug itself, e.g. antibiotics, which 
can also be charged (Frieß; 1998; Singh; 1994). Another strategy is to control 
release by changing the matrix dimensions. Release from dense extruded 
collagen devices is dependent on the length and the diameter of the rods. By 
decreasing the length and/or diameter of the extrudate a faster release was 
observed (Sano et al.; 2003). Beyond this, drug loading and drug hydrophilicity 
effect release as well. Higher drug loads or incorporation of larger drug particles 
lead to an increase in drug release due to formation of more and/or larger 
cavities (Gilbert et al.; 1990). The collagen matrix becomes more porous, the 
diffusion barrier decreases and the release is enhanced (Maeda et al.; 1999). 
Sparingly water soluble drugs are incorporated into collagen devices as crystals 
and have to be dissolved prior to release, resulting in lower delivery rates 
(Wallace et al.; 2003). Additionally, the liberation may be prolonged, if diffusion 
through more hydrophobic collagen parts plays a role (Silver et al.; 1997).  
1.3 Introduction to Mathematical Models  
Mathematical models of drug delivery systems can be used to provide 
information about diffusion processes, matrix degradation and drug release. If 
an adequate model is chosen, insights into the effects of varying parameters 
which influence the drug delivery, such as size and shape of the drug device 
and the drug-polymer ratio, can be given (Kanjickal et al.; 2004; Siepmann et 
al.; 2001). Consequently, these models contribute to a better understanding of 
processes occurring during drug release and can facilitate the optimization of 
existing drug delivery systems and the development of new systems without 
performing a multiplicity of experiments. A mathematical model describing drug 
release from dense collagen drug devices has to consider the three phases: 
swelling, diffusion and erosion (see 1.2.3.2). 
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In vivo, collagen is degraded enzymatically (see 1.2.2.2). Therefore, some 
basics of enzymatic reactions are presented, before mathematical models are 
discussed in more detail (nomenclature see Table 1-7). 
 
Table 1-7 Nomenclature  
a  half thickness of a film or radius of a sphere or cylinder 
A  surface area of the device 
B  surface erosion rate constant 
0C  initial drug load 
SC  solubility of the drug in the polymer 
0d  initial diameter of a cylinder 
D   diffusion coefficient of a substance 
0D  diffusion coefficient of a substance in the undegraded matrix 
[ ]0E  concentration of total enzyme 
[ ]E  concentration of free enzyme 
[ ]aE  concentration of adsorbed enzyme 
[ ]ES  concentration of enzyme-substrate complex  
f   fractional drug release rate 
J   flux of a substance 
1k  rate constant of formation of the ES complex 
1−k  rate constant of dissociation of the ES complex 
2k  catalysis rate 
ak  degradation rate of easily hydrolysable substrate 
adk  rate of adsorption 
bk  degradation rate of more difficult hydrolysable substrate 
dek  rate of desorption 
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K ′  half saturation constant 
DK  adsorption constant  
MK  Michaelis-Menten constant 
0l   initial length of a cylinder 
adm  weight after degradation 
bdm  weight before degradation 
n  Freundlich sorption exponent 
∞M  amount of released drug at matrix exhaustion 
SM  amount of substrate to bind one mole enzyme 
tM  amount of released drug at time t 
0p  drug permeability through the matrix before erosion 
[ ]P  concentration of product 
[ ]0S  concentration of total substrate 
[ ]S  concentration of unbound substrate 
[ ]aS  concentration of easily hydrolysable substrate 
[ ]bS  concentration of more difficult hydrolysable substrate 
t  time 
iv  net sum of synthesis and degradation rate 
0V  initial reaction rate 
  
α  fraction of total enzyme which can bind to the substrate 
δ  relative separation between erosion and diffusion fronts 
maxµ  maximum reaction rate 
0ρ  density of the matrix before hydrolysis  
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1.3.1 Enzymatic Reaction 
Enzyme catalyzed reactions are regarded as reactions in which an enzyme-
substrate complex (ES) is formed. The enzyme (E) binds to the substrate (S), 
converts the substrate into the product (P) and finally is released to be available 
as free enzyme again. This assumption was first made by Brown in 1892. Henri 
improved this approach in 1903 by more precise mathematical and chemical 
terms. He inserted equilibrium between free enzyme, enzyme-substrate 
complex and enzyme-product complex. By measuring the initial reaction rates 
of invertase in 1913, Michaelis and Menten came to a similar equation as Henri 
and provided the basis for modern enzymology (Cornish-Bowden; 1999). 
Nowadays, enzymatic reactions are described particularly by using the 
Michaelis-Menten equation. Assuming a reversible reaction between substrate 
and enzyme at early stages the following reaction takes place: 
E + S     ES      E + P  ( 1-1 ) 
with 1k  the rate constant of formation of the ES complex, 1−k  the rate constant 
of dissociation of the ES complex and 2k  the catalysis rate. In most cases, the 
final step is regarded as irreversible because only the degradation can be 
catalyzed by the enzyme (Tzafriri et al.; 2002). 
The initial reaction rate can be described by  
[ ]
[ ] MKS
S
V +=
*max
0
µ  ( 1-2 ) 
The Michaelis-Menten constant MK  is the substrate concentration at which the 
reaction rate is half of the maximum rate ( maxµ ). Michaelis-Menten kinetics 
describe reactions with saturation phenomena such as enzymatic reactions. 
Looking closer at enzymatic reactions, this kinetic is used to describe the 
degradation of soluble substrates (Bailey; 1986). However, many enzymatic 
reactions occur in heterogeneous systems. Examples for the action of soluble 
enzymes on insoluble substrates are the hydrolysis of collagen, cellulose and 
starch or the digestion of food in animal intestine (Lee et al.; 1980). The most 
k1 
k-1 
k2 
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distinct difference to the reaction with soluble substrates is the formation of the 
enzyme-substrate complex. For digestion of insoluble substrates this can only 
be achieved by diffusion of the enzyme towards the insoluble substrate and 
adsorption onto its surface. For a better understanding of these degradation 
mechanisms, going far beyond the original Michaelis-Menten kinetics, the 
degradation equations of collagen and cellulose will be discussed in more 
detail. 
Gaspers et al. investigated the behavior of bacterial collagenase on FALGPA 
(furylacryloyl-leucine-glycine-proline-alanine) attached to glass (Gaspers et al.; 
1994; Gaspers et al.; 1995). Initially, diffusion limited adsorption was observed, 
followed by lateral movement of collagenase on the surface towards reaction 
sites. During this process, the enzyme remains irreversibly adsorbed onto the 
surface, as was observed by Welgus et al. for human fibroblast collagenase 
(Welgus et al.; 1980). Collagenase is adsorbed by many weak physical bonds. 
The sum of interactions results in irreversible adsorption. During hydrolysis or 
migration along the collagen molecule, only few physical bonds are cleaved 
which are not sufficient to release collagenase from the surface. After 
disengagement, new links are formed nearby, resulting in enzymatic movement 
(Gaspers et al.; 1994). Collagenase remains active after adsorption and 
enzymatic conversion can occur (Gaspers et al.; 1995). Hence, degradation of 
collagen takes place in three steps: after diffusion of collagenase towards the 
collagen substrate, the enzyme has to adsorb onto the collagen surface and 
subsequently degradation can occur (see Figure 1-10 ). 
 
Figure 1-10  Schematic illustration of degradation of collagen matrices ( free collagenase,        
 adsorbed collagenase) 
diffusion of collagenase adsorption of collagenase collagen 
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1.3.1.1 Adsorption 
The prerequisite step for degradation of insoluble substrates is the adsorption of 
the enzyme. In general, adsorption is defined as adhesion of gas or liquid 
molecules onto a solid or liquid surface. Different approaches for describing this 
phenomenon have been taken. One of the simplest was proposed by Langmuir 
in 1916, who investigated the adsorption of gases onto solids. The resulting 
equation corresponds closely to the Michaelis-Menten equation (Cornish-
Bowden; 1999). Adsorbed molecules do not interact with themselves on the 
surface and affinity to all surface sites is the same (McLaren et al.; 1970). The 
number of adsorption sites per area are constant and only one molecule can 
adsorb per adsorption site which results in the formation of a monolayer of 
adsorbed molecules (Martin et al.; 1983). Adsorption can be described by: 
[ ]
[ ]
[ ]
[ ]EK
EK
S
E
D
Da
+= 10
 with 
de
ad
D k
k
K =  ( 1-3 ) 
The distribution between two phases is defined by the adsorption constant DK , 
which is the ratio of adsorption rate ( adk ) to desorption rate ( dek ). 
In contrast, the Freundlich isotherm describes a multiplicity of adsorption sites 
which differ in their energy (Rubingh et al.; 1992). The more adsorption sites are 
occupied, the lower is the required adsorption energy because interactions 
between adsorbed molecules take place (Haas; 2002). This results in a 
parabolic isotherm without a maximum in adsorption: 
[ ]
[ ] [ ]nDa EKS
E =
0
 ( 1-4 ) 
with n  a chemical-specific constant. 
However, strictly spoken, the above mentioned adsorption isotherms are 
applicable only to small solute molecules. Therefore, more complex adsorption 
kinetics may have to be taken into account for the adsorption of enzymes 
(McLaren; 1963) as for example a combination of Langmuir and Freundlich: 
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[ ]
[ ]nD
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Da
EK
EK
S
E
+= 10
 ( 1-5 ) 
Both, Freundlich and Langmuir, sorption isotherms are used to describe the 
enzymatic adsorption on insoluble substrates (McLaren et al.; 1970).  
Adsorption of human skin fibroblast collagenase on a fibrillar collagen gel is 
already completed after 12-15 minutes at 37°C (Welgus et al.; 1980). 
Consequently, the assumption that adsorption is faster than the enzymatic 
reaction is correct. McLaren et al. postulated that the adsorbed enzyme does 
not interact with itself on the surface and that the affinity to all reaction sites is 
the same. Therefore, they assumed a Langmuir sorption isotherm for gelatin 
degradation by trypsin (McLaren et al.; 1970). This assumption was affirmed by 
Welgus et al., who observed a linear Lineweaver-Burk plot for bound to free 
human fibroblast collagenase, indicating that all binding sites on collagen are 
equal (Welgus et al.; 1980). On the other hand, with data from Tsuk et al. (Tsuk 
et al.; 1961), McLaren suggested a Freundlich isotherm for gelatin degradation 
by trypsin, because Tsuk et al. observed that a higher surface area was 
covered with enzyme than the actual substrate surface area (McLaren; 1963; 
Schurr et al.; 1966). For collagen degradation by bacterial collagenase, the 
more appropriate approach seems to be the Freundlich isotherm, as was 
described by Rubingh et al. (Rubingh et al.; 1992). They investigated the 
degradation of Azocoll, a collagen-dye conjugate, by three different enzymes 
and obtained Freundlich sorption isotherms. This is in agreement with Gaspers 
et al. who postulated a non-uniformity of adsorption states of bacterial 
collagenase during degradation of FALGPA attached to glass (Gaspers et al.; 
1994). 
Adsorption of cellulase on cellulose can be divided in two sorption phases. 
Within the first 5-10 minutes, fast adsorption occurs which is followed by a 
slower uptake for several hours which results in equilibrium between adsorption 
and desorption. This equilibrium is described by first-order kinetics. Thereafter, 
a slight release of cellulase can be observed indicating digestion of cellulose. 
The active enzymes bind stronger than inactive enzymes (Ghose et al.; 1979), 
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as was also observed for collagenase (Gaspers et al.; 1994). The Langmuir 
isotherm was used as a general characterization of the adsorption (Lee et al.; 
1980; McLaren et al.; 1970). However, in 1988 Steiner et al. could demonstrate 
that adsorption results in a multimolecular layer of enzymes (Steiner et al.; 
1988). They distinguished between equations for low and high surface coverage 
when low substrate concentration is used. The equations are based on the law 
of mass action, the Michaelis-Menten equation, assuming reversible adsorption. 
For low surface coverage  
[ ]
[ ]
[ ]
[ ]0
0
0 SK
S
E
ES
+′=
α  ( 1-6 ) 
is valid, where SM MKK *=′  representing the half saturation constant and α  
the fraction of total enzyme which can bind to the substrate (Steiner et al.; 
1988). In 1974, Kim demonstrated that the initially adsorbed amount of cellulase 
is primarily responsible for the degradation of cellulose and is proportional to the 
initial hydrolysis rate (Lee et al.; 1980). This strengthened the assumption, that 
adsorption is the prerequisite step for degradation of insoluble substrates. 
Consequently, adsorption of bacterial collagenase on the surface of collagen 
can be included into the mathematical model by incorporation of a Freundlich 
sorption isotherm. 
1.3.1.2 Degradation 
After the enzyme adsorption, degradation of collagen can start. Collagen 
monomers in solution are digested according to the Michaelis-Menten kinetics. 
In contrast, degradation of fibrillar collagen depends on its age. Freshly 
reconstituted collagen fibrils behave similarly to diluted tropocollagens (Tzafriri 
et al.; 2002) because cross-links can still be hydrolyzed rather easily. 
Degradation of fibrillar collagen samples with more stable bonds or a higher 
degree of cross-linking is hyperbolically dependent on enzyme concentration 
(Steven; 1976). This anomaly is related to hindered enzymatic penetration into 
the fibril resulting in protection of collagen molecules within the fibrils (Steven; 
1976; Tzafriri et al.; 2002).  
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Based on the Michaelis-Menten equation, McLaren proposed different 
approaches to describe the digestion of insoluble substrates, depending on 
whether the enzyme can penetrate into the substrate or not (McLaren et al.; 
1970). Assuming that the reaction rate is not exclusively dependent on the initial 
enzyme concentration, but on the concentration of adsorbed enzyme, he 
inserted enzyme adsorption on the surface of the substrate into the Michaelis-
Menten equation (McLaren et al.; 1970). This assumption was affirmed by 
Rubingh et al. who observed a lag-time before linear degradation occurred. This 
delay was attributed to the establishment of a surface equilibrium concentration 
(Rubingh et al.; 1992). For a cross-linked insoluble gelatin gel it was assumed 
that enzymes, e.g. trypsin, are unable to penetrate into the substrate. Hence, 
enzymatic action is restricted to the surface. Because degradation products are 
soluble and will be removed from the surface, new surface areas will be 
exposed and degradation becomes surface dependent (Tsuk et al.; 1961). 
Based on these observations, McLaren developed a model in which Langmuir 
adsorption is combined with degradation (McLaren et al.; 1970). This equation 
is valid when adsorption is faster than degradation and desorption is the slowest 
step. 
[ ]
[ ] 10
0
0 −+
′′=
DKE
AEk
V  ( 1-7 ) 
k ′′  denotes the degradation rate, MD KK =−1  and aEEE +=0 . It must be pointed 
out that not all adsorbed enzyme molecules must inevitably build an enzyme-
substrate complex ( ESEa ≥ ) because adsorption can also occur at sites which 
can not be cleaved (McLaren et al.; 1970). By using data from Tsuk et al. (Tsuk 
et al.; 1961), more enzymes than a monolayer can be adsorbed and a 
Freundlich adsorption isotherm is valid: 
[ ]nD EKkV ′′=0  ( 1-8 ) 
with 43.0=n  as a geometrical interpretation based on the Freundlich isotherm 
(McLaren; 1963). Gyani defined four extremes of n . When adsorption between 
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two immiscible liquids is investigated, 1=n  is valid. In contrast, 32=n  presents 
complete surface coverage of a smooth solid. When 3
1=n  is observed, only 
adsorption on edges and cracks of the solids takes place and only distinct 
points are covered when 0=n  (Gyani; 1945). If n  is between 1/3 and 2/3, 
adsorption on edges and cracks and surface adsorption occur simultaneously. If 
n > 3
2 , penetration of the solute into the solid can take place (McLaren; 1963). 
Other assumptions were pursued by Okada et al. (Okada et al.; 1992a) and 
Tzafriri (Tzafriri et al.; 2002) who investigated the degradation of collagen fibers. 
Okada et al. assumed that erosion of Catgut is exclusively surface erosion and 
concluded that the square root of fiber mass 
bd
ad
m
m  decreases linearly with time 
and depends on the initial diameter 0d   and density 0ρ  of the matrix (Okada et 
al.; 1992a): 
t
d
k
m
m
bd
ad
0
0
2
1
ρ
−=  
( 1-9 ) 
Tzafriri jeopardized this linearity and the validity of adsorption isotherms on 
erodible surfaces. He developed a model for degradation of sparsely fibrillar 
collagen gels by human skin fibroblast collagenase based on the Michaelis-
Menten and diffusion equations (Tzafriri et al.; 2002). It was assumed that 
degradation is the rate-limiting step, that the erosion process is confined to the 
surface of fibrils, that only one specific cleavage site per fibril exists, and that 
enzyme and product diffusion are instantaneously compared to the time scale of 
degradation. By applying a quasi-steady-state assumption a model was 
developed which is dependent on four model parameters. Based on data from 
Welgus et al. (Welgus et al.; 1980), Tzafriri used a Langmuir adsorption to 
simulate adsorption, which is significantly faster than degradation. A linear 
relationship of the square root of fiber mass and time was found. MK  and catk  
(turnover number) of human skin fibroblast collagenase were determined and it 
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was concluded that this model is also valid for bacterial collagenase which 
cleaves at more than just one site (Tzafriri et al.; 2002). However, this 
interesting model can not be used for our dense collagen devices which show 
fibril surface erosion and matrix bulk erosion.   
Suga et al. developed a model for degradation of cross-linked dextran spheres. 
They also combined the Michaelis-Menten equation with diffusion equations for 
the enzyme and released substrate fragments (Suga et al.; 1975). 
Degradation of cellulose is more complex than digestion of collagen. On the one 
hand three major synergistic enzymes (endoglucanases, exoglucanases and β-
glucosidases) catalyze the reaction, and on the other hand competitive and 
non-competitive product inhibition by cellubiose and/or glucose is observed. 
Several models were proposed, assuming a pseudo-first-order enzymatic 
reaction with adsorption as a prerequisite step (Lee et al.; 1980; Sattler et al.; 
1989). Esterbauer et al. observed a two phase degradation resulting from an 
initial fast digestion followed by a slower one. Consequently, a distinction 
between easily hydrolysable cellulose aS  and more difficult digestible parts of 
the substrate bS  was made. This reflected the structural properties of the 
substrate, such as pore size, adsorption properties or accessibility (Esterbauer 
et al.; 1984). Based on these observations, Sattler et al. developed a simple 
model to describe the relation between extent of hydrolysis, enzyme dosage 
and reaction time (Sattler et al.; 1989). Simplification can be made by setting 
the initial substrate concentration as ba SSS +=0 , if the substrate consists of 
100% reactable molecules. They detected that both, the adsorbed amount of 
enzyme and the enzyme-substrate ratio at fixed reaction times follow a 
Langmuir dependency. Hence, a hyperbolic function must also be valid for the 
enzymatic degradation at these time points. Combining all observations, the 
digestion of cellulose can be described as: 
[ ]
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where K  indicates an independent constant for reaction times longer than 2 
hours. The degradation rate of the more difficult digestible parts of the 
substrate, bk , increases steadily with higher enzyme dosages leading to the 
conclusion that bS  is not saturated with enzyme during the enzymatic reaction. 
Consequently, a limited case of simple Michaelis-Menten kinetics can only be 
accepted for the digestion of aS , with MK  smaller than the enzyme 
concentration (Sattler et al.; 1989). 
Other approaches are based on the Michaelis-Menten kinetic. In 1965, 
Amemura et al. applied this kinetic directly to an insoluble cellulase-cellulose 
system. They concluded that the initial hydrolysis rate is not limited by 
adsorption or penetration phenomena, and that there is a constant number of 
binding sites. The model was improved by including terms for accessibility of 
cellulose and product inhibition (Lee et al.; 1980). McLaren adapted the 
Michaelis-Menten equation to the hydrolysis of insoluble substrates by referring 
the initial rate to the amount of adsorbed enzyme (McLaren et al.; 1970). For 
the hydrolysis of cellulose by cellulase a Freundlich isotherm was assumed. K  
and n  can be determined from adsorption isotherms. An increase in n , was 
attributed to a deeper enzymatic penetration into the swollen polymer (McLaren; 
1963). McLaren’s model can only be used for simple cellulose-cellulase 
reactions because substrate multiplicity, product inhibition and mode of action of 
cellulose are ignored (Lee et al.; 1980), but is of general interest to approach 
models for collagen materials. 
Further developments were made by Huang, who combined the enzymatic 
adsorption and the Michaelis-Menten kinetics with equations for competitive 
inhibition (Huang; 1975). For adsorption a fast process based on the Langmuir 
isotherm was assumed. A very complex model was developed by Kim which 
takes into account enzyme adsorption, formation and dissociation of the 
enzyme-substrate complex, product inhibition and enzyme deactivation (Lee et 
al.; 1980).  
In conclusion, mathematical modeling of degradation of insoluble collagen by 
bacterial collagenase is quite challenging, because normal Michaelis-Menten 
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kinetics is not sufficient to describe the complete enzymatic conversion 
correctly. Based on the Michaelis-Menten mechanism, equations for collagen 
degradation need to be developed, which take into account enzymatic 
adsorption phenomena and diffusion of collagenase and degraded collagen 
fragments. Some complex aspects described for the cellulose-cellulase system, 
such as substrate multiplicity, product inhibition or special mode of enzymatic 
action, need not be considered for a collagen degradation model. 
1.3.2 Drug Release from Biodegradable Devices 
As already pointed out in section 1.1, delivery of drugs from biodegradable 
polymers got into focus within the last decades, because patient compliance 
can be improved compared to non-biodegradable polymeric matrices. However, 
drug release is more complex than from non-biodegradable DDSs. Various 
mathematical models have been developed, because biodegradable polymers 
exhibit significant chemical and physiochemical differences (Siepmann et al.; 
2001). Consequently, it is important to reassess the chosen mathematical 
model for every drug device, even if only the geometry changes. 
1.3.2.1 Diffusion Controlled Drug Release 
Diffusion controlled drug release is extensively dependent on the structure of 
the device. In reservoir systems, the rate limiting step is the diffusion through a 
polymer membrane which surrounds the drug containing core. The release J of 
a drug a  is governed by Fick’s first law (Kanjickal et al.; 2004).  
dz
dC
DJ aaa −=  ( 1-11 ) 
The drug release from monolithic systems, which contain dissolved or dispersed 
drug throughout the entire device, is dependent on the solubility of the drug in 
the polymer and the drug load. If drug loading is below the drug solubility limit, 
the release by diffusion can be described by Fick’s second law (Kanjickal et al.; 
2004). 
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2
2
dz
CdD
dt
dC a
a
a =  ( 1-12 ) 
If the drug load 0C  is higher than the solubility of the drug in the polymer SC , 
the release is expressed by the Higuchi model (Siepmann et al.; 2001). 
( ) tCCCDAM SSt −= 02  ( 1-13 ) 
1.3.2.2 Swelling Controlled Drug Release 
Besides diffusion controlled drug release (Case I transport), the other extreme 
of diffusional behavior is drug release controlled by swelling (Case II transport). 
In Case II transport, swelling at the liquid front is the rate limiting factor because 
the mobility of the solvent is higher than the rearrangement of the polymer 
structure. For classifying the character of mass transport either the Deborah 
number, the swelling interface number or the power law can be used. All three 
distinguish between Case I and II and anomalous transport (Kanjickal et al.; 
2004).   
A transition between models of swelling and erosion controlled drug release 
was proposed by Lee, who developed an analytical solution for thin, surface 
eroding films, with a thickness of 2 a , based on the movement of a swelling and 
an erosion front (with a relative separation δ ) within the device. This theory 
predicts a zero-order release for surface eroding matrices (with a surface 
erosion rate constant B ) when the initial drug load 0C  becomes much larger 
than drug solubility in the polymer SC  (Siepmann et al.; 2001).  

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M St δτδ  ( 1-14 ) 
1.3.2.3 Erosion Controlled Drug Release 
Mathematical modeling of erosion controlled drug release is more challenging 
than the above mentioned models, because besides mass transfer, chemical 
reactions have to be considered. This kind of models can be divided in two 
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principle categories. The first ones, named empirical models, assume a single 
zero-order process to control drug release. Besides easy handling, they are of 
advantage if only one material is used. However, they fail if specific 
physicochemical processes have to be taken into account. Then, mechanistic 
models can be applied which also consider the underlying physical and 
chemical properties, e.g. diffusion mass transfer. These models are quite 
complex compared to empirical models, but more accurate and powerful 
(Siepmann et al.; 2001).  
Empirical models were proposed from Hopfenberg and Cooney for drug release 
controlled by surface erosion (Kanjickal et al.; 2004; Siepmann et al.; 2001). 
Both investigated the effect of polymer matrix geometry. Hopfenberg assumed 
that the drug release rate is proportional to the device surface and that all mass 
transfer processes result in one single zero-order process. A general model for 
surface erosion of slabs, cylinders and spheres with drug release as rate-
limiting step was developed. 
sf
t
aC
tk
M
M 

 −−=
∞ 0
011  ( 1-15 ) 
with 0k  a rate constant and sf  a “shape factor” set as 1 (slab), 2 (cylinder) and 
3 (sphere), respectively. This equation leads to zero-order drug release kinetics 
for slabs and to declining release rates with time for cylinders and spheres 
(Heller; 1984; Kanjickal et al.; 2004). Cooney established a more detailed model 
for surface eroding cylinders and spheres. He assumed that dissolution from 
non-porous homogeneous solids is covered by two main steps, detachment of 
an atom, molecule or ion from the solid surface, followed by diffusion through an 
adjacent stationary solvent layer into the incubation medium. Additionally, drug 
release is thought to be proportional to the surface area. This results in a single 
zero-order process for drug release, described by the following equation: 
( ) ( )( )
00
2
0
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2
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−−+−=  ( 1-16 ) 
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K  is a constant and f  the ratio of instantaneous drug release rate to the initial 
drug release rate. For slabs ( 0l / 0d approaches 0), a constant dissolution rate 
was found. Good differentiation can be made between rod like cylinders 
( 0l / 0d >>1), with relative drug release rates approaching zero up to drug 
exhaust, and disc like cylinders ( 0l / 0d <<1), with relative drug release rates 
remaining finite until the end (Kanjickal et al.; 2004; Siepmann et al.; 2001). 
Going one step further, descriptions of physical, chemical and physicochemical 
processes, which control drug delivery, can be incorporated in mechanistic 
models. Consequently, these models provide more information on the 
mechanism of drug release. Approaches were made with models with partial 
differential equations and simplified discrete models (Siepmann et al.; 2001). 
Heller established a model that describes the drug delivery from bulk eroding, 
water insoluble polymers digested by backbone cleavage (Heller; 1984). 
Assuming first-order kinetics for degradation, the model is based on the Higuchi 
equation. Additionally, a relationship between drug permeability at the beginning 
0p  and during erosion due to an increase in permeability of the matrix 
undergoing erosion is inserted. In the beginning, drug release rate decreases 
because diffusion path length increases. Subsequently, the rate increases due 
to an increase of matrix permeability. This results in an expression for 
quantifying drug release from thin, bulk eroding films with an initial drug load 0C  
above drug solubility in the polymer 
t
CpA
dt
dM Ktt 002
2
=  ( 1-17 ) 
where K  is a first-order degradation constant (Heller; 1984; Siepmann et al.; 
2001). 
Thombre et al. proposed a model for poly(orthoester) slabs which are degraded 
by an autocatalysis mechanism based on Fick’s second law (Thombre et al.; 
1985). They assumed perfect sink conditions and that diffusivities change 
continuously as a function of hydrolysis. However, description of the 
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microstructure of the device was not included into this model. The diffusion of 
four species i , occuring during degradation, was described as: 
( ) iiii vx
CtxD
xt
C +


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∂ 00 ,  ( 1-18 ) 
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( )

 −= 0
0
0 exp
D
DD
ii C
CCDD µ  ( 1-19 ) 
and x  is the space variable, µ  a dimensionless constant (Siepmann et al.; 
2001), 0DC  the concentration of undegraded and DC  the concentration of the 
degraded substrate at time t. 
Charlier et al. investigated the release rate of mifepristone from bulk eroding 
PLGA films (Charlier et al.; 2000). They observed an early drug delivery 
according to Higuchi, assuming that the diffusion coefficient does not change in 
the matrix because no degradation takes place. Subsequently, homogeneous 
erosion, following first-order kinetics, starts. The diffusion coefficient becomes 
dependent on the polymer molecular weight and the release rate no longer 
obeys the Higuchi kinetics. These observations were combined and gave the 
following equation (valid for ( 0C >> SC )): 
( )
k
eDCCAM
kt
S
t
12 00 −=  ( 1-20 ) 
where 002 DCCAF S=  and k  is the degradation constant. This equation was 
divided into an early release phase ( tFM t = ) and a release for later time 
points (
k
eFM
kt
t
1−= ) (Charlier et al.; 2000). 
The release of chlorhexidine gluconate from a cross-linked gelatin chip was 
modeled by Tzafriri using a finite element method (Tzafriri; 2000). Tzafriri 
assumed a fully swollen matrix undergoing bulk erosion, a drug load composed 
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of a mobile and immobile drug pool, and that most of the drug is released prior 
to erosion. The mobile drug can diffuse freely after hydration of the matrix, 
whereas the immobile drug can only diffuse after matrix degradation. 
Consequently, the release of mobile and immobile drug was modeled 
separately. Constant diffusion coefficients, independent of degradation, were 
applied because only small drugs were considered in this model. Immobilization 
can be chemical (conjugation to the polymer backbone) or physical (steric 
hindrance). Due to proportionality of immobilized drug and substrate 
concentration, an immobilizing capacity of the polymer was defined which is 
equal to the number of hindering cross-links per mole of fully swollen substrate 
for physical immobilization. Hence, the release rate becomes proportional to the 
degradation rate. Degradation was assumed to follow the Michaelis-Menten 
kinetics, because the fully swollen matrix does not restrict enzyme penetration 
(Tzafriri; 2000). 
Macromolecular drug release from bulk eroding PLGA microparticles was 
modeled by Batycky et al. (Batycky et al.; 1997). A microstructural model was 
used, assuming micropores in the sphere surface which coalesced to 
mesopores during degradation. Distinction between burst release, dependent 
on drug desorption from the particle surface and already existing mesopores, 
and drug release by Fickian diffusion through newly formed mesopores was 
made. Before the second phase could occur, an “induction phase”, necessary 
for formation of additional mesopores by coalescing of micropores, was 
implemented. However, effects of pH and interactions between protein and 
polymer were not implemented (Batycky et al.; 1997). 
Another subclass of mechanistic models is based on the Monte-Carlo-
simulation, first mentioned by Zygourakis in the late 1980’s. A two-dimensional 
grid is generated for the device to simulate the polymer microstructure with 
each cell representing drug, polymer, solvent and a pore void, respectively. The 
rate-limiting step is thought to be the detachment of molecules from the surface. 
Consequently, this model was used for simulating drug release from surface 
eroding devices. As soon as a cell comes into contact with the solvent, its 
lifetime starts to decrease and it finally dissolves instantaneously (Kanjickal et 
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al.; 2004; Siepmann et al.; 2001). These simulations were verified by Göpferich, 
who inserted several parameters, e.g. crystallinity, shape and porosity of the 
device. Last but not least, mass transport processes like diffusion were 
incorporated by including Fick’s second law. Hence, simulations were extended 
to bulk eroding systems and mass loss and degradation can be simulated 
individually (Göpferich; 1997b). Further improvement was achieved by 
Siepmann et al., who proposed a “comprehensive” model for bulk eroding 
microparticles which covers the initial burst, the subsequent zero-order release 
and the final rapid drug delivery (Siepmann et al.; 2002). 
In this thesis a mechanistic model for the drug release from dense matrices 
prepared from insoluble collagen type I was to be developed. Since, drug 
delivery from collagen devices is governed by two simultaneously occurring 
mechanisms, swelling and erosion controlled release (see 1.2.3.2), both had to 
be incorporated into the model. Diffusional release was adapted from Radu et 
al. (Radu et al.; 2002). Swelling and diffusion controlled drug release of 
indomethacin and gentamicin from dense collagen devices were described by 
assuming Fickian diffusion and concentration dependent diffusion coefficients of 
water and drugs (Radu et al.; 2002). These equations were transferred to higher 
molecular weight drugs, like FITC dextran 70. For erosion controlled drug 
release, a combination of bulk and surface erosion was taken as a basis and a 
model similar to Tzafriri appeared to be suitable (Tzafriri; 2000; Tzafriri et al.; 
2002). Figure 1-11 summarizes the mathematical modeling approach. 
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Figure 1-11 Schematic illustration of the mathematical model of dense collagen matrices (  drug 
release,  free collagenase,  adsorbed collagenase) 
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2 Goals of this thesis 
The aim of this thesis was to characterize the drug release from dense collagen 
matrices. For this purpose, a biodegradable device based on insoluble collagen 
had to be developed and the delivery of higher molecular weight compounds, 
e.g. dextrans and proteins, was investigated. Since drug release is covered by 
swelling, diffusion and erosion mechanisms (Frieß et al.; 1996b; Radu et al.; 
2002), a more fundamental understanding of these processes is needed to 
adopt and prolong delivery properties. Focus was put on the description of the 
enzymatic matrix erosion and its influence on drug release. Based on the 
collected data, a mathematical model had to be developed, in cooperation with 
the Institute of Applied Mathematics in Erlangen, which describes both, the drug 
release and the degradation of dense collagen implants in one model. To our 
knowledge, until this new model was presented, these processes are only 
implemented separately for collagen drug devices. Either the drug release from 
cross-linked hydrolyzed gelatin matrices (Tzafriri; 2000), the drug release 
controlled by diffusion from dense collagen devices (Radu et al.; 2002) or the 
degradation of a sparse fibrillar collagen gel by human skin fibroblast 
collagenase (Tzafriri et al.; 2002) were described in literature.  
In summary, the following targets were postulated: 
(I) Development and characterization of a dense drug delivery system based 
on insoluble collagen.  
(II) Characterization of the collagen degradation by bacterial collagenase. 
(III) Investigation and characterization of the in vitro matrix degradation/erosion 
of the developed dense drug delivery systems in the presence of bacterial 
collagenase.  
(IV) Investigation and characterization of the in vitro drug release of model drug 
compounds and/or proteins from the developed dense drug delivery 
systems. 
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(V) Development of a mathematical model, on the basis of the experimental 
results obtained from (I) – (IV), to simulate simultaneously drug release 
and matrix erosion of dense collagen devices.   
(VI) Investigation of the biocompatibility and the in vivo drug release from the 
developed dense drug delivery systems. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Collagen 
Three different qualities of insoluble collagen type I were used. An equine and a 
bovine collagen flavor were obtained from Innocoll GmbH (Saal/Donau, 
Germany). Both were derived from tendon and provided as lyophilized material. 
A more detailed characterization of these two materials was performed by 
Schlapp (Schlapp; 2001). For comparison, a second bovine collagen was 
provided from Lohmann & Rauscher GmbH & Co. KG (Rengsdorf, Germany). 
This material was extracted from corium and had a slightly higher IEP of 6.7 
compared to the other two materials (equine: 6.5; bovine tendon: 6.4). The 
bovine corium material was obtained as a 1% (w/w) aqueous dispersion and 
was subsequently lyophilized to improve storage stability (see 3.2.1.5).  
3.1.2 Wound Dressings 
Two wound dressings, containing bovine corium collagen type I were 
investigated. Suprasorb® C (Lohmann & Rauscher GmbH & Co. KG, Rengsdorf, 
Germany), consisting exclusively of collagen and a wound dressing containing 
collagen and oxidized regenerated cellulose (ratio 45/55; Promogran®, Johnson 
& Johnson Medical Limited, Gargrave, Skipton, UK).  
3.1.3 Enzymes 
3.1.3.1 Collagenase 
Bacterial collagenase from Clostridium histolyticum (CHC) was obtained from 
Sigma Aldrich Chemie GmbH (Taufkirchen, Germany). This crude collagenase 
is a lyophilized mixture of all seven known forms of collagenase (α: 68 kDa; β: 
115 kDa; γ: 79 kDa; η: 130 kDa; δ: 100 kDa; ε: 110 kDa and ζ : 125 kDa) 
(Mookhtiar et al.; 1992) and contained additionally 35 units/mg solid caseinase 
activity. The activity of collagenase was 1.2 units/mg solid referred to the 
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hydrolysis of FALGPA (1 unit hydrolyzes 1µmol of FALGPA (furylacryloyl-
leucine-glycine-proline-alanine) per minute at pH 7.5 in the presence of calcium 
ions) (Sigma Aldrich; 1998). 
3.1.3.2 Gelatinase A 
Matrix metalloproteinase 2 (MMP-2; gelatinase A) was purchased from Roche 
Diagnostics GmbH (Penzberg, Germany) and from Sigma Aldrich Chemie 
GmbH (Taufkirchen, Germany). Both qualities of MMP-2 were isolated from 
human fibrosarcoma cells. After activation with 2.5mM APMA (p-
aminophenylmercuricacetate) (30min at 37°C) the specific activity was 200 
units/mg referring to hydrolysis of collagen type IV (Roche Diagnostics; 2004b) 
for the Roche enzyme. In literature, no data for the activity of the Sigma enzyme 
was available. We determined an activity which was only 1.14 units/mg.  
3.1.3.3 Gelatinase B 
Matrix metalloproteinase 9 (MMP-9; gelatinase B) was also purchased from 
Roche Diagnostics GmbH (Penzberg, Germany). The enzyme was isolated 
from human blood. After activation with trypsin (10min at 37°C) and subsequent 
stop of activation with aprotinin (10min at 37°C), the specific activity was 
≥200mU/mg referring to hydrolysis of DNP-peptide (Roche Diagnostics; 2004a). 
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3.1.4 Model Compounds 
Table 3-1 Model compounds 
Model Drug Description Supplier 
Bovine Serum Albumin 
(BSA) 
catalogue # A-6793 Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
FITC dextran 20 catalogue # FD-20S Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
FITC dextran 70 catalogue # FD-70S Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
FITC dextran 150 catalogue # 46946 Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
 
 
For electron spin resonance (ESR) investigations, BSA was spin-labeled. 
Labeling was performed according to the protocol of Katzhendler et al. 
(Katzhendler et al.; 2000a): 160mg 3-carboxy-2,2,5,5-tetramethyl-1-
pyrrolidinyloxy (PCA),  266mg N-hydroxysuccinimide (NHS) and 148mg 
N,N´dicyclohexylcarbodiimide (DCC) were dissolved in 16ml dimethyl sulfoxide 
(DMSO) and stirred at room temperature for 24h. A 20mg/ml BSA solution in 
45ml 0.1M sodium borate buffer pH 8.8 was prepared. 15ml of the DMSO 
solution was added to the protein solution, mixed well and incubated at room 
temperature for 4h. 24µl NH4Cl was added and the solution was incubated at 
room temperature for 10min. A 2d dialysis against water at 4°C followed. 
Subsequently, the material was lyophilized (see 3.2.1.5). 
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3.1.5 Reagents and Buffers 
 
Table 3-2 Reagents 
Reagent Description Supplier 
APMA p-aminophenylmercuricacetate; 
catalogue # A9563 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
Aprotinin catalogue # 981532 Roche Diagnostics GmbH 
(Penzberg, Germany) 
BCA Protein Assay 1 part CuSO4 
50 parts bicinchoninic acid (BCA) 
KMF Laborchemie Handel 
GmbH, Lohmar, Germany 
CaCl2* 2H2O p.a. VWR International GmbH 
(Darmstadt, Germany) 
D2O heavy water; mind. 99.8% VWR International GmbH 
(Darmstadt, Germany) 
DCC N,N´Dicyclohexylcarbodiimide; 
catalogue # 36650 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
DMSO dimethyl sulfoxide Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
EDC 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide; catalogue 
# 03449 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
EnzCheck® 1mg/ml DQ gelatin in water  MoBiTec GmbH (Göttingen, 
Germany) 
FALGPA furylacryloyl-leucine-glycine-proline-
alanine; catalogue # F5135 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
HCl 1M VWR International GmbH 
(Darmstadt, Germany) 
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NaCl p.a. Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
Na2HPO4 1M VWR International GmbH 
(Darmstadt, Germany) 
NaN3 p.a. Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
NaOH 1M VWR International GmbH 
(Darmstadt, Germany) 
NH4Cl ammonium chloride VWR International GmbH 
(Darmstadt, Germany) 
NHS N-hydroxysuccinimide; catalogue # 
56480 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
PCA 3-carboxy-2,2,5,5-tetramethyl-1-
pyrrolidinyloxy; catalogue # 25,332-4 
Sigma Aldrich Chemie GmbH 
(Taufkirchen, Germany) 
sodium borate p.a. VWR International GmbH 
(Darmstadt, Germany) 
Tris*HCl Tris(hydroxymethyl)aminomethane VWR International GmbH 
(Darmstadt, Germany) 
Trypsin catalogue # 108919 Roche Diagnostics GmbH 
(Penzberg, Germany) 
Water demineralized water  
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Table 3-3 Buffer systems 
Buffer pH Composition 
Sodium borate buffer 8.8 0.1M sodium borate 
Tris buffer 6.8 1M Tris*HCl 
Tris buffer 7.5 0.05M Tris*HCl, 0.2M NaCl, 0.01 CaCl2* 2H2O, 0.01% NaN3 in 
water 
Tris buffer (D2O) 7.5 0.05M Tris*HCl, 0.2M NaCl, 0.01 CaCl2* 2H2O, 0.01% NaN3 in 
D2O 
 
 
3.2 Methods 
3.2.1 Matrix Preparation 
3.2.1.1 Collagen Powder 
Collagen powder was prepared by redispersion of lyophilized collagen material 
in water at 10% (w/w). The pH was adjusted to 7.4. After swelling at room 
temperature for 1h, the dispersion was centrifuged at 5000rpm (10°C, 10min). 
The residuum was split into portions of approximately 100mg, dried in a 
desiccator and finally dried under vacuum at 25°C. The dried material was 
ground with a Pulverisette 14 (Fritsch GmbH, Idar-Oberstein, Germany). 
Particle size was determined by sieve analysis and particles smaller than 
180µm were used.   
3.2.1.2 Collagen Minirods 
Minirods were prepared by using a micro twin screw extruder (MiniLab® Micro 
Rheology Compounder, Thermo Haake GmbH, Karlsruhe, Germany) (see 
Figure 3-1). Extrusion could be controlled by the operation panel or by PC 
(Polylab MiniLab® software). 
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Figure 3-1 MiniLab® Micro Rheology Compounder (Thermo Haake GmbH, Karlsruhe, Germany) 
 
Lyophilized collagen material was cut into pieces of approximately 0.25cm³. If 
pulverized collagen was used, the powder was inserted directly into the mini 
compounder. Without pre-swelling of the collagen pieces, the extruder was 
loaded with approximately 7g material by alternately adding collagen and water 
first pressure sensor 
second pressure sensor 
outlet  
temperature sensor  
for material 
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or an aqueous PCA-BSA or FITC dextran 20, 70 and 150 solution, respectively. 
Loading of the extruder was performed until the second pressure in the bypass 
can be monitored. After homogenization for approximately 5min at 20°C, a 
strand was extruded. Obtained rods contained approximately 40% (w/w) 
collagen and 4% (w/w) PCA-BSA or 0%, 1% and 2% (w/w) FITC dextran, 
respectively. Collagen strands were dried hanging at room temperature, 55% 
r.h. for 5d. Subsequently, the rods were cut into pieces of 20mg weight, 10mm 
length and 1.7mm diameter. For release studies rods of 20mm, 30mm and 
40mm length, respectively, and strands of 0.4mm, 0.8mm and 1.2mm diameter, 
respectively, were produced as well. Rods with reduced diameter were 
manufactured by fixing dies with a diameter of 0.5mm, 1mm and 1.5mm 
diameter, respectively, in front of the outlet (diameter 2mm). Minirods were 
stored in a desiccator (45% r.h.) at room temperature.  
3.2.1.3 DHT Cross-linking 
For dehydrothermal cross-linking (DHT), samples were placed in a vacuum 
chamber (Memmert GmbH & Co. KG, Schwabach, Germany) and the following 
DHT protocol (see Table 3-4) was applied.  
 
Table 3-4 DHT cross-linking program 
Step Time [h] Temperature [°C] Vacuum [mbar] 
Start  25 -- 
Initial drying 0.5 25 0.1 
Ramp  0.5 110 0.1 
DHT cross-linking 120 110 0.1 
Ramp  25 0.1 
End  25 -- 
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3.2.1.4 EDC Cross-linking 
Cross-linking with EDC was performed before collagen matrices were prepared. 
1% (w/w) collagen in water was adjusted to pH 3.5 with 1M HCl and pre-swollen 
for 1h. After dispersion for 10min with an Ultraturrax® (IKA-Werk, Staufen, 
Germany), the pH was adjusted to 5.1 with 1M Na2HPO4 and 10% stock 
solutions of EDC and NHS (molar ratio 5:2) were added. Four different 
collagen/EDC-ratios were used: 1g/0.0169mg, 1g/0.0677mg, 1g/0.2031mg and 
1g/1.15mg. The dispersion was homogenized and the reaction was performed 
for 2h at 25°C under pH-control. Subsequently, the pH was adjusted to 9.1 by 
adding 1M Na2HPO4 and 1M NaOH. After another 2h, the pH was adjusted to 
6.4 for both tendon materials and 6.6 for the bovine corium material, 
respectively, using 1M HCl. After 10 washing steps, using 100ml water each 
time, residues were lyophilized (see 3.2.1.5). 
3.2.1.5 Lyophilization 
Lyophilization was performed in a ε2-12D special freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany) with collagen 
dispersions of bovine corium raw material and all materials which were cross-
linked with EDC. Collageneous materials were cast in plastic Petri dishes 
(diameter: 10cm) to a height of 1cm. Samples were lyophilized according to the 
following program: 
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Table 3-5 Lyophilization program 
Step Time [h] Temperature [°C] Vacuum [mbar] 
Start  20 -- 
Ramp 2 -20 -- 
Freezing  2 -20 -- 
Ramp 3 15 0.1 
Primary drying 25 15 0.1 
Ramp 1 25 0.1 
Secondary drying 15 25 0.1 
 
   
3.2.2 Characterization of the Collagen Matrices 
3.2.2.1 Macroscopic Studies 
Pictures were taken with a Sony Cyber Shot 3.3 Mega Pixel camera. 
3.2.2.2 Scanning Electron Microscopy (SEM) 
Surface morphology of non-swollen and swollen minirods was investigated. 
Minirods were swollen without and with 0.1µg/ml (0.04 Mandl units/ml) bacterial 
collagenase at 37°C. After 2d, minirods were shock frozen in liquid nitrogen and 
subsequently lyophilized (see 3.2.1.5). Dry minirods were sputtered with carbon 
(MED 020 coating system, BalTec GmbH, Liechtenstein) and analyzed with a 
SEM XL-20 (Philips, Eindhoven, The Netherlands). 
3.2.2.3 Determination of Density  
Density of minirods was calculated from the determined weight and calculated 
sample volume.  
3.2.2.4 Karl-Fischer Titration 
Residual moisture in dried minirods was determined by Karl-Fischer titration 
using a titrator with Head-Space oven (Analytik Jena AG, Jena, Germany). 
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Sealed samples were fixed in the oven chamber and heated to 60°C for 30min. 
Vaporized water was transported into the Karl-Fischer cell, determined 
coulometrically and calculated as water amount in % (w/w). Measurements 
were carried out at least in duplicate. 
3.2.2.5 Differential Scanning Calorimetry (DSC)  
Samples were analyzed with a DSC 204 Phoenix machine (Erich Netzsch 
GmbH & Co. Holding KG, Selb, Germany). Samples (3-7mg) were incubated in 
1ml Tris buffer pH 7.5 at room temperature for at least 2h. Subsequently, 
samples were transferred in aluminum pans, 10µl buffer was added and 
containers were sealed. Samples were heated and cooled from 20 to 90°C at 
5°C/min. Analyses were performed in triplicate against an empty reference pan. 
For statistical analysis the t-test was applied (p<0.001). 
3.2.2.6 Swelling Studies 
Minirods of a length of 5mm were placed in a 24-well plate and incubated at 
37°C in Tris puffer pH 7.5 without, with 0.1µg/ml (0.04 Mandl units/ml) and with 
6.7µg/ml (2.06 Mandl units/ml) bacterial collagenase, respectively. For studies 
with collagenase, the enzyme was added after 30min swelling. The change in 
diameter was recorded with a digital video camera (JVC TK-C1380, JVC 
Professional Products GmbH, Friedberg, Germany; lens: Vivitar 55mm f2.8 
macro) and pictures were analyzed with an image analysis system (Comet-
Version 3.52a, Nikon GmbH) and Microsoft Photo Editor. Swelling was 
analyzed at least in triplicate. 
3.2.2.7 Pulsed Field Gradient Nuclear Magnetic Resonance Spectroscopy 
(PFG-NMR)  
The self-diffusion coefficient of water was determined by PFG-NMR coupled 
with magic angle spinning (MAS). Equine non cross-linked minirods were 
incubated at 37°C for 24h in a 10% (w/w) FITC dextran 70 solution in Tris buffer 
pH 7.5 (D2O) and in pure Tris buffer pH 7.5 (D2O), respectively, before NMR-
measurements were performed according to Pampel et al. (Pampel et al.; 
2002). Detection was conducted with a Bruker DMX 600 spectrometer operating 
at 600.13MHz for 1H. A Bruker 4mm HR-MAS probe was used which is 
3 Materials and Methods 63 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
equipped with 1H, 13C and 2H lock channels and pulsed field gradient 
capabilities. The investigation was performed at 37°C with a typical 90° pulse 
length of about 10.5µs, a rotating frequency of 3500Hz and a gradient pulse 
length of 1ms  with a diffusion time of 50ms. The maximal gradient strength 
(0.48T/m) was calibrated using a water-filled HR-MAS rotor by recording the 1H-
spectrum with the gradient on. The self-diffusion coefficient of water was 
monitored using the HDO signal at 4.57ppm. Progressive gradient strengths of 
4-85% of 0.48T/m were applied to obtain serial one-dimensional spectra, which 
were used to calculate the self-diffusion coefficient by plotting the integrated 
water signal intensity against the applied field gradient.  
3.2.3 Characterization of the Model Drugs 
3.2.3.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
SDS-PAGE was performed under non-reducing conditions using an XCell II 
Mini-Cell system (Novex, San Diego, USA). Samples were dissolved in Tris 
buffer pH 6.8 and heated for 15min at 95°C. After centrifugation, 10µl aliquots 
were loaded into NuPAGE® Novex 10% Bis-Tris Pre-Cast gels 1.0mm 
(Invitrogen GmbH, Karlsruhe, Germany). Gels were run with a constant current 
of 30mA in a MES running buffer (Invitrogen GmbH, Karlsruhe, Germany). After 
staining with a coomassie blue kit (Colloidal Blue Staining Kit; Invitrogen GmbH, 
Karlsruhe, Germany) according to the vendor’s protocol, the gels were dried 
using a DryEasy® Gel Drying System (Invitrogen GmbH, Karlsruhe, Germany). 
3.2.3.2 Fluorescence Correlation Spectroscopy (FCS) 
Diffusion coefficients of FITC dextran 20, 70 and 150 in water were measured 
by FCS with a ConfoCor 2 (Carl Zeiss GmbH, Jena, Germany). Experiments 
were performed with an Argon laser (488nm) at room temperature. A standard 
solution of 10nM Alexa488 (diffusion time 26µs) was used. Diffusion times were 
measured, analyzed with autocorrelation curves and converted into diffusion 
coefficients (Magde et al.; 1974). Diffusion coefficients at room temperature 
were converted by the Stokes-Einstein equation to diffusion coefficients at 
37°C. Measurements were carried out in triplicate. 
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3.2.4 Characterization of the Enzymatic Reaction 
3.2.4.1 Determination of Enzyme Activity 
The enzymatic activity of CHC was determined for 2 weeks by incubating 
10µg/ml (4 Mandl units/ml) collagenase in Tris buffer pH 7.5 at 37°C. The 
remaining enzymatic activity was determined in the supernatant by applying 
either a continuous FALGPA assay or the EnzCheck® assay kit. Time 
dependent activity of MMP-2 (19.1mg/ml or 1.67µg/ml dependent on the 
supplier), MMP-9 (6.8ng/ml) and CHC (0.1µg/ml) over 2h was determined by 
using the EnzCheck® assay kit only. Determinations were performed five fold. 
3.2.4.1.1 FALGPA Assay 
A specific activity assay for bacterial collagenase based on the enzymatic 
cleavage of FALGPA (Van Wart et al.; 1981) was used. The decrease in 
absorbance was measured over 6min at 345nm (25°C) using a 
ThermoSpectronic UV1 photometer (Thermo Electron Corporation, Egelsbach, 
Germany) and the change in absorption per minute was calculated.  
3.2.4.1.2 EnzChek® Gelatinase / Collagenase Assay Kit 
Activity of all three enzymes was investigated with the EnzChek® (MoBiTec 
GmbH, Göttingen, Germany) (Molecular Probes; 2001). Samples were 
incubated with DQ gelatin at room temperature, protected from light. Active 
enzymes cleave the fluorescent labeled gelatin and fluorescence was measured 
(493nm/518nm ± 10nm) after appropriated time intervals (MMP-2: 25h, MMP-9: 
1h, bacterial collagenase: 3h) by using a Cary Eclipse fluorimeter (Varian 
Deutschland GmbH, Darmstadt, Germany). 
3.2.4.2 Binding studies  
Unless otherwise noted, 2mg matrices were incubated at 37°C for 120min in 
1.1ml Tris buffer pH 7.5, containing 21ng or 1840ng (depending on the supplier) 
activated MMP-2, 7.5ng activated MMP-9 and 110ng bacterial collagenase, 
respectively. During incubation, samples from the supernatant were collected 
and analyzed at defined time points (0, 30, 60 and 120min). Bacterial 
collagenase binding was analyzed by two different assays. Binding of 
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gelatinases was determined by the EnzChek® only (see 3.2.4.1). For statistical 
analysis the t-test was applied (p<0.001). Data for the mathematical model was 
determined with 20mg minirods. Investigations were performed five fold. 
3.2.4.3 Sorption Studies 
Sorption studies were performed in Tris buffer pH 7.5 at 37°C. 20mg minirods or 
collagen powder was incubated with 5µg/ml (2 Mandl units/ml) collagenase. 
Over 24h, the remaining enzymatic activity in the supernatant was determined 
by using the EnzChek® and the adsorbed enzyme amount was calculated. To 
verify the amount of collagenase which is bound unspecifically in the matrix, 
samples were incubated for distinct time intervals and washed several times 
with Tris buffer pH 7.5. The supernatant and all washing solutions were 
investigated for remaining enzymatic activity. Furthermore, the sorption 
isotherm and sorption constants were determined. Different amounts of 
collagenase (2.5 – 30µg/ml) were incubated with minirods for 1h. The enzymatic 
activity in the supernatant was measured with the EnzChek® and the adsorbed 
enzyme amount was calculated. Analyses were carried out in triplicate. 
3.2.4.4 Determination of the Degradation Constants 
Samples, containing 5-200mg collagen powder or 5-100mg minirods were 
incubated with 0.1µg/ml (0.04 Mandl units/ml), 0.4µg/ml (0.16 Mandl units/ml), 
1.25µg/ml (0.5 Mandl units/ml) and 2µg/ml (0.8 Mandl units/ml) collagenase, 
respectively, at 37°C. Samples were taken periodically and stored at -80°C to 
stop the enzymatic degradation process. Degraded soluble collagen fragments 
were quantified by a BCA-assay (Smith et al.; 1985) at 562nm using a 
densitometer (CS 9301 PC; Shimadzu Corp., Tokyo, Japan). The amount of 
soluble collagen was calculated from a standard curve obtained with gelatin A 
180, because the standard BSA calibration curve can not be used for the 
determination of collagen fragments (Geiger; 2001; Smith et al.; 1985). The 
Michaelis-Menten constants and kcat’s were calculated. Investigations were 
performed in duplicate. 
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3.2.5 In vitro Degradation Studies 
10mm minirods were incubated in 2ml Tris buffer pH 7.5 at 37°C (20mm: 5ml; 
30mm: 7ml; 40mm: 15ml). After addition of 0.1µg/ml (0.04 Mandl units/ml) and 
6.7µg/ml (2.06 Mandl units/ml) collagenase, respectively, the complete 
incubation medium was replaced at designated time points. FITC dextran 
release (see 3.2.6.1) and collagen degradation were determined 
simultaneously. Supernatants were analyzed for soluble collagen fragments in 
96 well plates using the BCA assay (see 3.2.4.4). Degradation was determined 
in triplicate. 
3.2.6 In vitro Release Studies 
3.2.6.1 FITC Dextrans 
10mm minirods were incubated in 2ml Tris buffer pH 7.5 at 37°C (20mm: 5ml; 
30mm: 7ml; 40mm: 15ml). At designated time points, the complete incubation 
medium was replaced and the FITC dextran release and the matrix degradation 
(see 3.2.5) were determined simultaneously. FITC dextran release was 
determined by fluorescence measurement (495nm/525nm ± 10nm; Cary 
Eclipse fluorimeter (Varian Deutschland GmbH, Darmstadt, Germany)) in 96 
well plates. With respect to the development of the mathematical model, 
different experimental setups were performed. No collagenase, 0.1µg/ml (0.04 
Mandl units/ml) or 6.7µg/ml (2.06 Mandl units/ml) enzyme was added to the 
samples. Enzyme was added after 0.25h pre-swelling or after 6d FITC dextran 
release in absence of collagenase. FITC dextran release was analyzed in 
triplicate.  
3.2.6.2 BSA 
10mm minirods were incubated in 2ml Tris buffer pH 7.5 at 37°C with 0.1µg/ml 
(0.04 Mandl units/ml) or without collagenase. At designated time points, 
minirods were removed and the water film at the surface was removed carefully 
by blotting with an adsorbent paper. The samples were loaded into an 
eppendorf cap and placed inside the loop-gap resonator of an L-band ESR 
spectrometer (1GHz, RadicalScope mt 500-L, Magnettech GmbH, Berlin, 
Germany). Measurements were performed in triplicate at room temperature with 
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the following parameters: central magnetic field 49mT, sweep of the central 
magnetic field 15mT, microwave 3dB, frequence of modulation 100kHz, 
amplitude of modulation 0.14mT and scan time 30sec. 
3.2.7 In vivo Studies 
In vivo studies were conducted in adult domestic pigs. Six pigs were available 
and observations were made at six different time points (3, 5, 7, 14, 28 and 
56d). Minirods were implanted subcutaneously into the ear backs. For surgery 
protocol see Thorwarth et al. (Thorwarth et al.; 2005). One ear per pig was used 
for samples intended for ESR measurements and the other for histological 
investigations. After sacrificing, the ears were immediately frozen at -80°C.  
3.2.7.1 Electron Spin Resonance Spectroscopy (ESR) 
The frozen blocks were thawed and stippled into thin layer chromatography 
(TLC) capillaries for investigation of different parts of the explanted material. 
Distinction was made between interior and exterior parts of the minirods, tissue 
next (1-2mm) to and distant (>5mm) from the minirods and cartilage. Samples 
between day 5 and 56 were investigated. Measurements were performed with 
an X-band ESR spectrometer (9.3GHz, MiniScope MS 200, Magnettech GmbH, 
Berlin, Germany) at 37°C using the following parameters: central magnetic field 
335.6mT, microwave 10dB, amplitude of modulation 0.2mT and scan time 
30sec. Determinations were performed in triplicate.  
3.2.7.2 Histology 
Histological evaluations were also performed at day 3. The frozen blocks were 
thawed and fixed in paraffin and 4% formalin. For staining, specimens were 
dehydrated with an ascending alcohol series at room temperature and were 
intermediary fixed on Xylol. For a general overview, slides were stained with 
hemalaun and eosin (HE). Additionally, the sectioned samples were stained 
with antibodies against collagen type I, collagen type III, transforming growth 
factor (TGF) β and interleukin 1β, respectively. Stained samples were examined 
under a light microscope (Axiovert 25, Carl Zeiss AG, Göttingen, Germany) and 
pictures were taken with a Sony Cyber Shot 3.3 Mega Pixel camera. 
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3.2.8 Mathematical Discretization 
A mathematical model to describe drug release from collagen matrices 
undergoing enzymatic degradation was established.  For a numerical simulation 
the resulting equations were discretized in space by the mixed Raviart-Thomas 
finite element method of lowest order and in time by the backward Euler 
scheme. The mixed finite element method locally preserves mass which is an 
appreciable advantage of this approach. The equations are fully coupled and 
therefore solved simultaneously by a damped version of Newton's method. The 
linear systems of the Newton iteration are solved by a multigrid algorithm. 
Having determined the concentration of the collagen at the n-th time point, the 
drug release equation can be solved and it can be proceed to the next time 
step. The problem was implemented in the software package UG, version 3.8. 
Two dimensional simulations were performed on a SUN BLADE 100 
workstation. 
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4 Results and Discussion 
For the development of an adequate mathematical model, it is important to 
characterize physical and chemical changes of device properties during drug 
release (Siepmann et al.; 2001). Drug liberation from hydrophilic polymers like 
collagen is governed by different mechanisms (see 1.2.3). Before diffusion 
controlled release or release by enzymatic and/or non-enzymatic degradation 
can take place, swelling occurs after contact with aqueous incubation media 
(Gombotz et al.; 1995). Since dense collagen matrices were investigated in this 
study, it must also be dealt with a drug fraction whose delivery is hindered by 
the collagen matrix structure. This part can not to be released until collagen 
linkages are digested.  
4.1 Characterization of Collagen Matrices 
Initially, dry matrices and swelling of collagen matrices had to be analyzed, to 
define the fundamental features of the mathematical model. Furthermore, early 
stages of the drug device development were mainly based on swelling 
investigations (see 4.1.2.1).  
4.1.1 Characterization of Dry Collagen Matrices 
Monolithic implants often have a cylindrical shape and are commonly produced 
by extrusion (Kissel et al.; 1991). Extrusion of collagen is easy in handling and 
gentle for incorporated drugs, because neither heating, nor the use of organic 
solvents is required. In general, aqueous collagen masses can be extruded 
directly and resulting strands can be dried at room temperature (Fujioka et al.; 
1998). Collagen drug devices, named minirods, were prepared by extrusion of 
approximately 40% (w/w) aqueous collagen dispersions (water content of raw 
material: approximately 9% (w/w)). Resulting strands were dried for 5d at room 
temperature, 55% r.h. to obtain rods with approximately 1.7mm in diameter and 
10mm in length (see Figure 4-1).  
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Figure 4-1 Dry equine EDC 1 cross-linked collagen minirod 
 
The residual moisture of the hydrophilic matrix, determined by Karl-Fischer 
titration, is important with respect to the stability of potentially incorporated 
drugs. Furthermore, these values were necessary to feed the mathematical 
model and to determine release and degradation data correctly. After storage in 
a desiccator (45% r.h.) at room temperature, minirods had a residual water 
content of approximately 6% (w/w). No change in the water content was 
observed for cross-linked materials or if a model compound, e.g. FITC dextran 
or BSA, was incorporated. These results were in agreement with Kutz who 
investigated the water sorption of collagen hydrolysates (Kutz; 1988). He 
determined 8.5% (w/w) water content at 20°C/45% r.h. for Gelita Collagel®.   
4.1.1.1 Matrix Density 
The surface of dry extrudates was studied by scanning electron microscopy 
(SEM) (see Figure 4-2). The lateral surface of equine and bovine tendon 
materials was dense before contact with liquids. A parallel orientated surface 
pattern according to the direction of extrusion was observed, resulting from the 
stress applied during the extrusion process (Sano et al.; 2003). A similar 
surface morphology was observed for both tendon materials independent of 
cross-linking (see Figure 4-2a-d), whereas the lateral surface of bovine corium 
EDC 1 cross-linked minirods appeared slightly scalier (see Figure 4-2e-f). The 
cross-section looked similar for all minirods. A longitudinal orientation of 
collagen bundles and small cavities could be observed (see Figure 4-2g-h).  
 
 
approx. 10mm
approx. 1.7mm
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Figure 4-2 SEM micrographs of the surface of dry collagen minirods 
 a; b: lateral surface of equine non cross-linked minirods 
 c; d: lateral surface of equine EDC 1 cross-linked minirods 
 e; f: lateral surface of bovine corium EDC 1 cross-linked minirods 
 g; h: cross-section of bovine corium EDC 1 cross-linked minirods 
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Beyond optical investigations, the minirod density was calculated. In general,  
extruded devices show a density close to their particle density (Ghebre-
Sellassie; 2003). Consequently, the calculated density values had to be 
compared to an apparent collagen density of 1.32g/cm³ reported in the literature 
(Weadock et al.; 1984) and to an apparent density of 1.3g/cm³ determined for 
dense collagen minipellets (Maeda et al.; 1999). All minirods had lower 
densities than values reported in literature (see Table 4-1). Unloaded minirods 
showed densities between 1.008 and 1.109g/cm³. No significant differences in 
apparent density were observed for non cross-linked and EDC 1 cross-linked 
matrices and between collagen materials extracted from different animal 
sources. If minirods prepared from tendon collagen were loaded with FITC 
dextran, device density remained almost constant if FITC dextran 70 was 
incorporated (unloaded equine non cross-linked minirods: 1.098g/cm³, FITC 
dextran 70 loaded extrudates: 1.109g/cm³). The density decreased with a FITC 
dextran 20 load (0.983g/cm³) or a FITC dextran 150 load (0.899g/cm³). 
Increasing the FITC dextran 70 content to 2% (w/w) led also to a decrease in 
the apparent density of equine non cross-linked minirods (0.829g/cm³), as did 
the incorporation of FITC dextran 70 in bovine corium EDC 1 cross-linked 
matrices (0.927g/cm³). Thus, loading with FITC dextran affected the matrix 
structure and induced a reduced minirod density.  
In summary, the presented observations showed that the extrusion of high 
concentrated collagen masses was possible and yielded dense, homogeneous 
matrices with a highly orientated structure (resembling the structure of tendon 
(Maeda et al.; 1999)). Apparent densities were decreased compared to the 
apparent collagen density.  
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Table 4-1 Calculated apparent densities of collagen minirods 
Minirods Density [g/cm³] 
Bovine corium non cross-linked 1.008 
Bovine corium EDC 0.25 cross-linked (loaded with 1% FITC dextran 70) 0.717 
Bovine corium EDC 1 cross-linked 1.025 
Bovine corium EDC 1 cross-linked (loaded with 1% FITC dextran 70) 0.927 
Bovine corium EDC 3 cross-linked (loaded with 1% FITC dextran 70) 1.089 
Bovine tendon non cross-linked 1.075 
Bovine tendon non cross-linked (loaded with 1% FITC dextran 70) 1.055 
Bovine tendon EDC 1 cross-linked (loaded with 1% FITC dextran 70) 1.154 
Equine non cross-linked 1.098 
Equine non cross-linked pulverized 0.598 
Equine non cross-linked (loaded with 1% FITC dextran 70) 1.109 
Equine non cross-linked (loaded with 2% FITC dextran 70)  0.829 
Equine non cross-linked (loaded with 1% FITC dextran 20)  0.983 
Equine non cross-linked (loaded with 1% FITC dextran 150) 0.899 
Equine EDC 1 cross-linked 1.109 
Equine EDC 1 cross-linked (loaded with 1% FITC dextran 70) 1.011 
Equine EDC 1 cross-linked (loaded with 1% FITC dextran 20) 0.791 
Equine EDC 1 cross-linked (loaded with 1% FITC dextran 150) 0.804 
Equine EDC 3 cross-linked (loaded with 1% FITC dextran 70) 0.948 
Equine EDC 17 cross-linked (loaded with 1% FITC dextran 70) 0.999 
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4.1.1.2 Differential Scanning Calorimetry (DSC)  
In order to identify the midpoint of transition, also known as melting temperature 
(Tm) of the collagen devices, DSC investigations were performed. Knowledge of 
this temperature is important to understand the physicochemical changes 
during in vitro and in vivo tests and to avoid temperature induced variations 
during storage. Furthermore, the degree of cross-linking can be judged 
indirectly, because the melting point of swollen collagen samples raises with an 
increase in cross-linkages due to stronger interactions between collagen fibers 
(Frieß et al.; 1996a; Geiger; 2001). In the dry state, a Tm of approximately 
103°C was determined by Frieß (Frieß; 1999), indicating that collagen can be 
stored under dry conditions at room temperature without temperature induced 
changes. For fully swollen collagenous materials, incubated in Tris buffer pH 7.5 
before DSC analysis, an endothermal peak in DSC spectra between 40 and 
65°C was observed (see Figure 4-3, Figure 4-4 and Table 4-2). No additional 
peaks were detected during subsequent cooling and second heating (see 
Figure 4-3), indicating the complete and irreversible denaturation during the first 
run (Frieß et al.; 1996a).  
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Figure 4-3 DSC scan of a pre-swollen bovine corium EDC 1 cross-linked collagen minirod 
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The difference between Tm of dry and fully swollen collagen materials was in 
agreement with Kopp et al., who observed higher denaturation temperatures, 
when the water content of collagen matrices was reduced (Kopp et al.; 1989).  
DSC measurements of equine non cross-linked raw material and minirods (Tm 
(raw material) = 53.2°C ± 0.9°C and Tm (minirods) = 53.6°C ± 0.2°C) showed, 
that extrusion did not affect the denaturation temperature significantly 
(p>0.001). Overall, the observed thermal behavior corresponded to data 
presented by Piez, who proposed a single melting temperature at 55°C for 
homogeneous fibrillar collagen from rat tail tendon and calf skin (Piez; 1985).  
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Figure 4-4 Melting temperatures of bovine corium and equine collagen raw materials cross-
linked with different EDC ratios determined by DSC (average ± SD; n=3) 
 
EDC cross-linking resulted in an increase in the denaturation temperature 
(Pieper et al.; 1999) for all three investigated materials (see Figure 4-4 and 
Table 4-2). The upper limit of 17 was adapted from Olde Damink et al. (Olde 
Damink et al.; 1996b). Changing the cross-linking ratio of collagen is a potent 
tool to control the physicochemical properties of the manufactured delivery 
devices. Cross-linking is limited due to the number of reacting amino acids 
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(Frieß et al.; 1996a; Geiger; 2001). This could be manifested by an increase in 
Tm of EDC cross-linked collagens which leveled off between 62°C and 68°C 
(see Figure 4-4). Especially for preparation of equine EDC cross-linked 
matrices, ratios above 1 did not enhance stabilizing properties.  
 
Table 4-2 Melting temperatures, determined by DSC, of different kinds of collagen type I raw 
materials (average ± SD; n=3) 
Sample Tm [°C] 
Equine DHT cross-linked  52.0 ± 1.3 
Bovine tendon non cross-linked  50.8 ± 0.9 
Bovine tendon EDC 1 cross-linked  60.3 ± 0.7 
 
 
The Tm of equine DHT cross-linked material did not increase compared to non 
cross-linked collagen (see Table 4-2). This was also observed by Pieper et al. 
for bovine tendon collagen type I and it was concluded that no distinct matrix 
stabilization takes place due to simultaneous cross-linking and denaturation 
(Pieper et al.; 1999). Gorham et al. even determined a decreased Tm for bovine 
corium collagen cross-linked at 120°C compared to cross-linked materials at 
60°C, 80°C and 100°C, respectively. This was attributed to an increase in 
denaturation with increasing cross-linking temperatures (Gorham et al.; 1992).  
Natural cross-linking depends on animal species, animal age and type of tissue 
(Frieß; 1999). Two different bovine collagens were compared with the equine 
tendon collagen. One bovine material was extracted from corium (= bovine 
corium collagen), whereas the bovine tendon material is composed of tendon 
collagen. Compared to equine non cross-linked collagen, lower denaturation 
temperatures were determined for both bovine non cross-linked materials (Tm 
(equine material) = 53.2 ± 0.9°C; Tm (bovine corium material) = 39.4 ± 1.2°C 
and Tm (bovine tendon collagen) = 50.8°C ± 0.9°C). This indicated that these 
materials had a lower number of natural cross-links than the equine samples. 
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The decrease of Tm of bovine corium collagen compared to the bovine tendon 
material can be explained by a higher natural cross-linking in tendon than in 
corium, by different grades in purification and the different collagen fiber 
arrangement. In general, tendon materials consists of almost exclusively 
collagen type I after extraction and collagen fibers are orientated in parallel, 
whereas collagen materials extracted from skin may still contain remainders of 
other protein components and the fibers are arranged across each other 
(Gilbert; 1988b; Ruszczak et al.; 2003). Geiger detected denaturation 
temperatures of 55 – 59°C for insoluble bovine tendon non cross-linked 
collagen type I, similar to our bovine tendon collagen material. The variation in 
Tm was attributed to different cross-linking protocols (Geiger; 2001). Due to the 
low Tm and an onset temperature of 32.1 ± 0.5°C, bovine corium non cross-
linked collagen devices are less suitable for preparing drug delivery devices, 
because during incubation at 37°C physicochemical properties change and no 
constant release conditions can be provided for the complete investigation 
interval. Hence, this type of collagen was only used as cross-linked material in 
further investigations. 
4.1.2 Transport of Water in Collagen Matrices 
After characterization of the collagen material and the dry collagen matrices, the 
behavior in aqueous environment was investigated. Since collagen is a 
hydrogel, which swells after contact with water, the water penetration was 
studied in more detail. 
4.1.2.1 Swelling of Collagen Matrices  
Diffusion controlled drug release can be restricted e.g. by cross-linking, 
increasing the polymer concentration or by increasing the matrix dimensions 
(see 1.2.3.1). If swelling of collagen devices is minimized, a denser matrix 
structure is preserved longer and the release can be reduced due to a tighter 
diffusion barrier (Fujioka et al.; 1995; Sano et al.; 2003). Consequently, besides 
changing the matrix dimensions, variations in swelling properties and cross-
linking ratios can be used to control release rates. The exclusion criterion in 
early matrix development was the swelling behavior in pure Tris buffer pH 7.5 at 
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37°C. The influence of bacterial collagenase (CHC) on swelling behavior was 
investigated as well, to gain information about the interplay of swelling and 
enzymatic degradation which is important for fitting the mathematical model 
(see 4.5). 
4.1.2.1.1 Swelling Without Addition of Collagenase 
Since tablets, produced by dry compaction, disintegrated already after 0.75h 
incubation at 37°C, further drug delivery devices were produced by extrusion. In 
general, minirods exhibited a two stage swelling process (see Figure 4-5). After 
fast initial swelling, a first plateau mostly of constant diameter and weight was 
reached, during which water distribution within the device takes place. This was 
followed by a second swelling phase, occurring more slowly than the first one, 
which is characterized by rearrangement of collagen structures (Frieß et al.; 
1996b). After reaching the second plateau, the minirods started to disintegrate.  
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Figure 4-5 Schematic swelling process, demonstrated on the swelling profile of bovine corium 
EDC 1 cross-linked collagen minirods in Tris buffer pH 7.5 at 37°C (average ± SD; 
n=3) 
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Initially, two preparation methods were tested: minirods were prepared with 
pulverized equine non cross-linked collagen (particle size < 180µm) or with the 
lyophilized raw material. Swelling can be reduced compared to tablets, but still 
was too pronounced for minirods prepared from the pulverized collagen 
material. As can be seen in Figure 4-6, minirods disintegrated already after 5h. 
To obtain powdered collagen, lyophilized raw material must be dispersed in 
water, subsequently air dried and finally grinded. Strong intra- and interhelical 
interactions resulted, which led to dense and hard matrices. These were 
transferred into particles by milling. Prior to extrusion, collagenous powder was 
hydrated again. But the dense particles showed only minor swelling and no 
homogeneous viscous collagen mass could be produced. Ductile deformation 
was also reduced which resulted in poor collagen cohesion during extrusion. 
Hence, interconnection inside the extrudates were less compared to minirods 
prepared directly from lyophilized collagen raw material (see Figure 4-6).  
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Figure 4-6 Swelling profiles of equine non cross-linked collagen minirods prepared from 
lyophilized and pulverized material in Tris buffer pH 7.5 at 37°C (average ± SD; n=3) 
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This could also be manifested by the calculated apparent densities (see Table 
4-1). Minirods composed of lyophilized collagen showed a density of 
1.098g/cm³, whereas pulverized starting material led to extrudates with a 
density of 0.598g/cm³. Hence, further minirods were manufactured directly from 
raw material. Minirods prepared from lyophilized equine collagen reached their 
first swelling plateau after 5h and remained at this level for another 18h. 
Subsequently, a swelling rate of 0.008/h was observed before the second 
swelling equilibrium was entered (see Figure 4-6).  
For comparison, extrudates containing atelocollagen which were prepared by 
Japanese groups were used (Fujioka et al.; 1995). These extrudates are named 
minipellets. Swelling at 37°C was investigated for 24h (Maeda et al.; 1999). A 
fast swelling during the first 3h was observed, before the diameter and weight 
remained constant over the next 24h (increase in diameter: 50–100%, maximal 
change in weight: approximately 300%). The swelling profile and the change in 
weight during the 24h were almost similar to our minirods. However, swelling of 
our minirods was slightly delayed and less pronounced (60% increase in 
diameter at the first swelling plateau after 5h) and the matrices disintegrated 
later than the Japanese minipellets. As was demonstrated by Fujioka et al. 
(Fujioka et al.; 1995) and Maeda et al. (Maeda et al.; 1999), the swelling rate of 
collagen drug devices is influenced by the manufacturing and drying method 
and the concentration of the basic collagen dispersion. The Japanese 
minipellets, as well as our minirods, were prepared by extrusion and 
subsequent air drying. They differ in the used collagen, insoluble equine 
collagen type I and soluble atelocollagen (dermal bovine collagen type I with 
removed telopeptides) for minirods and minipellets, respectively, and in the 
collagen concentration (40% (w/w) versus 30% (w/w) collagen). The slightly 
delayed swelling of our minirods can be attributed to the higher degree in 
natural cross-links and the higher concentration of collagen. In contrast to 
minipellets, our minirods showed significant longitudinally (l/lo=1.3 after 24h) 
and diagonally swelling. Since the swelling direction is related to the direction of 
shrinkage during drying (Maeda et al.; 1999), it was consistent that minirods 
swelled in both directions, because during drying a uniform shrinkage of 
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approximately 0.85 in length (l/lo) and diameter (d/do) was observed. Minipellets, 
prepared by the Japanese group, were dried lying on a plate and consequently 
only shrinkage in diameter was detected (Maeda et al.; 1999).   
To investigate the influence of natural cross-linking on the swelling behavior, 
three different collagen qualities were used to prepare minirods. As was already 
demonstrated by DSC analysis (see 4.1.1.2), natural cross-linking in tendon is 
more pronounced than in corium, and equine collagen is more cross-linked than 
the two bovine materials. The fast swelling of the bovine corium material 
corresponded to the low Tm (Tm (bovine corium) = 39.4 ± 1.2°C) and the slightly 
lower apparent matrix density (see Table 4-1). Since an onset temperature of 
32.1 ± 0.5°C was measured, matrix disintegration started almost 
instantaneously after contact with buffer at 37°C. This manifested itself in a very 
short equilibration time (1h) and a fast rearrangement of the collagen structures 
before disintegration of the minirods started after approximately 10h (see Figure 
4-7).  
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Figure 4-7 Swelling profiles of non cross-linked collagen minirods prepared from different 
collagen sources in Tris buffer pH 7.5 at 37°C (average ± SD; n=3) 
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Due to a higher natural cross-linking degree in tendon, the collagen fiber 
structure is closer and penetration of the incubation medium is more hindered 
(Frieß et al.; 1996b). Bovine tendon extrudates showed a smaller increase in 
diameter than bovine corium minirods (1.4 compared to 1.8) during the first 
swelling phase (see Figure 4-7). This observation was consistent with the 
slightly higher calculated apparent matrix density (see Table 4-1) and the higher 
Tm (see 4.1.1.2) for the bovine tendon material. Natural cross-linking is even 
more pronounced in the equine collagen, because this material is in general 
prepared from older animals (Schlapp; 2001). Since the two dry tendon 
matrices had almost the same apparent density (see Table 4-1), the first 
swelling phase was similar for both minirods. The difference in number of 
natural, age-depending cross-links became apparent in the second swelling 
phase. Equine minirods exhibited a second swelling rate over 140h with 
0.008/h, whereas bovine tendon matrices had a swelling rate of 0.021/h for 77h. 
This indicated that an increase in cross-links delayed the rearrangement of 
collagen structures by fixation of collagen fibers (Frieß et al.; 1996b). Based on 
the observed swelling behavior, both tendon collagen variations appeared to be 
suited as matrix material for drug delivery devices in the non cross-linked state. 
In order to further improve mechanical properties and reduce swelling, collagen 
was additionally cross-linked. Two different methods were carried out. Physical 
cross-linking was performed by DHT treatment after extrusion. During DHT 
cross-linking, interchain bonds are formed throughout the matrix by reducing the 
distances between neighboring molecules (Wang et al.; 1994; Weadock et al.; 
1984). However, this method is accompanied by partial denaturation (Weadock 
et al.; 1996). Since this treatment results in fixation of the three dimensional 
collagen network without destruction of the triple helix (Weadock; 1986), it can 
only be performed with the final drug loaded minirods. In contrast, collagen was 
cross-linked with EDC before extrusion. Raw material was swollen and 
incubated with the cross-linking reagents. EDC diffuses into the collagen matrix 
and reaction times between 1h and 7h are sufficient to achieve a homogeneous 
cross-linking structure (De Paoli Lacerda et al.; 2005). EDC cross-linking results 
in intra- and interhelical, but no intermicrofibrillar, linkages (Zeeman et al.; 
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1999). After drying, the cross-linked material was extruded and loaded with 
drugs. If this preparation step would be performed with loaded minirods, side 
reactions with incorporated drug molecules and drug depletion due to diffusion 
processes may occur.  
The effect of EDC cross-linking on swelling behavior was investigated with 
bovine corium collagen minirods (see Figure 4-8). At a low cross-linking ratio 
(EDC 0.25), the first swelling rate was similar to non cross-linked minirods, but 
water equilibration required more time. The second swelling rate occurred at 
less than half the rate of non cross-linked matrices (0.076/h compared to 
0.195/h) and took place over a longer time period. This reflected the hindered 
rearrangement of the collagen structure (Frieß et al.; 1996b) and corresponded 
to the higher Tm detected for the cross-linked minirods (see Figure 4-4). 
However, this slight cross-linking did not lead to a pronounced improvement of 
the mechanical properties of the matrices. If the cross-linking degree was 
further increased, a decrease in the amount of penetrating solvent and in 
swelling were detected. These effects were described in literature as well 
(Charulatha et al.; 2003; Frieß et al.; 1996a; Frieß et al.; 1996b; Radu et al.; 
2002; Rehakova et al.; 1996). The extent of the first swelling plateau was 
reduced by increased cross-linking, as was already observed for different 
degrees in natural cross-linking (see Figure 4-7). During the first swelling phase, 
EDC 1 and EDC 3 cross-linked minirods showed similar swelling, whereas 
differences could be detected by entering the second swelling phase (see 
Figure 4-8). The second swelling rate of EDC 1 cross-linked matrices (0.009/h) 
was similar to the swelling rate of equine non cross-linked minirods (see Figure 
4-7). Since the swelling ratio correlates inversely to the cross-linking density 
(Pek et al.; 2003), the number of cross-links for both materials was comparable 
(Weadock et al.; 1984). DSC data (see Figure 4-4) indicated a similar tendency, 
because melting temperatures were approximately the same (Tm (equine non 
cross-linked material) = 53.2 ± 0.9°C and Tm (bovine corium EDC 1 cross-linked 
collagen) = 55.2°C ± 1.1°C). With further cross-linking, more collagen fibers 
were fixed through intra- and interhelical linkages and structure rearrangement 
was further delayed. This became apparent in a lower swelling rate (0.002/h) of 
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EDC 3 cross-linked extrudates. Comparison to equine material showed that the 
bovine corium EDC 3 cross-linked swelling rate was similar to the swelling rate 
of equine EDC 1 cross-linked minirods (see Figure 4-9) as were their 
denaturation temperatures (Tm (equine EDC 1 cross-linked material) = 62.2 ± 
2.1°C and Tm (bovine corium EDC 3 cross-linked collagen) = 66.3°C ± 2.3°C). 
Hence, more additional cross-links had to be introduced into the bovine corium 
raw material to receive materials which are equally stabilized as the equine 
material.  
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Figure 4-8 Influence of the cross-linking ratio on the swelling of bovine corium EDC cross-
linked collagen minirods in Tris buffer pH 7.5 at 37°C (average ± SD; n=3) 
 
Variation in EDC cross-linking degree was also investigated for equine 
minirods. Due to the higher number in natural cross-links, ratios higher than 
EDC 1 had no additional positive effect on the minimization of swelling, because 
the maximal number in cross-links was already reached. The same conclusion 
could be drawn from DSC data (see Figure 4-4). A similar saturation effect was 
observed by Frieß et al. for differently GTA cross-linked bovine collagen films 
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(Frieß et al.; 1996b) and by Geiger for EDC, GTA and HMDIC (hexamethylene-
diisocyanate) cross-linked bovine collagen sponges (Geiger; 2001). 
The influence of DHT cross-linking on the swelling behavior was examined for 
equine minirods. Both cross-linking procedures, EDC and DHT treatment, 
reduced strongly swelling compared to non cross-linked minirods (see Figure 
4-9). The first swelling phase was almost similar for both cross-linked materials 
resulting in an increase of diameter to approximately d/d0=1.2 after 1h. The 
subsequent water equalization in EDC devices was slower than in DHT 
minirods (154h compared to 28h). EDC cross-linked minirods showed a second 
swelling rate (0.002/h) and a second plateau at d/d0=2, which was higher than 
that of DHT minirods (0.001/h, d/d0=1.5). This difference could be explained by 
the fixed three dimensional matrix structures after DHT treatment, which limit 
the rearrangement of collagen structures. EDC cross-linked minirods retained 
their flexibility, because no stabilizing intermicrofibrillar cross-links were 
introduced (Zeeman et al.; 1999) and a faster structure rearrangement could be 
detected. The less pronounced swelling of DHT treated collagen was in 
agreement with Pieper et al., who observed a reduced water binding capacity 
compared to non cross-linked or EDC cross-linked collagen (Pieper et al.; 
1999). Wang et al. also observed a reduced swelling ratio of DHT collagen and 
attributed this phenomenon to occupied or removed water binding sites and to a 
more hindered water penetration into the dense matrix structure. The 
interfibrillar slipping is limited and the matrix is fixed three-dimensionally (Wang 
et al.; 1994). Geiger and Gorham et al. concluded that DHT treatment with 
increasing temperatures results in lower collagen solubility and consequently in 
increased collagen hydrophobicity (Geiger; 2001; Gorham et al.; 1992). The 
second swelling rate of cross-linked matrices was significantly lower than that of 
non cross-linked minirods due to fixation of collagen fibers and consequently 
slower rearrangement of the collagen inner structures (Frieß et al.; 1996b). This 
was consistent with DSC observations, because higher Tm-values were 
determined for equine EDC 1 cross-linked collagen than for the non cross-
linked material. Tm of equine DHT treated collagen was almost similar to that of 
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the non cross-linked material, because of partially collagen denaturation (see 
1.2.1.2 and 4.1.1.2).     
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Figure 4-9 Influence of the cross-linking method on the swelling of equine collagen minirods 
in Tris buffer pH 7.5 at 37°C (time points indicate start of the second swelling 
phase) (average ± SD; n=3) 
 
Summarizing the presented results showed that swelling of minirods can be 
controlled by different ways. Starting with non cross-linked collagen material 
demonstrated that swelling could be suppressed by preparing extrudates from 
lyophilized raw material instead from pulverized material. Furthermore an 
effective tool to control the swelling properties of minirods was to use different 
insoluble collagen type I flavors which vary in their natural cross-linking degree. 
Least swelling was obtained with equine tendon material. To further reduce 
swelling, two different cross-linking methods were investigated. DHT treated 
minirods showed less swelling than EDC cross-linked extrudates. However, 
EDC cross-linked material was used in further experiments, since EDC cross-
linking was performed prior to drug loading and preparation of minirods without 
damaging the drug as compared to the 110°C treatment of drug loaded 
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matrices. Increasing the EDC cross-linking ratio resulted in maximal stabilizing 
effects for a ratio of 1. 
4.1.2.1.2 Swelling in the Presence of Collagenase 
In vivo and in vitro drug release depends on swelling and enzymatic matrix 
degradation (see 1.2.3). Therefore, water uptake was studied in the presence of 
0µg/ml, 0.1µg/ml (0.04 Mandl units/ml) and 6.7µg/ml (2.06 Mandl units/ml) 
bacterial collagenase, respectively. Different enzyme concentrations were used, 
because the in vivo concentration of collagenase is not constant in all tissues 
and changes with disease (Parks; 1999). For example, intestinal collagenase 
(MMP-1) is increased 65-fold in chronic foot ulcers compared to traumatic 
wounds (Lobmann et al.; 2002). In vivo / in vitro - correlation of collagenase 
concentration is not well documented in the literature. Okada et al. investigated 
the degradation of Catgut (Okada et al.; 1992a) and found a correlation 
between in vivo and in vitro concentration of bacterial collagenase of 2.5µg/ml. 
But data for enzymatic activity of CHC was missing and therefore, adaptation of 
this concentration had to be handled with care. Frieß set 2.5 µg/ml (1.15 Mandl 
units/ml) as in vitro concentration and concluded after subcutaneous 
implantation of dense collagen matrices in mice, that this concentration was 
chosen too high to receive good in vivo / in vitro – correlation of degradation 
rates (Frieß; 1999). Another approach was made by Yannas et al., who 
investigated the degradation of bovine tendon collagen tapes (Yannas et al.; 
1975). Good in vivo / in vitro - correlation was found by using 3.5 Mandl units/ml 
bacterial collagenase. Nevertheless, this enzymatic concentration appeared to 
be extremely high. To bracken the range of possible concentrations of 
collagenase, two extreme enzymatic concentrations were used to observe the 
influence of enzymatic degradation on swelling. 6.7µg/ml collagenase was set 
as the high end enzymatic concentration due to fast matrix degradation and 
simple preparation by dilution. 0.1µg/ml collagenase was chosen as minimal 
concentration, because this concentration still allowed investigations of 
enzymatic activity with the EnzCheck® (detection limit: 7ng/ml (Molecular 
Probes; 2001), see 4.2.1 and 4.2.2). 
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Figure 4-10 Swelling profiles of equine non cross-linked collagen minirods in the presence of 0, 
0.1 and 6.7µg/ml bacterial collagenase, respectively, at 37°C (time point indicates 
point of separation in swelling profiles between 0 and 0.1µg/ml enzyme) (average ± 
SD; n=3) 
 
In general, penetration of collagenase can be considered to be very slow due to 
adsorption phenomena (see 4.2.2.4) and slow diffusion through the dense 
matrix structure. As can be seen in Figure 4-10, the influence on swelling 
behavior could be neglected for the first 3d for low enzymatic concentrations 
which were used in release and degradation studies. The second swelling rate 
was more than doubled when minirods were incubated with 0.1µg/ml 
collagenase (0.02/h compared to 0.008/h). Due to enzymatic degradation of 
cross-links, minirods became less dense and a faster rearrangement of the 
collagen fibers could take place. If incubation was performed with higher 
concentrations of collagenase, extensive degradation overlaid swelling and the 
swelling behavior could not be followed anymore. The matrix became less 
dense due to simultaneous pronounced cleavage of collagen fibrils and the 
second swelling rate of 0.064/h indicated a fast collagen fiber rearrangement. 
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The maximum in matrix diameter (d/d0=2.1) was already reached after 12h, 
followed by disintegration of the minirods (see Figure 4-10).  
Since incubation of equine non cross-linked minirods showed no distinct 
difference in swelling kinetics during the first 3d if collagenase was present or 
not, the effect of 0.1µg/ml collagenase on the swelling behavior of EDC 1 cross-
linked minirods was also investigated. The first swelling phase followed the 
same profile for experiments without and with 0.1µg/ml collagenase, resulting in 
a plateau of d/d0=1.25 for equine EDC 1 cross-linked minirods and 1.4 for 
bovine corium EDC 1 cross-linked extrudates, respectively. As was already 
observed for equine non cross-linked minirods (see Figure 4-10), differences 
occurred in the second swelling phase. Again, the swelling rate increased by a 
factor of more than 2 when collagenase was added (bovine corium EDC 1: 
0.024/h to 0.009/h; equine EDC 1: 0.004/h to 0.002/h). 
Changes in surface morphology during swelling were investigated by SEM. The 
orientated structure of equine non cross-linked minirods was preserved during 
incubation in Tris buffer pH 7.5 at 37°C. Compared to dry minirods (see Figure 
4-2), the surface was more porous, the collagen material was defibrated (Sano 
et al.; 2003) and collagen strands stuck out of the minirod surface (see Figure 
4-11a, c). Minirods, exposed to 0.1µg/ml collagenase, also exhibited a smoother 
surface (see Figure 4-11b, d). Fringed collagen fiber bundles were missing, 
because they could be easily reached by collagenase, degraded and removed. 
Additionally, very small pores could be observed beneath the first surface layer, 
indicating that the enzyme attacked collagen inside the swollen device as well. 
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Figure 4-11 SEM micrographs of the lateral surface of equine non cross-linked collagen minirods 
after 2d swelling at 37°C 
 a; c: without collagenase 
 b; d: in the presence of 0.1µg/ml collagenase 
 
The cross-section of minirods incubated with collagenase exhibited larger pores 
than minirods swollen in pure buffer (see Figure 4-12). 
 
Figure 4-12 SEM micrographs of the cross-section of equine non cross-linked collagen minirods 
after 2d swelling at 37°C 
 a: without collagenase 
 b: in the presence of 0.1µg/ml collagenase 
b a 
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4.1.2.2 Diffusion Coefficient of Water in Minirods 
The self-diffusion coefficient of water in equine non cross-linked collagen 
minirods was determined by PFG-NMR (pulsed field gradient nuclear magnetic 
resonance) coupled with magic angle spinning (MAS) to receive a higher 
spectral resolution. The resulting 1H NMR spectrum is shown in Figure 4-13.  
 
 
Figure 4-13 1H NMR spectrum of water in equine non cross-linked minirods  
 
The signal of water appears at 4.57ppm. A self-diffusion coefficient of 5.76*10-2 
cm²/h inside the minirods was obtained by plotting the integrated water signals 
against the applied field gradient (see Figure 4-14). The determined self-
diffusion coefficient was in the range of the water self-diffusion coefficient in 
cartilage, e.g. determined as 7.0*10-2cm²/h by Knauss et al. (Knauss et al.; 
1999), and the self diffusion coefficient of bulk water in hydrated collagen 
(7.92*10-2cm²/h) (Traore et al.; 2000). This indicated that the matrix structure of 
equine non cross-linked collagen minirods resembles the composition of 
cartilage, as was already demonstrated by Maeda et al. for minipellets 
containing atelocollagen (Maeda et al.; 1999). Compared to the diffusion 
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coefficient of pure water (8.64*10-2cm²/h) (Pampel et al.; 2002), the diffusion of 
water inside the collagen minirods was only slightly restricted 
(D(solution)/D(minirod)=0.67). Hence, water interacts with the collagen 
structures during swelling and its mobility becomes restricted.    
 
 
Figure 4-14 Determination of the self-diffusion coefficient of water in equine non cross-linked 
minirods (the slope is equivalent to the self-diffusion coefficient) 
 
In an attempt to measure the self-diffusion coefficient of FITC dextran 70 inside 
equine non cross-linked minirods by PFG-NMR, the matrices were pre-swollen 
in Tris buffer pH 7.5 (D2O) containing 10% (w/w) FITC dextran 70. However, the 
used MAS setup does not provide a gradient strength which enables the 
detection of the rather slow diffusing FITC dextran 70. If the minirods were 
loaded using the highly concentrated dextran solution, the rotational 
experimental setup made the unambiguous detection impossible, because the 
FITC dextran 70 solution was squeezed out of the collagen matrix during the 
diffusion measurement. In minirods pre-swollen in pure Tris buffer pH 7.5 (D2O), 
the FITC dextran 70 concentration was too low to be detectable (see Figure 
4-13). In conclusion, the applied experimental setup was not adequate for the 
measurement of FITC dextran 70 diffusion in dense collagen minirods. 
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4.1.3 Summary 
Collagen is a member of the group of hydrophilic biodegradable polymers and 
swells in contact with aqueous solutions. It is important to investigate the 
physicochemical properties of collagen devices for a correct description and 
modeling of drug release. Implant manufacturing was optimized in the early 
matrix development stages mainly on data obtained by DSC and swelling 
investigations. Except for bovine corium non cross-linked collagen (Tm=39.4 ± 
1.2°C) all materials have a Tm above 40°C, indicating that these kinds of 
collagen were stable during in vivo and in vitro examinations and could be used 
to prepare drug devices. Implants, prepared by extrusion, exhibited a highly 
orientated collagen fiber bundle structure, according to the direction of 
extrusion, which was even preserved during swelling. Water uptake was 
reduced, matrix disintegration delayed and diffusion barriers for drug release 
were maintained longer than e.g. in compressed tablets. 
Different collagen type I materials were compared and it was concluded from 
swelling and DSC analysis that the number of natural cross-links is lower in 
corium than in tendon collagens and increases with animal age (Tm (equine 
material) = 53.2 ± 0.9°C, matrix disintegration after 24d; Tm (bovine tendon 
collagen) = 50.8°C ± 0.9°C, matrix disintegration after 12d; Tm (bovine corium 
material) =: 39.4 ± 1.2°C, matrix disintegration after 0.5d). The mechanical 
stability of collagen minirods was further enhanced by additional cross-links, 
introduced by physical (DHT) or chemical (EDC) treatment. Although lesser 
swelling was observed for DHT cross-linked matrices (DHT: swelling rate of 
0.001/h, second plateau at d/d0=1.5; EDC: swelling rate of 0.002/h, second 
plateau at d/d0=2), EDC cross-linked extrudates were used in further 
experiments, because incorporated drugs may be damaged by the high 
temperatures applied during DHT treatment. Increasing the molar EDC cross-
linking ratio led to an increase in number of cross-links. This was accompanied 
by an increase in Tm (e.g. Tm (bovine corium collagens): EDC 0 = 39.4 ± 1.2°C; 
EDC 0.25 =: 46.0 ± 0.5°C; EDC 1 =: 55.2 ± 1.1°C; EDC 3 = 66.3 ± 2.3°C) and a 
delay and reduction in swelling (matrix disintegration of bovine corium collagens 
after 0.5d (EDC 0); after 1d (EDC 0.25), after 10d (EDC 1) and after 9.5d (EDC 
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3), respectively). However, this effect was limited by available cross-linking 
sites, especially for the equine collagen, at a ratio of 1.  
To obtain deeper insight into the behavior of water inside the minirods, the self-
diffusion coefficient was determined by pulsed field gradient nuclear magnetic 
resonance (PFG-NMR). The self-diffusion coefficient inside the matrices was 
decreased compared to the self-diffusion coefficient in solution 
(D(solution)/D(minirod)=0.67), because water interacts with the collagen 
structures during swelling. 
In summary, the presented data showed that the swelling properties of collagen 
drug delivery devices, and in consequence the diffusion barriers delaying the 
drug release, could be controlled by using different collagen type I materials 
and/or by introducing additional cross-links. For release and degradation 
studies, collagen matrices will be prepared by extrusion with either non cross-
linked or EDC 1 cross-linked, lyophilized, non-grinded collagen. A concentration 
of 0.1µg/ml CHC will be used in the in vitro investigations to simulate in vivo 
conditions.  
For development and implementation of the mathematical model of drug 
release from dense collagen matrices, an initial water content of 6% (w/w) of dry 
minirods and swelling data of minirods incubated in pure buffer were used, 
because of a similar swelling behavior in the presence of low bacterial 
collagenase concentrations.  
4.2 Characterization of Degradation 
Besides swelling, the second reason for changes in matrix dimensions is 
degradation of the collagenous matrix material. Especially release from devices 
with a higher cross-linking density is also controlled by erosion. Because of this 
important influence, matrix digestion by collagenases and gelatinases was 
studied in more detail to collect data for feeding the mathematical model (see 
4.5). The most important group of MMPs which is responsible for collagen 
degradation is the group of collagenases. Enzymatic cleavage of insoluble 
substrates can only occur after enzyme adsorption (see 1.3.1). Binding to 
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different collagen matrices, including determination of sorption isotherms had to 
be investigated, before the degradation constants were determined. These data 
were used to fit and verify the mathematical model presented in section 4.5. 
Beyond these detailed investigations for collagenase, loss in activity and 
binding to several matrices were examined for human gelatinase A (=MMP-2) 
and human gelatinase B (=MMP-9). In former times, it was assumed that 
gelatinases can not cleave the helical parts of collagen and that they initiate 
only the second step of collagen digestion, the degradation of collagenous 
fragments into amino acids (see 1.2.2.2). But Okada et al. demonstrated that 
“MMP-9 plays a key role in the initial depolymerization step of collagen fibrils” 
by attacking the telopeptides of collagen type I (Okada et al.; 1995). Aimes et al. 
were able to proof that MMP-2 can cleave collagen type I even within its helical 
parts (Aimes et al.; 1995) Consequently, nowadays the synergistic action of 
collagenases and gelatinases is assumed to be important for in vivo collagen 
cleavage. Another reason for expanding the investigations was the important 
role of MMP-2 and MMP-9 in wound healing, especially their behavior in chronic 
wounds. Delayed healing often corresponds with an elevated level of gelatinase 
A and B (Trengove et al.; 1999; Wysocki et al.; 1993). 
4.2.1 Time Dependency of Activity of MMPs 
Enzymes loose their activity during in vitro incubation (Cullen et al.; 2002a), 
depending on buffer system and temperature. In vivo this loss is not as 
important as in vitro due to continuous re-production. Consequently, the time 
dependency of enzymatic activity had to be taken into account, especially if 
sorption and degradation studies were performed over longer time periods. In 
the mathematical model (see 4.5), this degradation kinetics was incorporated to 
overcome the difference between in vitro – in vivo circumstances. 
The loss in activity of bacterial collagenase during incubation was determined 
by two different activity assays (an assay with FALGPA (furylacryloyl-leucine-
glycine-proline-alanine) and the EnzCheck®). After 24h incubation at 37°C in 
Tris buffer pH 7.5, enzymatic activity was reduced to 90% of the initial activity. 
Subsequently, the activity decreased to 80% after 48h and remained constant 
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at this level over 2 weeks (see Figure 4-15). This was in agreement with Olde 
Damink who determined a loss in enzymatic activity of 10% after incubation for 
24h and 30% loss after 48h incubation at 37°C (Olde Damink et al.; 1995). The 
loss in enzymatic activity corresponded also to observations from Soru et al., 
who reported that collagenase was stable at least for one hour at 40°C and 
assumed that after 24h at this temperature 20% of activity was lost (Soru et al.; 
1972). 
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Figure 4-15 Time dependence of the activity of 10µg/ml bacterial collagenase at 37°C, 
determined by FALGPA and EnzChek® analysis, respectively (average ± SD; n=5) 
 
Human MMPs are secreted in vivo as zymogens (see 1.2.2.2). During 
activation, an approximately 10kDa fragment is cleaved (Overall; 1991). In vitro, 
human MMPs have to be activated as well; commercially available zymogens of 
MMP-2 by reaction with APMA (p-aminophenylmercuricacetate) and MMP-9 
with trypsin / aprotinin. For organomercurial agents, chelating with the 
conserved prodomain cystein residue is proposed. The cystein is displaced 
(Okada et al.; 1992b) and the zinc ion of the active site becomes available for 
substrate binding, leading to autocatalytic activity (Shapiro et al.; 1995). By 
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using trypsin activation, a subsequent stop of activation is necessary. Otherwise 
the enzyme would be degraded completely (Okada et al.; 1992b).  
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Figure 4-16 Time dependence of the activity of 100ng/ml bacterial collagenase, 1672.7ng/ml 
(Sigma) or 19.1ng/ml (Roche) MMP-2 and 6.8ng/ml MMP-9, respectively, at 37°C 
(average ± SD; n=5) 
 
The time dependent change in enzymatic activity was investigated over 2h 
which represented the incubation time for sorption studies (see Figure 4-16). 
Compared to collagenase both gelatinases were rather instable. This was in 
agreement with Cullen et al., who determined a loss of combined MMP activity 
in diabetic wound fluids of approximately 30% after 30min and 45% after 1h 
incubation (Cullen et al.; 2002a). In our studies, MMP-9 lost 30% of its initial 
activity within 2h. For gelatinase A two different qualities were used. The 
enzyme supplied from Roche showed a higher initial activity and a more stable 
behavior than the Sigma quality. These results suggested that the human 
gelatinases could only be used for short time studies, whereas with bacterial 
collagenase investigations over a longer time period than 2h could be 
performed without pronounced reduction in enzymatic activity. 
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4.2.2 Enzymatic Binding Studies on Collagenous Materials 
To characterize the enzyme-substrate interaction properly, binding studies on 
collagenous materials for all three enzymes were performed. For method 
development, binding on two wound dressings, available on the German market 
(Vasel-Biergans; 2004), was determined. Due to their porous structure, 
enzymes can penetrate easily into the sponges and consequently a large 
surface area was available for binding. As examples for collagenous sponges, 
used in chronic wound therapy, Suprasorb® C (Lohmann & Rauscher GmbH & 
Co. KG, Rengsdorf, Germany), composed exclusively of bovine corium collagen 
type I, and Promogran®, containing bovine corium collagen type I and oxidized 
regenerated cellulose (ORC) (ratio 45/55; Johnson & Johnson Medical Limited, 
Gargrave, Skipton, UK), were chosen. Bovine corium non cross-linked minirods 
(prepared from the same collagen as Suprasorb® C) were also investigated, to 
have the possibility to compare collagen sponges with dense collagen matrices. 
4.2.2.1 Development of Test Conditions 
The first set of experiments was performed with the FALGPA assay. This assay 
is one of the most frequently used activity assays for bacterial collagenase 
because of a rapid and simple test protocol (Van Wart et al.; 1981). Gaspers et 
al. mentioned that the FALGPA analysis is near the sensitivity limit, but reported 
repeatable results with approximately 10% standard derivation for each 
individual investigation (Gaspers et al.; 1995). When the supernatant was 
investigated directly, many visible degradation products were in the tested 
sample which interfere the UV measurement. After 60min, approximately 25% 
active collagenase for both wound dressings was recovered (see Figure 4-17a). 
To enhance sensitivity and reproducibility, two different setups were tested. On 
the one hand the supernatant was centrifuged prior to measurement and on the 
other hand a filtration step was performed before analysis. Filtration was slightly 
superior to centrifugation, but variability in the results was still high (see Figure 
4-17b, c). To obtain more reliable results, we replaced the FALGPA assay by a 
more sensitive fluorimetric assay (EnzChek® (Molecular Probes; 2001)). Due to 
easier handling, samples were centrifuged before measurement to avoid 
4 Results and Discussion 99 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
interference of degradation products. Reproducibility was strongly enhanced 
(see Figure 4-17d).  
 
 
Figure 4-17 Activity of collagenase after 60 minutes incubation with 2mg Suprasorb® C and 2mg 
Promogran®, respectively, at 37°C (average ± SD; n=5) 
 a: untreated sample; determined by FALGPA analysis 
 b: centrifuged sample (7500rpm; 5min); determined by FALGPA analysis 
 c: filtrated sample (0.2µm); determined by FALGPA analysis 
 d: centrifuged sample (7500rpm; 5min); measured with the EnzCheck®  
 
Because enzymes were investigated separately in these setups, the EnzChek® 
assay could be used for all three. If all enzymes would be investigated together 
in one sample, no differentiation would be possible. Simultaneous degradation 
of fluorescent labeled gelatin would take place and even more specific methods, 
such as gelatin zymography for MMP-2 and 9, have to be applied (Cullen et al.; 
2002a).  
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4.2.2.2 Gelatinase B (MMP-9) 
Adsorption of gelatinase B was more pronounced than binding of collagenase 
(see Figure 4-17d; Figure 4-18). Although, MMP-9 is not as specific for collagen 
type I as collagenase, Okada et al. demonstrated that cleavage in the 
telopeptide region of the α2 chain takes place (Okada et al.; 1995). In 
consequence, the pretreatment of the collagen material is very important, 
because MMP-9 can only form specific binding complexes with collagen 
telopeptides. Already after 30min approximately 54% enzyme was bound to 
Suprasorb® C (see Figure 4-18). This effect was slightly more evident with 
Promogran®. The amount of enzyme (30% of the initial MMP-9 concentration) 
bound on Promogran® remained constant over 2h indicating that after 30min 
maximal binding of approximately 60% was reached. In diabetic wound fluids, 
Cullen et al. also observed after 2h a binding of approximately 30% of initial 
activity on Promogran® (Cullen et al.; 2002a). The residual enzymatic activity of 
MMP-9 after 30min in the presence of Suprasorb® C decreased at the same 
rate as the loss in activity of gelatinase B in buffer. Thus, binding was also 
completed after 30min and during the residual observation period equilibrium 
between bound and unbound enzyme was established. Binding of MMP-9 on 
collagen minirods was investigated as well. During the first hour no significant 
binding could be measured (p<0.001). After 2h the extent of binding was 
comparable with the binding capacity of Promogran®. For both materials a 
binding of approximately 40% was observed. This delay in binding could be 
explained by the denser matrix structure and in consequence the more hindered 
access to the binding sites. 
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Figure 4-18 Binding of 7.5ng gelatinase B on 2mg collagenous matrices at 37°C 
(line: enzyme activity in buffer, numbers: difference of enzymatic activity without 
and in the presence of  matrices; average ± SD; n=5) 
 
4.2.2.3 Gelatinase A (MMP-2) 
Due to differences in stability (see Figure 4-16) and in specific activity of MMP-2 
from different suppliers, these experiments were carried out with two different 
qualities. The first experiments were performed with gelatinase A from Roche. 
Both wound dressings showed no pronounced binding of MMP-2 (see Figure 
4-19). Data obtained for gelatinase A from Sigma indicated slight binding after 
30min incubation for both wound dressings (see Figure 4-20). However, the 
residual MMP-2 activity remained constant over the complete observation 
period in the presence of collagenous wound dressings (Suprasorb® C: 
approximately 60%; Promogran®: approximately 50% of the initial activity), 
indicating that no MMP-2 was bound after 2h. No binding of MMP-2 was 
detected in the presence of the collagen minirods as well. 
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Figure 4-19 Binding of 21ng gelatinase A (Roche) on 2mg collagenous matrices at 37°C 
(line: enzyme activity in buffer, numbers: difference of enzymatic activity without 
and in the presence of  matrices; average ± SD; n=5) 
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Figure 4-20 Binding of 1.84µg gelatinase A (Sigma) on 2mg collagenous matrices at 37°C 
(line: enzyme activity in buffer, numbers: difference of enzymatic activity without 
and in the presence of  matrices; average ± SD; n=5) 
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Since MMP-2 digests collagen type I (Aimes et al.; 1995) and degradation could 
be made visible by comparing Suprasorb® C incubated with and without 
gelatinase A (see Figure 4-21), the enzyme has to interact with the substrate.  
 
 
Figure 4-21 Suprasorb® C incubated without (left) and with 1.84µg (right) gelatinase A (Sigma) 
for 2 hours at 37°C 
 
However, binding could not be quantified with the applied test conditions. A 
possible explanation might be, that the used enzymatic concentrations, 21ng 
(Roche) and 1840ng (Sigma) per 1.1ml, respectively, strongly exceed the 
concentration of gelatinase A in vivo (e.g. 103pg/ml active enzyme in diabetic 
foot ulcers (Lobmann et al.; 2002)). Hence, binding effects were too low to be 
detected. The detection limit of the EnzChek® does not allow a variation in 
MMP-2 concentration. Therefore, the substrate – enzyme ratio was reduced by 
increasing the collagen concentration (10mg matrices instead of 2mg collagen). 
With this modification, binding could be made visible (see Figure 4-22). After 
30min incubation, Suprasorb® C could bind approximately 35% enzyme. 
Reduction in MMP-2 activity in the medium was more pronounced in the 
presence of Promogran®, approximately 50% of the enzyme was bound after 
30min. The binding capacity was nearly constant for one hour for both wound 
dressings (Suprasorb® C: approximately 35%; Promogran®: approximately 
50%). After 2h, 10% less binding was observed for both materials (Suprasorb® 
C: approximately 20%; Promogran®: approximately 40%).  
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In literature it is documented that the growth of several cell types, e.g. 
fibroblasts, can be enhanced in the presence of collagen type I (Pachence et 
al.; 1987). Furthermore, MMP-2 secretion and activation is more pronounced, 
when fibroblasts are cultured with collagen type I (Azzam et al.; 1992).  
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Figure 4-22 Binding of 1.84µg gelatinase A (Sigma) on 10mg collagenous matrices at 37°C 
(line: enzyme activity in buffer, numbers: difference of enzymatic activity without 
and in the presence of  matrices; average ± SD; n=5) 
 
It was concluded, that MMP-2 might maintain its activity when it is bound to this 
type of collagen. By assuming equilibrium between unbound and bound 
gelatinase A, the increase in enzymatic activity in the incubation medium after 
2h could be traced back to an exchange of detached active enzymes with MMP-
2 molecules which lost their activity by remaining in the incubation medium. 
Thus, the increased enzyme activity in the medium did not necessarily indicate 
a release of enzyme. This effect was not as pronounced for gelatinase A from 
Roche than for the Sigma quality, because MMP-2 from Roche was in general 
more stable (see Figure 4-16). Still, no binding of gelatinase A was detected in 
the presence of collagen minirods (see Figure 4-22). This could be explained by 
the denser matrix which hinders the penetration of enzyme molecules. The 
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specific binding in the interior of the collagen helix becomes more difficult and 
fewer enzyme molecules can be adsorbed on minirods. 
4.2.2.4 Bacterial Collagenase (CHC) 
Both wound dressings do bind collagenase due to the specificity of the enzyme 
towards collagen (see Figure 4-23). Incubating Suprasorb® C with CHC resulted 
in a more pronounced decrease of collagenolytic activity in the medium as 
compared to collagenase incubated in buffer. This indicated that the enzyme 
was bound onto to wound dressing and could be detracted from the simulated 
wound fluid. Promogran® bound collagenase to a similar degree. After 30min 
incubation, the extent of binding (approximately 18%) was similar for both 
wound dressings. After incubation for 60min, the amount of enzyme bound to 
Suprasorb® C increased to approximately 34% collagenase and was slightly, but 
not significantly (p<0.001), higher as compared to Promogran®. At the 120min 
time point, approximately 62% enzyme was adsorbed on both wound dressings.  
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Figure 4-23 Binding of 110ng collagenase on 2mg collagenous matrices at 37°C 
(line: enzyme activity in buffer, numbers: difference of enzymatic activity without 
and in the presence of  matrices; average ± SD; n=5) 
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The dense collagen minirods showed delayed and less pronounced binding. 
Only approximately 10% of collagenase was bound over the complete 
observation period. The enzyme binds to specific binding sites inside the 
collagen fibers, but due to the dense matrix structure, penetration is hampered, 
the surface area is reduced and binding sites become limited (Steven; 1976).  
In summary, the binding of bacterial collagenase and human gelatinase A and B 
on collagenous surfaces was investigated. In vitro, bacterial collagenase was 
more stable than the two human MMPs. Still, after 2 weeks approximately 80% 
of its initial activity could be measured and CHC can therefore be used for the 
longer investigations periods required in release and detailed binding and 
degradation studies. After establishment of adequate test conditions, adsorption 
on collagen wound dressings and collagen minirods was determined. Both 
wound dressings, Suprasorb® C and Promogran®, approved for chronic wound 
treatment, did not differ much in their sorption profiles for all enzymes. In 
general, binding was enhanced with longer incubation times. Up to now, the 
binding mechanism is not completely identified. It is generally agreed, that 
collagen acts as a competitive substrate for all three enzymes. By presenting 
additional binding sites, the elevated enzymatic breakdown of tissue in chronic 
wounds can be repressed (Cullen et al.; 2002b). Besides this, the granulation 
phase can be enhanced by adsorption of wound fluid and the repair process 
may be initiated again (Vasel-Biergans; 2004). The second component of 
Promogran®, ORC, is negatively charged at pH 7.5 and can bind positively 
charged atoms, such as the zinc and calcium ions in MMPs (Cullen et al.; 
2002b). Therefore, a non-specific binding mechanism was proposed for 
Promogran®. It was assumed, that proteases bind physically without 
participation of their active sites and that their active sites are only obstructed by 
sterical features (Cullen et al.; 2002a). Almost no binding of MMP-2 and MMP-9 
can be observed on minirods, prepared from the same collagen as Suprasorb® 
C. This indicated that the density of the device and in consequence the 
accessible surface area is a crucial factor for adsorption. 
After investigation of the binding of MMP-2 and -9 on three different samples, 
the focus was put on the interaction of bacterial collagenase with collagen 
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minirods. For the development of the mathematical model (see 4.5), sorption 
isotherms of CHC on collagen surfaces were needed.  
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Figure 4-24 Sorption of 5µg/ml collagenase at 37°C on 20mg equine non cross-linked collagen 
minirods (a), on different collagen minirods (20mg) (b) and on 20mg bovine corium EDC 
1 cross-linked minrods and powder (c) (n=3) 
 
Therefore, the time interval of investigation was expanded to 24h and the 
sorption on collagen powders and minirods prepared from the three different 
raw materials was investigated. Before sorption isotherms could be determined, 
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the time of equilibrium in enzyme – substrate complexes must be known. In 
general, after a fast binding of collagenase, the adsorbed enzymatic amount 
remained constant for at least 24h (see Figure 4-24a), irrespectively whether 
collagen powder or minirods was used. Focusing on the first hour of adsorption 
(see Figure 4-24b, c), it was demonstrated that all accessible reaction sites 
were reached within this time interval, irrespectively of the used matrix form or 
collagen. Subsequently the number of enzyme-substrate complexes was almost 
constant due to simultaneously occurring sorption and desorption. After 
adsorption, CHC moved along the collagen fibers, until a specific binding site 
was reached. Cutting of the collagen helix could take place and subsequently 
diffusion along the collagen fibers continued (Gaspers et al.; 1994; Paige et al.; 
2002). Binding sites within the matrix which were inaccessible at the beginning 
became accessible due to matrix swelling and degradation (Steven; 1976). 
Consequently, collagenase would not be released before the number of binding 
sites became less than enzyme molecules (Gaspers et al.; 1994; Welgus et al.; 
1980). Sorption on EDC 1 cross-linked minirods was less pronounced than on 
non cross-linked minirods (see Figure 4-24b). Collagenase still diffused towards 
the collagenous surface, but enzymatic binding sites were blocked by cross-
links (Zeeman et al.; 1999). The new linkages also restricted binding, because 
the pre-requisite untwisting of tropocollagen (French et al.; 1992) became more 
difficult. Similar adsorption on equine and bovine corium EDC 1 cross-linked 
minirods was observed. Another factor which highly influenced adsorption is the 
density of the device. By comparing minirods and powder prepared from bovine 
corium EDC 1 cross-linked collagen, this effect became obvious (see Figure 
4-24c). The collagen powder exhibits a greater surface area than the minirods, 
consequently more binding sites were accessible and the extent of sorption was 
higher.  
The strength of adsorption was investigated by washing equine non cross-
linked minirods with Tris buffer pH 7.5 after incubation with CHC. The amount of 
collagenase, detectable in the supernatant at the end of incubation, decreased 
over time (see Figure 4-25), indicating that with longer incubation times more 
collagenase was attached onto collagen minirods. Analyzing the washing 
4 Results and Discussion 109 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
solutions showed that with longer incubation periods, more washing steps were 
needed to free collagenase. Hence, it was assumed that a longer contact of 
collagenase with collagen led to a more specific manner in binding. On the one 
hand more binding sites got accessible due to swelling and on the other hand 
more enzyme molecules were able to reach specific binding sites after diffusion 
along the collagen fibers. 
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Figure 4-25 Detectable amount of collagenase in washing solutions after incubation of 20mg 
equine non cross-linked minirods with 5µg/ml collagenase at 37°C (w: washing 
step) 
 
Since in average approximately 1µg collagenase could be removed by 
subsequent washing steps (see Figure 4-24a and Figure 4-25), it was 
concluded that this amount was only entrapped physically in the collagen 
matrix, but not bound specifically onto the collagen surface. 
4.2.3 Determination of Sorption Isotherms 
Similar time courses of adsorbed collagenase were observed for concentrations 
between 0.005 – 0.08mg/ml enzyme. Since only a fraction of complete added 
enzyme can be bound on collagen (e.g. approximately 10% within 2h, see 
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Figure 4-23) and the maximal amount of collagenase was already adsorbed 
between 0.5h and 1h (see Figure 4-24), sorption isotherms can be studied after 
1h incubation. The first approach of a sorption isotherm was a linear 
relationship between adsorbed enzymatic amount and added CHC 
concentration (see Figure 4-26).  
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Figure 4-26 Linear fit of adsorbed collagenase on 20mg equine non cross-linked minirods after 
1h incubation at 37°C 
 
The approximate molar ratio of collagenase to collagen was calculated and a 
linear relationship (R²=0.9831) with no upper limit could be detected (see Table 
4-3). Seifter et al. noticed 150-200 cuts per α-chains, depending on the kind of 
used collagen (Seifter et al.; 1971) and French et al. identified at least 4 cuts 
per α-chain (French et al.; 1992). The calculated ratios indicated that more 
enzymes than available binding sites could be bound. Consequently, adsorption 
was not described sufficiently by a linear correlation and more complex 
isotherms had to be considered. 
As was already discussed in section 1.3.1.1, several proposals based on either 
the Langmuir or Freundlich isotherm for adsorption of collagenase on collagen 
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surfaces were made in literature. Combining the two observations, maximum in 
binding after 0.5h to 1h (see Figure 4-24) and no upper adsorption limit (see 
Table 4-3), led to the conclusion that a Freundlich isotherm described 
adsorption best.   
 
Table 4-3 Concentration dependent molar ratio of adsorbed collagenase on collagen equine 
non cross-linked minirods 
Concentration of collagenase 
[mg/ml] 
Molar ratio 
(collagenase :  collagen) 
0.0001 210 : 1 
0.005 489 : 1 
0.01 1720 : 1 
0.02 2331 : 1 
0.03 3640 : 1 
0.05 5385 : 1 
 
 
Sorption isotherms were determined after 1h incubation with 0.005 – 0.03mg/ml 
collagenase. At this time point, the equilibrium in enzyme-substrate complexes 
was established and no distinct degradation was observed. Experimental data 
were fitted with the Freundlich equation (see Figure 4-27). 
The influence of the surface area on the extent of sorption could be seen by 
comparison of equine non cross-linked minirods with powder. Collagen powder 
has a larger relative surface area than minirods. Hence, more enzyme 
molecules could be bound (see Figure 4-27b). 
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Figure 4-27 Sorption isotherms on 20mg collagen minirods (a) and on 20mg equine non cross-
linked collagen powder (b) at 37°C (average ± SD; n=3) 
 
For low enzyme concentrations, sorption isotherms were nearly identical for all 
investigated minirods, irrespectively of cross-linking degree or collagen source 
(see Figure 4-27a). If the enzymatic concentration was increased, a slightly 
higher sorption of collagenase on equine non cross-linked minirods was 
observed compared to equine EDC 1 cross-linked extrudates. This was 
consistent with the assumption that additional cross-links restrict enzymatic 
binding (Zeeman et al.; 1999). However, bovine corium EDC 1 cross-linked 
minirods adsorbed higher amounts of collagenase than the other two kinds of 
minirods. A slightly higher surface area than in equine EDC 1 cross-linked 
matrices was accessible for enzymes, because bovine corium EDC 1 cross-
linked minirods exhibited a similar swelling as equine non cross-linked minirods 
(see 4.1.2.1.1). Additionally, the lowest Michaelis-Menten constant of minirods 
was detected for bovine corium EDC 1 cross-linked minirods (see Table 4-5), 
indicating that a strong interaction between substrate and enzyme took place. 
For all samples, n -values greater than 2/3 were observed (see Table 4-4). This 
indicated that the enzyme can penetrate into the collagen matrix (McLaren; 
1963). 
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Table 4-4 Parameters of the Freundlich fits of Figure 4-27 (average ± SD; n=3) 
Sample y=k1 xn R2 
equine non cross-linked minirod k1 =0.12±0.04 
n =0.85±0.07 
0.989 
equine EDC 1 cross-linked minirod k1 =0.06±0.01 
n =0.95±0.01 
0.997 
bovine corium EDC 1 cross-linked minirod k1 =0.13±0.05 
n =0.97±0.09 
0.988 
equine non cross-linked powder k1 =0.11±0.01 
n =1.05±0.01 
1 
 
 
According to the literature (Gyani; 1945), different extreme Freundlich sorption 
exponents are defined (see 1.3.1.2).  
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Figure 4-28 Theoretical evaluation of the Freundlich sorption exponent n  of the collagenase 
sorption on equine non cross-linked minirods (dots represent experimental data) 
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For the development of the mathematical model (see 4.5), the complete range 
of possible n -values was fitted to the experimental data (see Figure 4-28). It 
was observed that the adsorption was described best, if n  was in the range of 
2/3< n <1. For lower n -values, simulated results were not consistent with 
experimental observations. Since n  was fitted in the mathematical model, solely 
n -values in the range of 2/3<n <1 were tested in the mathematical model (see 
4.5). 
4.2.4 Determination of Degradation Constants 
After adsorption and binding of collagenase on collagen surfaces, enzyme-
substrate complexes can be formed and degradation starts. To investigate 
whether it is sufficient to describe the degradation of insoluble collagen by using 
the original Michaelis-Menten kinetic without consideration of adsorption 
phenomena, the degradation constants of collagen powder and minirods were 
determined.  
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Figure 4-29 Lineweaver-Burk plots of 2µg/ml collagenase acting on equine non cross-linked 
collagen matrices (n=2) 
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Although a heterogeneous enzymatic reaction took place, kinetics similar to the 
usual homogeneous Michaelis-Menten kinetic could be observed (Okada et al.; 
1992a). Hence, typical Lineweaver-Burk diagrams were used to assess 
degradation constants (see Figure 4-29). The stability of the enzyme-substrate 
complex can be characterized by KM and is dependent on the enzyme-substrate 
combination (Stryer; 1996).  
For insoluble non cross-linked equine collagen, KM values were in the range of 
2.5 - 3.8 * 10 - 5 mol/l, whereas KM values of cross-linked collagens were lower 
(see Table 4-5). This indicated that the binding on cross-linked collagen was 
stronger and more specific. For comparison of different enzyme-substrate 
combinations, the turnover number kcat is more suitable. This constant provides 
information about the reaction velocity of the enzymatic reaction. The 
degradation rate of equine non cross-linked collagen powder (kcat=750h-1) was 
in the range of values of soluble rat collagen type I gels (kcat=900-2100h-1 
(Mallya et al.; 1992) and kcat=1000h-1 (Lin et al.; 1999)), whereas degradation 
rates of non cross-linked minirods and EDC 1 cross-linked matrices were lower 
(see Table 4-5).  
 
Table 4-5 Collagenolytic degradation constants of collagen powder and minirods (n=2) 
Powder Minirods Sample 
KM [mol/l] kcat [h-1] KM [mol/l] kcat [h-1] 
equine non cross-linked  2.55*10 -5 750 3.8*10 -5 174 
equine EDC 1 cross-linked  1.33*10 -5 51.1 1.97*10 -5 33.4 
 
Due to a less compact matrix structure, collagen powders have a higher relative 
surface area and more reaction sites are accessible for collagenase (see Figure 
4-24c). Hence, collagen powders were degraded faster than the minirods of the 
same material. This assumption could be manifested by several publications: 
4 Results and Discussion 116 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
Bicsak et al. investigated the degradation of soluble and fibrillar guinea pig skin 
collagen type I by tadpole back-skin collagenase (Bicsak et al.; 1984) and 
Birkedal-Hansen et al. determined the catalytic properties of human fibroblast-
type collagenase acting on bovine collagen type I (Birkedal-Hansen et al.; 
1993). Both detected lower kcat values for fibrillar than for soluble substrates 
(e.g. 1653h-1 for the degradation of soluble bovine collagen type I by human 
fibroblast-type collagenase and 11.4h-1 for the degradation of bovine collagen 
type I fibrils; (Birkedal-Hansen et al.; 1993)). McLaren observed a higher kcat for 
trypsin degradation of a gelatin solution than for a gelatin gel (McLaren et al.; 
1970). This phenomenon was attributed to the tertiary structure of the fibrils and 
the gel, respectively, which hampers the binding of the enzymes (McLaren et 
al.; 1970) and the access of water molecules to the hydrolysis site (Hasty et al.; 
1987). Since number in cross-links increased from equine non cross-linked 
collagen to EDC 1 cross-linked materials (see 4.1.1.2), a similar conclusion to 
McLaren’s proposal could be drawn from the presented experimental data. 
Summarizing these results, one can conclude that the enzymatic degradation of 
insoluble collagen is not described sufficiently by using only the Michaelis-
Menten equation. The enzymatic reaction rate of insoluble substrates is not 
exclusively dependent on the substrate concentration, but also on the matrix 
surface. Consequently, the adsorption process of the enzyme (see 4.2.2.4 and 
4.2.3) and the reaction rate of the cleavage itself must be considered to 
characterize the enzymatic reaction properly and both processes had to be 
incorporated into the mathematical model (see 4.5).  
4.2.5 Summary  
In the first part of this section, the binding of bacterial collagenase (CHC) and 
human gelatinase A and B on different collagen matrices was investigated. 
Wound dressings which contain collagen exhibited a more pronounced enzyme 
binding than dense bovine corium non cross-linked minirods. Due to a higher 
accessible binding surface approximately 60% CHC, approximately 30% MMP-
2 and approximately 45% MMP-9, respectively, were bound on the two collagen 
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sponges after 2h, whereas significant binding was only detected for MMP-9 on 
dense collagen extrudates (p<0.001). 
In the second part, interaction of CHC with dense collagen matrices was 
investigated in more detail. Adsorption was completed between 0.5h and 1h, 
irrespectively of collagen preparation and matrix shape, and the extent of 
sorption maintained constant for at least 24h. With longer incubation times, the 
fraction of specifically bound CHC increased. It was demonstrated that the 
extent of adsorption is influenced by the relative surface area and additional  
cross-linking. In this equilibrium state, sorption isotherms were measured and 
experimental data were fitted with the Freundlich isotherm. Since n -values 
greater than 2/3 were detected, it was assumed that collagenase can penetrate 
into the collagen matrix. According to literature (Bailey; 1986), simple Michaelis-
Menten kinetic can only be applied to soluble substrates. Hence, degradation of 
insoluble collagen substrates by CHC was studied by dividing the enzymatic 
reaction in two stages: a prerequisite adsorption step, followed by the true 
degradation. To verify whether enzyme adsorption is a necessary step for 
degradation, degradation constants for insoluble collagen powders and minirods 
were determined. Equine non cross-linked powder had a degradation rate in the 
range of soluble collagens (kcat (equine non cross-linked powder) = 750h-1 
versus 900h-1 < kcat (soluble rate collagen type I) < 2100h-1). An increase in 
cross-linking degree and a decrease in surface area (investigation of minirods) 
resulted in lower reaction rates (33h-1 < kcat < 175h-1). From the presented data it 
was concluded that the enzymatic reaction was dependent on adsorption and 
that this process had to be included into a precise description of the degradation 
mechanism. The obtained results from adsorption and degradation studies were 
incorporated in the mathematical model by using a Freundlich sorption isotherm 
and by inserting the measured kcat (=k2 in chapter 4.5) values and the calculated 
adsorption rates (
M
cat
K
k
k =1  ; (Tzafriri et al.; 2002)). 
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4.3 In vitro Release of FITC Dextran   
In the previous section, the collagen matrix was characterized in more detail. 
Especially the interaction between collagenase and collagen was investigated, 
because parenterally implanted collagen drug devices undergo enzymatic 
degradation. The next step towards a mathematical model for drug release from 
dense collagen matrices was to investigate the release of model drug 
compounds from collagen extrudates. Two different experimental protocols 
were followed. On the one hand, a special experimental setup for the 
development of a model exclusively describing drug release controlled by 
erosion was needed. For this purpose, release was monitored for 6d in absence 
of collagenase. On day 6, 0.1µg/ml collagenase was added and release and 
degradation were determined in parallel. This setup was applied to eliminate the 
contribution of drug release by diffusion and swelling and to guarantee a fully 
swollen matrix. Consequently, the parameters which are necessary to develop 
the part of the mathematical model describing the drug release due to matrix 
degradation could be obtained. On the other hand, an experimental setup was 
chosen to simulate in vivo circumstances: 0.1µg/ml bacterial collagenase was 
already added to the minirods after a 0.25h pre-swelling phase in pure Tris 
buffer pH 7.5 at 37°C. Here, the release profile was more complex than in the 
first setup, because swelling, diffusion and erosion dependent drug release 
occurred simultaneously. To cover these complex mechanisms, the diffusion 
equations from the model of swelling controlled release presented by Radu et 
al. (Radu et al.; 2002) and the model of erosion controlled drug release, 
developed in this thesis (see 4.5), were combined. Data from the second 
experimental setup was used to test the mathematical model. 
Since collagen devices swell in contact with aqueous liquids, water penetrates 
into the matrix and water soluble drugs dissolve (Sano et al.; 2003). Maeda et 
al. postulated that after drug dissolution the drug solution retains inside the 
hydrated collagen matrix (Maeda et al.; 1999), before release through water 
filled pores can occur (Gilbert et al.; 1988a). Weadock postulated that the gaps 
between staggered collagen tropocollagens (see Figure 1-1) build the pores 
which are prerequisite for diffusional drug release of water soluble compounds 
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(Weadock; 1986). Since collagen extrudates became highly hydrated after 
contact with water (approximately 70% water), a main part of drug delivery is 
covered by diffusion controlled release (Radu et al.; 2002). Hence, the diffusion 
coefficients in water of three model compounds were determined, before 
influences of experimental setup, collagen raw material, matrix dimensions and 
drug properties on drug release were investigated. 
4.3.1 Diffusion Coefficient of FITC Dextrans 
Movement of water soluble drugs inside and out of collagen matrices can be 
described by diffusion. After dissolution, these drugs can either diffuse directly 
out of the swollen matrix or their diffusion is hindered because either the 
collagen mesh is too tight or the molecular weight of the drug is too high 
(Rosenblatt et al.; 1989). In the second case the matrix has to be degraded, 
before drug diffusion can occur. To cover these processes, diffusion 
phenomena were implemented in the mathematical model (see 4.5). Since 
direct measurement of diffusion coefficients in dense non-transparent matrices 
is very challenging (see 4.1.2.2), the diffusion coefficients of FITC dextran 20, 
70 and 150 were determined in water by fluorescence correlation spectroscopy 
(FCS). The diffusion coefficient of FITC dextran 70 at 23°C was determined with 
1.7*10-3cm²/h. Similar results were obtained by Singh and Shenoy (Shenoy et 
al.; 1995; Singh; 1994). For FITC dextran 20 2.1*10-3cm²/h and for FITC dextran 
150 1.27*10-3cm²/h were obtained. The diffusion coefficient is particularly 
dependent on the temperature and the molecular size of the investigated drug. 
By applying the Stokes-Einstein equation the diffusion coefficients can be 
converted to 37°C, the temperature at which release and degradation studies 
were performed (FITC dextran 70: 2.4*10-3cm²/h; FITC dextran 20: 3*10-3cm²/h 
and FITC dextran 150: 1.8*10-3cm²/h). Besides movement of drugs, 
collagenase also has to diffuse towards the collagen surface, before binding 
and degradation can take place. Because fluorescent labeling of collagenase 
may alter its properties, FITC dextran 70 was used to simulate collagenase in 
these experiments. To verify whether the diffusion coefficient of FITC dextran 
70 could be used for modeling collagenase, results were compared with 
literature. Seifter et al. measured a diffusion coefficient of collagenase A (MW: 
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105kDa) of 1.55*10-3cm²/h at 20°C in water (Seifter et al.; 1959). By conversion 
with the Stokes-Einstein equation a diffusion coefficient of 2.2*10-3cm²/h at 37°C 
was obtained. Gaspers et al. determined, by two different methods, a diffusion 
coefficient of collagenase of 2.4*10-3cm²/h in bulk solution and different buffers 
(Gaspers et al.; 1994). The diffusion coefficients of collagenase, given in 
literature, were in good agreement with the measured FITC dextran 70 diffusion 
coefficient. Consequently, this diffusion coefficient could be used for both, 
collagenase and FITC dextran 70, in the mathematical model (see 4.5). 
Furthermore, the diffusion coefficient of the degradation products was 
necessary. According to French et al. (French et al.; 1992), degradation of the 
collagen triple helix resulted in fragments of a maximal molecular weight of 
approximately 70kDa. Therefore, the diffusion coefficient of FITC dextran 70 
was used as the upper limit for the diffusion coefficient of the products (see 4.5).  
4.3.2 Influence of Experimental Setup  
4.3.2.1 Variation in Concentration of Collagenase  
Initial experiments were conducted with collagen minirods of a length of 40mm. 
FITC dextran 70 release was observed in the presence of 6.7 µg/ml, 0.1µg/ml 
collagenase and without addition of enzyme (see Figure 4-30a). The matrix 
degradation was analyzed simultaneously in collagenase containing samples 
(see Figure 4-30b). In absence of collagenase drug release was incomplete. 
Only approximately 55% FITC dextran 70 was released by swelling and 
diffusion during the observation period. Adding 0.1µg/ml enzyme resulted in 
complete matrix disintegration after 21d (see Figure 4-30b) which led to further 
drug release by erosion. 50% of the drug fraction which was initially immobilized 
inside the minirods could be delivered, but still not the complete drug load could 
be released. In the presence of 6.7µg/ml collagenase FITC dextran 70 was 
delivered completely after 72h and the collagen matrix was entirely eroded at 
this time point. Matrix erosion started after a short lag phase of approximately 
0.5h which is necessary to reach equilibrium in adsorption of collagenase on the 
matrix surfaces (see 4.2.2.4). The more enzymes were added, the more 
enzyme molecules could bind and cleave the collagen helices (see Table 4-3) 
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and a faster digestion was the consequence (see Figure 4-30b). A similar 
observation was made by Park et al., who investigated the in vitro degradation 
of collagen - hyaluronic acid scaffolds (Park et al.; 2002). Increasing the 
concentration of collagenase resulted in a decrease of the remaining scaffold 
weight after 24h. In conclusion, the release rate and the immobilized drug 
fraction could be controlled by addition of collagenase.  
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Figure 4-30 Effect of the concentration of collagenase on FITC dextran 70 release (a) and collagen 
degradation (b) of 40mm equine non cross-linked minirods (0 / 0.1 / 6.7µg/ml enzyme was 
added after 0.25h; average ± SD; n=3) 
 
Maeda et al. investigated the release of HSA from collagen minipellets, 
prepared from a 30% (w/w) atelocollagen dispersion. Almost complete release 
occurred within 2d from his standard formulation with 20% HSA in absence of 
collagenase (Maeda et al.; 1999). Investigating the release mechanism in more 
detail showed that a 3h swelling controlled release phase was followed by 36h 
of diffusion control which was dependent on the simultaneous matrix swelling 
and drug dissolution (Maeda et al.; 1999). No drug was immobilized inside the 
minipellets, suggesting that these drug devices were less compact after contact 
with aqueous solutions than our minirods, because non cross-linked 
atelocollagen was used for manufacturing (Fujioka et al.; 1995). These 
observations led to the conclusion that the release from our minirods must be 
diffusion, swelling and erosion controlled. 
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To determine whether the entrapped drug fraction could be released erosion 
controlled, collagenase was added after 6d, because at this time point drug 
release by swelling and diffusion control was finished (see Figure 4-30a). A 
second release stage was observed (see Figure 4-31a) and the remaining drug 
fraction was released. The hindering inter- and intramolecular bonds of the 
collagen mesh were enzymatically cleaved and the formerly immobilized FITC 
dextran 70 could diffuse out of the drug device. 
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Figure 4-31 Effect of the concentration of collagenase on FITC dextran 70 release (a) and collagen 
degradation (b) of 40mm equine non cross-linked minirods (0.1 / 6.7µg/ml enzyme was 
added after 6d; average ± SD; n=3) 
 
The initial release rates of the second release phase were similar for both 
enzyme concentrations (see Figure 4-31a), but matrix degradation was faster in 
the presence of 6.7µg/ml collagenase (see Figure 4-31b). Hence, drug release 
was completed earlier, when more enzymes were present, because the 
hindering collagenous mesh was untightened earlier (completion after 8d for 
6.7µg/ml collagenase, compared to 12d in the presence of 0.1µg/ml 
collagenase). 
In this section, experiments were performed with 40mm minirods, because for 
investigations with 6.7µg/ml collagenase a high substrate concentration is 
required to monitor the collagen degradation properly. This enzyme 
concentration was chosen rather high and did not represent in vivo 
circumstances. In further in vitro experiments only the 0.1µg/ml concentration 
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was used. Furthermore, implants of a length of 40mm are not suitable for 
parenteral applications in humans. Consequently, unless otherwise noted, the 
following investigations were conducted with 10mm extrudates. 
4.3.2.2 Variation in Time of Collagenase Addition 
By comparing two different enzyme addition time points (0.25h versus 6d) 
almost congruent release profiles were observed (see Figure 4-32a). In contrast 
to 40mm extrudates (see Figure 4-30), 100% drug recovery was achieved for 
10mm minirods. Differences in release curves occurred between day 2 and 6 
due to depletion of mobile drug inside the matrix in absence of collagenase. If 
collagenase was present during the complete observation period, no such 
stagnancy in release rates could be detected. 
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Figure 4-32 Effect of the time point of collagenase addition on FITC dextran 70 release (a) and 
collagen degradation (b) of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h or 6d; x-axes in the right graph: enzyme addition after 6d (top) and 
enzyme addition after 0.25h (bottom); average ± SD; n=3) 
 
A surface erosion process for the degradation of lyophilized collagen devices 
was proposed from Olde Damink et al., because a zero-order weight loss was 
determined in the presence of collagenase (Olde Damink et al.; 1996a). This 
assumption was based on observations by Steven, who postulated that 
collagen is digested by degradation of individual tropocollagen filaments 
(Steven; 1976). Similar conclusions were made by Okada et al., who assumed 
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that collagen suture fibers were eroded from the surface to the core (Okada et 
al.; 1992a). They attributed their proposal to the low water content of the fiber 
and the large size of collagenase which limits enzyme penetration into the 
dense fiber.  
Looking closer at the erosion of equine non cross-linked minirods (see Figure 
4-32b), a two-step degradation could be observed. This was also described for 
the degradation of insoluble collagens by cathepsins and pepsin (Etherington; 
1977). In the beginning swelling takes place and rapid digestion, mainly of 
collagen filaments at the surface, occurs. Due to this combined effect of 
swelling and degradation, an almost linear degradation could be observed 
(Frieß et al.; 1996b). This stage was more pronounced for completely swollen 
equine non cross-linked minirods (see Figure 4-32b), because enzyme 
molecules can penetrate more easily into the collagen matrix (Lenz; 1993) and 
degradational turnover increased. In contrast, if collagenase was added after 
0.25h, penetration was more restricted, because of coinciding matrix swelling. 
The next degradation stage is dominated by a slower occupation of the 
remaining free reaction sites due to sorption phenomena and slower enzyme 
penetration into the matrix. This phase is regulated by steric factors, by the rate 
of product release and the decreased number of enzyme cleavage sites. For 
some materials Etherington even observed a third phase with no further 
digestion due to collagen resistance (Etherington; 1977). The observed 
degradation profiles, neither zero- nor first-order kinetic over the complete 
degradation range, led to the conclusion that equine non cross-linked minirods 
were not degraded by a simple surface erosion process. Since profiles 
resembled the digestion curves presented by Etherington (Etherington; 1977), a 
combination of surface and bulk erosion of collagen minirods was assumed. 
Summarizing the influences of addition of different collagenase concentrations 
at two different time points showed that a higher concentration of collagenase 
led to faster release and degradation profiles and that the addition to fully 
swollen matrices even enhanced this effect due to easier enzyme penetration 
and binding.  
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4.3.3 Influence of Collagen Raw Material  
After evaluation of the test conditions, influences of matrix material, matrix 
dimensions and drug properties on release were examined. The purpose was to 
achieve a matrix system which controlled drug delivery mainly by erosional 
mechanisms and which consequently showed reduced drug release by 
instantaneous diffusion.  
4.3.3.1 Variation in Pretreatment of Collagen Material  
As was already detected by swelling studies, minirods prepared from pulverized 
equine collagen material showed a more pronounced swelling than extrudates 
prepared from lyophilized raw material (Figure 4-6). Minirods prepared from 
pulverized equine collagen material exhibited an apparent density which was on 
half of the density of minirods of lyophilized collagen material (0.598g/cm³ 
compared to 1.098g/cm³; see Table 4-1). Due to this less compact matrix 
structure, more aqueous channels can be built and drug release is enhanced 
(Maeda et al.; 1999).  
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Figure 4-33 Effect of the collagen material pretreatment on FITC dextran 70 release(a) and collagen 
degradation (b) of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was added 
after 6d; average ± SD; n=3) 
 
The release was determined with the “two interval” setup, to study the change in 
drug release controlled by diffusion. Release by diffusion became enhanced 
and a higher initial burst release occurred if minirods were prepared from 
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pulverized equine collagen. A similar observation was made by Maeda et al. for 
the release from three different collagen preparations (Maeda et al.; 1999). A 
porous collagen sponge, a collagen film and the collagen minipellet were 
investigated and it was demonstrated that lower swelling properties reduce the 
initial release rates. After 24h approximately 80% FITC dextran 70 was released 
compared to 60% from minirods produced of lyophilized collagen (see Figure 
4-33a). The lack in matrix cohesion became also apparent in the fast 
degradation after addition of 0.1µg/ml collagenase. The devices were degraded 
completely within 2d, whereas minirods prepared from lyophilized raw collagen 
were resistant for approximately one week (see Figure 4-33b).  
4.3.3.2 Variation in Animal Source  
To verify whether the matrix material itself or only the preparation technique 
influences the drug release, different collagen materials were used to produce 
minirods. With non cross-linked material, drug loaded minirods of equine and 
bovine tendon collagen were manufactured. Extrudates of bovine corium non 
cross-linked collagen were not suited as delivery devices, due to a fast 
disintegration at 37°C (see Figure 4-7). Release of FITC dextran 70 was slower 
from equine minirods than from bovine tendon matrices (see Figure 4-34a): 
65% dextran was released during the first 24h from equine minirods, whereas 
85% was delivered from the bovine tendon extrudates.  
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Figure 4-34 Effect of the animal source on FITC dextran 70 release (a) and collagen degradation (b) of 
10mm non cross-linked minirods (0.1µg/ml enzyme was added after 0.25h; average ± SD; 
n=3) 
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Since natural cross-linking of bovine materials was less pronounced than in 
equine collagen types (see 4.1.1.2) (Schlapp; 2001), diffusion of FITC dextran 
70 was less hindered and a higher amount of drug was free to diffuse. Due to 
the lower cross-linking degree in the bovine tendon collagen material, fewer 
linkages had to be cleaved before a degraded collagen fragment could be 
solubilized (Olde Damink et al.; 1996a) and degradation became faster (see 
Figure 4-34b) (Schlapp; 2001). 
In conclusion, the equine collagen material appeared to be more appropriate to 
produce collagen minirods with controllable properties, because matrix erosion 
and (diffusion controlled) FITC dextran 70 release were less pronounced than of 
bovine materials. 
4.3.3.3 Variation in Cross-linking  
Release could further be reduced by collagen cross-linking with EDC (see 
Figure 4-35a). New intra- and interhelical bonds are built (Zeeman et al.; 1999), 
which led to reduced swellability (see Figure 4-8), increased matrix stability 
(Zeeman et al.; 1999) and denser matrices (see Table 4-1) (Frieß et al.; 1996b). 
For 3d, similar release profiles were observed for equine non cross-linked and 
both bovine EDC 1 cross-linked minirods. During the first 24h, 45% FITC 
dextran 70 was released from equine EDC 1 cross-linked implants, whereas 
60% was delivered from the other three kinds of minirods (see Figure 4-35a). 
Release was completed after 19d for bovine corium minirods and after one 
month for both tendon materials. Due to the additional cross linkages, equine 
and bovine tendon EDC 1 cross-linked minirods became more resistant against 
collagenolytic attack than bovine corium EDC 1 cross-linked extrudates and 
equine non cross-linked devices (see Figure 4-35b). Bovine corium EDC 1 
cross-linked minirods were degraded completely after 19d, whereas bovine 
tendon EDC 1 cross-linked extrudates were digested after 51d and equine EDC 
1 cross-linked matrices after 59d. The penetration of collagenase was more 
restricted (Olde Damink et al.; 1996a) and the available binding surface was 
reduced, because binding and cleavage sites were partially blocked by cross-
links (Gilbert et al.; 1990). Besides this, degradation was analyzed by 
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quantification of collagen fragments in the supernatant. Thus, retarded 
degradation was also measured, because cleavage products could only diffuse 
out of the matrix inside at a reduced rate due to the hindering cross-links 
(Charulatha et al.; 2003) and more scissions are needed to release a collagen 
fragment (Gilbert; 1988b). A more distinct two step degradation profile could be 
observed for all EDC 1 cross-linked minirods than for the equine non cross-
linked matrices. Especially the second degradation phase, which was slowest 
for equine EDC 1 cross-linked matrices, indicated that digestion was reduced 
due to a more hindered diffusion of collagenase and collagen fragments. Similar 
conclusions were drawn by Schurr et al. for the degradation of a non cross-
linked and disulfide cross-linked gelatin gel (Schurr et al.; 1966). A 
homogeneous digestion was observed for the non cross-linked gel, whereas the 
dimensions of the cross-linked matrix decreased steadily. This was attributed to 
the restricted enzyme penetration resulting in surface degradation. 
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Figure 4-35 Effect of the animal source on FITC dextran 70 release (a) and collagen degradation (b) 
of 10mm EDC 1 cross-linked minirods (0.1µg/ml enzyme was added after 0.25h; similar 
legend for release and degradation; average ± SD; n=3) 
 
To characterize the release properties of our minirods in more detail, 
comparison with release data from minipellets was made. Release of BSA from 
minipellets, prepared from a 2% (w/w) atelocollagen dispersion, was studied by 
Maeda et al. at 5°C in absence of collagenase (Maeda et al.; 2003). Within the 
first day, the same drug portion (approximately 60-70%) was released as from 
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our equine non cross-linked, bovine corium and bovine tendon EDC 1 cross-
linked minirods (approximately 60% for each kind of minirod; see Figure 4-35a), 
incubated at 37°C in the presence of 0.1µg/ml collagenase. The remaining drug 
was delivered over 3d from minipellets (Maeda et al.; 2003), whereas the 
release was slower for our minirods. Consequently, minirods showed superior 
release kinetics, because even at higher temperatures and in an enzymatic 
environment the release could be more prolonged. The same group prepared 
minipellets from 30% (w/w) atelocollagen dispersions and investigated the 
release of different HSA loads at 37°C in absence of collagenase for 2 and 3 
days, respectively (Maeda et al.; 1999). During the first 24h approximately 35% 
HSA was released from minipellets loaded with 5% HSA. This initial release 
was only slightly lower compared to our equine EDC 1 cross-linked minirods 
which released approximately 45% during this time period (see Figure 4-35a). 
The retardation in drug release could be explained by two effects. On the one 
hand, the higher viscosity of concentrated formulations delays drug release by 
diffusion compared to devices prepared from 2% (w/w) collagen dispersions. On 
the other hand, Fujioka et al. postulated that drugs can only be taken up into 
collagen fibers if low concentrated collagen dispersion are used (Fujioka et al.; 
1998). Therefore, a pre-lyophilization step of a low concentrated collagen-drug 
mixture was performed, before minipellets containing 30% collagen were 
prepared. Consequently, both effects of retardation in delivery could be 
combined in the 30% minirods (Fujioka et al.; 1998). The slightly faster release 
during the first 24h from our equine EDC 1 cross-linked minirods can be 
explained by the fact that the delay in release was achieved only by the denser 
collagen mesh due to the high concentrated collagen mixture with additional 
inter- and intrahelical cross-linkages and not by drug incorporation into collagen 
fibers, because a pre-lyophilization step was not performed.   
4.3.3.3.1 Variation in EDC Cross-linking Ratio 
Variation in EDC cross-linking ratio was performed for equine tendon and 
bovine corium collagen. As was already demonstrated by swelling studies, 
increasing the EDC ratio from 1 to 3 or 17 for equine minirods did not lead to 
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further stabilizing effects (see 4.1.2.1.1). Such saturation effects in cross-linking 
were also observed by Frieß et al. (Frieß et al.; 1996b) and Geiger (Geiger; 
2001). Degradation studies and investigation of FITC dextran 70 release 
confirmed these results, because higher rates occurred with cross-linking ratios 
of 3 and 17 (see Figure 4-36). Drug release by diffusion occurred even slightly 
faster than from equine non cross-linked minirods. Since in highly cross-linked 
collagen materials (EDC 3 and 17) many new intra- and interhelical bonds are 
introduced, interfibrillar interlockings due to compression during extrusion could 
become difficult. This resulted in extrudates which exhibited lower cohesion, 
detectable by the slightly decreased apparent density (see Table 4-1; EDC 0: 
1.109g/cm³, EDC 1: 1.011g/cm³, EDC 3: 0.948g/cm³, EDC 17: 0.999g/cm³), and 
consequently a faster swelling and degradation.  
0 144 288 432 576 720 864
0
10
20
30
40
50
60
70
80
90
100
110
96 108 120 132 144 156 168
70
80
90
100
 
 
 
 
re
le
as
ed
 F
IT
C
 d
ex
tra
n 
[%
]
time [h]
a
144 288 432 576 720 864
0
20
40
60
80
100
 
 
de
gr
ad
ed
 c
ol
la
ge
n 
[%
]
time [h]
 EDC 0
 EDC 1
 EDC 3
 EDC 17
b
 
Figure 4-36 Effect of the EDC cross-linking ratio on FITC dextran 70 release (a) and collagen 
degradation (b) of 10mm equine minirods (0.1µg/ml enzyme was added after 6d; similar 
legend for release and degradation; average ± SD; n=3) 
 
Drug release from EDC cross-linked bovine corium minirods was compared to 
release from equine non cross-linked matrices. Since natural cross-linking in the 
bovine corium material was less pronounced than in equine tendon collagen, 
additional cross-linkages had to be introduced into the bovine material to 
improve its mechanical properties (see 4.1.1.2). However, release and 
degradation rates of all investigated EDC cross-linking ratios were increased 
compared to equine non cross-linked minirods (see Figure 4-37). This was 
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attributed to the lower apparent matrix density (see Table 4-1) and the different 
pattern in cross-linkages. EDC cross-linking does only introduce new inter- and 
intramolecular bonds (Zeeman et al.; 1999), whereas the natural cross-links in 
equine extrudates are also located interfibrillarly. The fastest drug release from 
EDC cross-linked bovine corium minirods was observed for the EDC 0.25 ratio 
and was already completed after 4d (see Figure 4-37a). Since DSC 
measurements showed that completely swollen EDC 0.25 cross-linked bovine 
corium minirods started to undergo thermal changes at 40°C (see Figure 4-4), 
rapid disintegration and degradation at 37°C (see Figure 4-37b) was the logical 
consequence. This behavior was analogous to bovine corium non cross-linked 
matrices which even had a Tm below 40°C. As was already observed for equine 
EDC cross-linked minirods (see Figure 4-36), an increase in EDC cross-linking 
degree could decrease matrix stabilization. For bovine corium EDC cross-linked 
extrudates the highest investigated ratio of 3 resulted in a more pronounced 
initial FITC dextran 70 release than from EDC 1 cross-linked minirods, because 
degradation was elevated during the first 6h (see Figure 4-37).  
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Figure 4-37 Effect of the EDC cross-linking ratio on FITC dextran 70 release (a) and collagen 
degradation (b) of 10mm bovine corium minirods (0.1µg/ml enzyme was added after 
0.25h; average ± SD; n=3) 
Consequently, the EDC 1 cross-linking degree was assumed to be the most 
appropriate cross-linking ratio for bovine corium minirods (and for equine 
matrices) to prepare dense drug delivery devices with reduced release and 
degradation properties.   
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4.3.3.3.2 Variation in Cross-linking Method  
Besides chemically, equine minirods were also cross-linked physically by DHT 
treatment of the final minirods after extrusion of the collagen material. Since this 
method was solely applied in an early matrix development stage, only release 
data of 40mm extrudates in the presence of 6.7µg/ml collagenase were 
collected. Compared to non cross-linked equine minirods, release and 
degradation was delayed for the DHT cross-linked matrices (see Figure 4-38).  
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Figure 4-38 Effect of the cross-linking method on FITC dextran 70 release (a) and collagen 
degradation (b) of 40mm equine minirods (6.7µg/ml enzyme was added after 0.25h; 
average ± SD; n=3) 
 
The FITC dextran 70 load was released completely after one week, whereas 
release from non cross-linked extrudates already reached 100% within 3d. 
These time intervals were identical to the time necessary for complete digestion 
of the matrices. Degradation of DHT cross-linked minirods was not as markedly 
suppressed as for EDC treated materials and the digestion rates during the 
second degradation phase were higher than for EDC collagens, indicating that 
penetration of collagenase was less restricted. This was in agreement with 
Pieper et al., who determined a similar degradation behavior in the presence of 
collagenase for non cross-linked and DHT cross-linked porous collagen 
matrices, but an enhanced resistance of EDC cross-linked materials (Pieper et 
al.; 1999). As was already discussed in 4.1.2.1.1, DHT cross-linking was not 
4 Results and Discussion 133 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
used for further preparation of minirods due to potential thermal damages of the 
incorporated drug.  
In this section it was demonstrated that release and degradation behavior of 
collagen minirods could be controlled on the one hand by the used collagen raw 
material and on the other hand by the introduction of additional cross-linkages. 
Minirods prepared from lyophilized equine EDC 1 cross-linked collagen showed 
the lowest release and degradation profiles in the presence of collagenase. 
4.3.4 Influence of Matrix Dimensions  
Another approach to control the delivery properties of collagen minirods is to 
vary the matrix dimension or geometry. Since the surface area is a crucial factor 
for drug delivery by diffusion and enzyme binding, devices with a low ratio of 
surface area to volume should show reduced release and degradation rates. 
However, implant dimensions are often restricted by the application method and 
drug load (Sano et al.; 2003). Extruded minirods were chosen as most 
promising matrices. For cylinders either the length or the diameter could be 
changed. Different aspect ratios (length/diameter) were produced and tested 
with respect to FITC dextran 70 release and collagen degradation.  
4.3.4.1 Variation in Length of Minirods  
Longer minirods, which had a higher aspect ratio, exhibited a slower release of 
FITC dextran 70 (see Figure 4-39a). This was in agreement with Maeda et al., 
who also observed this trend for HSA delivery (Maeda et al.; 1999). Due to 
extrusion, collagen fibers were highly orientated in the drug device and 
consequently the lateral side surface was higher in density than the cross-
section (see Figure 4-2, Figure 4-11, Figure 4-12). Maeda et al. postulated that 
the slower release from longer extrudates was also related to this phenomenon, 
because drug delivery is more difficult from the smoother lateral side surface of 
the minipellet than from the more porous cross-section (Maeda et al.; 1999). 
The release was determined with the “two interval” setup, to study the change in 
drug release controlled by diffusion. With elongating, the portion of the lateral 
side surface increased relatively (from 93.1% for 10mm minirods to 97.6% for 
40mm matrices) and the release during the first 24h without addition of 
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collagenase was decreased from approximately 60% from 10mm minirods to 
35% from 40mm matrices.  
0 72 144 216 288
0
10
20
30
40
50
60
70
80
90
100
110 a
aspect ratios
 6.5
 13.3
 22.8
 
 
re
le
as
ed
 F
IT
C
 d
ex
tra
n 
70
 [%
]
time [h]
144 168 192 216 240 264 288
0
20
40
60
80
100
aspect ratios
 6.5
 13.3
 22.8
 
 
de
gr
ad
ed
 c
ol
la
ge
n 
[%
]
time [h]
b
Figure 4-39 Effect of the minirods length on FITC dextran 70 release (a) and collagen 
degradation (b) of equine non cross-linked minirods (0.1µg/ml enzyme was added 
after 6d; 10mm (aspect ratio of 6.5); 20mm (aspect ratio of 12.3); 40mm (aspect ratio 
of 22.8); average ± SD; n=3) 
 
The entrapped drug portion after 6d was increased from 25% in 10mm 
extrudates to 50% in 40mm minirods. After addition of collagenase, similar 
release rates during the first 8h occurred for all three minirods, resulting from 
similar degradation profiles (see Figure 4-39). A two phase degradation profile 
was observed (Etherington; 1977), which was similar for all minirods because of 
the same cross-linking degree. 
If collagenase was added already at the beginning of the experiments, the same 
effects were observed. Elongation resulted in a slower release profile (see 
Figure 4-40a) due to the anisotropic release behavior of the extrudates. 
Compared to the pure swelling and diffusion controlled drug delivery (see 
Figure 4-39a), release was faster for all minirods, because erosion dependent 
release occurred additionally. During the first 24h approximately 65%, 60% and 
50% FITC dextran 70 was liberated from 10mm, 20mm and 30mm matrices, 
respectively (compared to 60%, 40% and 35% released by diffusion from 
10mm, 20mm and 40mm matrices, respectively).  
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Figure 4-40 Effect of the minirods length on FITC dextran 70 release (a) and collagen 
degradation (b) of equine non cross-linked minirods (0.1µg/ml enzyme was added 
after 0.25h; 10mm (aspect ratio of 6.1); 20mm (aspect ratio of 12.2); 30mm (aspect 
ratio of 18.8); average ± SD; n=3) 
 
Degradation occurred at a similar rate for all three lengths (see Figure 4-40b). 
The two stage degradation was not as pronounced as for the fully swollen 
matrices (see Figure 4-39b), because less tropocollagens were accessible in 
the beginning and the first degradation phase was diminished. Since the 
specific surface of all minirods was almost similar (surface/volume 
approximately 2.6mm-1) and the degradation of minirods differing in length was 
identical within each setup (see Figure 4-39b and Figure 4-40b), the proposal of 
Maeda et al. that the change in release occurred due to the variation in relative 
proportion of the dense lateral surface to the overall surface area could be 
confirmed. 
4.3.4.2 Variation in Diameter of Minirods 
For in vivo applications, implants should be as small as possible to avoid 
foreign-body reactions and to achieve good patient compliance (Fujioka et al.; 
1994). However, drug dosage and administration method limit the range of 
possible implant diameters (Sano et al.; 2003). Reduction in diameter led to an 
extreme increase of aspect ratios, which represented an increase in proportion 
of lateral to overall surface area. With decreasing the diameter of minirods, an 
augmentation in initial drug release rates took place (see Figure 4-41a). A 
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similar observation was made for the HSA release from minipellets (Sano et al.; 
2003). This could be explained by the shorter diffusion pathways for water and 
drug molecules and the increased specific surface area (surface/volume ratio: 
2mm: 2.8mm-1; 1.5mm: 3.4mm-1; 1mm: 4.9mm-1; 0.5mm: 9.1mm-1). Water 
penetration and swelling were accelerated (Maeda et al.; 2004b) and a higher 
specific surface is available through which release can occur and at which 
collagenase can bind. However, observed degradation profiles indicated only a 
minimal increase in degradation rate with reduction in extrudate diameter (see 
Figure 4-41b). 
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Figure 4-41 Effect of the diameter of minirods on FITC dextran 70 release (a) collagen 
degradation (b) of 20mg equine non cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h; 2mm (aspect ratio of 6.1); 1.5mm (aspect ratio of 12.1); 1mm 
(aspect ratio of 32.9); 0.5mm (aspect ratio of 204.0); average ± SD; n=3) 
 
Based on the observed results, it was concluded that release kinetics can be 
controlled by adjusting the dimensions of minirods. Besides the specific surface 
area, important for enzyme binding and drug release by diffusion, the ratio of 
lateral- to cross-section influences the drug delivery due to the different surface 
structures and in consequence anisotropic release properties. 
A further change in matrix geometry, e.g. towards a collagen slab, was not 
performed experimentally, but could be simulated with the developed 
mathematical model (see 4.5).  
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4.3.5 Influence of FITC Dextran  
4.3.5.1 Variation in Molecular Weight  
Since drug release from collagen devices is partially diffusion controlled, drug 
release should become slower with increasing molecular weight (Gilbert et al.; 
1988a) and a higher drug fraction should be entangled inside the matrix in 
absence of collagenase. Therefore, the influence of the molecular weight of the 
model compound on drug release was investigated. FITC dextrans of different 
molecular weight were used to avoid drug dependent collagen – drug - 
interactions. Their diffusion coefficients in water were determined by FCS (see 
4.3.1), as were their hydrodynamic radii (rH(FITC dextran 20): 3.97nm; rH(FITC 
dextran 70): 4.91nm; rH(FITC dextran 150): 6.56nm). Before the complex 
release mechanism composed of swelling, diffusion and erosion dependent 
delivery was investigated, pure swelling and diffusion controlled release was 
monitored (see Figure 4-42a). Similar release profiles were observed for FITC 
dextran 70 and 150. FITC dextran 20 was released faster than the other two 
model drug compounds: approximately 80% was liberated during the first 24h 
compared to 60% of FITC dextran 70 and 150. After this fast initial release no 
further significant release over the next 5d could be detected for all three 
minirods. Consequently, the molecular size of the drug primarily influenced the 
extent of the initial release by diffusion. Release profiles indicated that during 
the initial swelling the pore diameter was greater than the hydrodynamic radius 
of FITC dextran 20, because of its fast unhindered diffusional delivery. Initial 
swelling was completed after 23h (see Figure 4-9) and the molecular size has 
no more significant influence on the release kinetic. This was in agreement with 
the measured diffusion coefficients in water which were nearly identical for all 
three compounds (see 4.3.1). Furthermore, Fujioka et al. postulated that there 
does not need to be a relationship between the molecular size of proteins and 
their in vitro release rate observed in this phase of release (Fujioka et al.; 1998) 
and Weadock et al. suggested that at low swelling ratios, e.g. ratios of wet to 
dry matrix weight of 4, drug diffusion through collagen barriers can be 
insensitive to variations in molecular drug size (Weadock et al.; 1987). After 6 
days, 15% of FITC dextran 20 and 25% of FITC dextran 70 and 150 were 
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entrapped within the matrix and could only be released after matrix degradation. 
After addition of collagenase, this immobilized drug portion was delivered over 
5d (FITC dextran 20 and 150) and 6d (FITC dextran 70), respectively (see 
Figure 4-42a).    
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Figure 4-42 Effect of the molecular weight of FITC dextran on drug release (a) and collagen 
degradation (b) of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was 
added after 6d; average ± SD; n=3) 
 
Degradation profiles were almost similar for all three incorporated dextran 
flavors, suggesting that the degradation of completely swollen extrudates is 
independent of the incorporate drug and that the molecular weight of the 
incorporated compound did not affect the structural integrity of the swollen 
minirods (see Figure 4-42b). During the first 8h a rapid linear degradation 
occurred. Afterwards, the degradation rate slowed down due to a decrease in 
enzymatic binding sites on the collagen surface.   
Drug release in the presence of collagenase followed an almost identical profile 
for all three types of FITC dextrans (see Figure 4-43a). FITC dextran 70 delivery 
was slightly slower (release after 24h 60%, compared to 80% for FITC dextran 
150 and 20), because these minirods had the highest apparent density (see 
Table 4-1; FITC 20: 0.983g/cm³, FITC dextran 70: 1.109g/cm³, FITC dextran 
150: 0.899g/cm³) and were consequently degraded at a lower degradation rate 
(see Figure 4-43b). Almost no difference in release pattern was observed for 
FITC dextran 20 and 150 devices. Assuming homogeneous drug distribution, 
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more FITC dextran 150 than FITC dextran 20 was immobilized per matrix 
volume (see Figure 4-42a). Since erosion behavior was similar for these 
minirods, proportionally more immobilized FITC dextran 150 than FITC dextran 
20 could be set free and FITC dextran 150 made up the difference from the 
diffusion dependent drug release. 
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Figure 4-43 Effect of the molecular weight of FITC dextran on drug release (a) and collagen 
degradation (b) of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h; average ± SD; n=3) 
 
Summarizing the effects of variation in molecular weight of incorporated drug 
compounds in equine non cross-linked minirods showed that FITC dextran 20 
could freely diffuse in these matrices, because similar release profiles during 
the first 24h were observed in absence and presence of 0.1µg/ml collagenase 
(see Figure 4-42a and Figure 4-43a). In contrast, diffusion was restricted for 
FITC dextran 70 and 150 due to a higher hydrodynamic radius than matrix pore 
size. Initial release of FITC dextran 150 from equine non cross-linked matrices 
could be enhanced if collagenase was added, whereas this effect was less 
pronounced for FITC dextran 70 containing extrudates, because of their high 
apparent density (see Table 4-1). Comparing the release behavior after the first 
day, showed that erosion dependent release became important for all three 
kinds of dextran. Degradation of fully swollen equine non cross-linked minirods 
was similar irrespectively of the incorporated drug. If digestion of collagen 
extrudates was monitored in the presence of collagenase added already after 
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0.25h, the difference in apparent matrix density became more dominant, 
because the denser FITC dextran 70 minirods showed the slowest degradation 
profile.    
The influence of the molecular weight on drug release was more pronounced for 
equine EDC 1 cross-linked minirods than for equine non cross-linked matrices. 
Again, first of all pure swelling and diffusion controlled release was investigated, 
before release dependent on swelling, diffusion and matrix erosion was studied 
in more detail. According to their hydrodynamic radius, FITC dextran 20 was 
delivered faster than FITC dextran 70. FITC dextran 150 showed the slowest 
release during the first 6d when no collagenase was present (see Figure 4-44a). 
After 24h, 75% drug was released from minirods containing FITC dextran 20, 
whereas release of FITC dextran 70 and 150 was approximately 55%. After 2d, 
no further drug was delivered from FITC dextran 20 and 150 extrudates 
indicating that the complete mobile drug fraction was already released. In 
contrast, FITC dextran 70 delivery went on until approximately 70% was 
released after 6d.  
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Figure 4-44 Effect of the molecular weight of FITC dextran on drug release (a) and collagen 
degradation (b) of 10mm equine EDC 1 cross-linked minirods (0.1µg/ml enzyme was 
added after 6d; average ± SD; n=3) 
 
Compared to equine non cross-linked minirods (see Figure 4-42a), higher drug 
contents were immobilized inside the cross-linked collagen matrices. For FITC 
dextran 20 and 70 5% drug was added to the immobile fraction, whereas the 
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portion of FITC dextran 150 could be increased from 25% to 40%. This 
indicated that with additional cross-linking of the collagen drug device, the pore 
size was reduced and drug release by diffusion could be repressed which 
became effective especially for FITC dextran 150. Besides this, cross-linking of 
equine minirods resulted in a higher resistance against enzymatic attack and 
erosion controlled FITC dextran release could be reduced as compared to drug 
release from non cross-linked matrices (see Figure 4-42 and Figure 4-44). 
Complete FITC dextran 20 load was delivered from equine EDC 1 cross-linked 
matrices after 8d, whereas already after 5d 100% FITC dextran 20 could be 
detected in the supernatant of equine non cross-linked minirods. Due to the 
higher molecular weight of FITC dextran 150, more drug molecules were 
immobilized by the collagen matrix and FITC dextran 150 could not be delivered 
completely before day 22 (compared to 5d from non cross-linked minirods). 
Since both EDC 1 cross-linked devices were degraded at similar rates (see 
Figure 4-44b), it was concluded that for the delivery of the remaining 
immobilized FITC dextran fractions less collagen had to be digested to obtain 
complete FITC dextran 20 release (approximately 50% matrix degradation was 
sufficient) than for the FITC dextran 150 minirods (100% digestion was 
required). This confirmed the assumption that more drug molecules were 
immobilized in dense collagen matrices when their molecular weight was 
increased. As was already observed for equine non cross-linked minirods (see 
Figure 4-43b), equine EDC 1 cross-linked FITC dextran 70 extrudates showed a 
slower degradation behavior (see Figure 4-44b) than equine EDC 1 cross-linked 
matrices loaded with FITC dextran 20 and 150, respectively. Since swelling of 
EDC 1 cross-linked matrices was not as pronounced as for non cross-linked 
minirods after 6d (see Figure 4-9) and FITC dextran 70 matrices were denser 
than the other drug loaded matrices (see Table 4-1; FITC 20: 0.791g/cm³, FITC 
dextran 70: 1.011g/cm³, FITC dextran 150: 0.804g/cm³), penetration of 
collagenase and drug diffusion were more restricted. This resulted in a delayed 
complete FITC dextran 70 release from equine EDC 1 cross-linked minirods 
over 34d (see Figure 4-44a).  
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In the presence of collagenase, higher initial release rates were detected for 
equine EDC 1 cross-linked FITC dextran 20 and 150 matrices (see Figure 
4-45a) than in absence of the enzyme (see Figure 4-44a), because swelling, 
diffusion and erosion controlled delivery occurred simultaneously. Within 24h 
90% FITC dextran 20 and 65% FITC dextran 150, respectively, were delivered 
when 0.1µg/ml collagenase was present (compared to 75% FITC dextran 20 
and 55% FITC dextran 150 liberation when collagenase was absent). Similar 
FITC dextran 70 delivery within the first 24h (approximately 55% release) was 
observed for equine EDC 1 cross-linked matrices, irrespectively of collagenase 
presence. Since these minirods exhibited the highest apparent density (see 
Table 4-1) the lowest degradation profile was the consequence (see Figure 
4-45b) and release was independent of erosion during the first 72h.  
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Figure 4-45 Effect of the molecular weight of FITC dextran on drug release (a) and collagen 
degradation (b) of 10mm equine EDC 1 cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h; average ± SD; n=3) 
 
For equine EDC 1 cross-linked FITC dextran 20 and 150 devices a more 
pronounced digestion was detected and both types of minirods were degraded 
in a similar fashion. This resulted in a more delayed release of FITC dextran 
150 due to more interactions with the cross-linked collagen structure (Weadock 
et al.; 1987).  
For bovine corium material, the influence of different EDC cross-linking ratios on 
release of FITC dextran 20 and 70 were tested (see Figure 4-46a). The drug 
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release profiles indicated a fast release from EDC 0.25 minirods independent of 
the molecular weight of FITC dextrans, because of a fast matrix erosion in the 
presence of 0.1µg/ml collagenase at 37°C (see Figure 4-37 and Figure 4-46b). 
This suggested that this cross-linking treatment did not create enough linkages 
to reduce the free diffusion of the drugs as was also concluded for the FITC 
dextran 20 release from equine non cross-linked minirods. At a cross-linking 
ratio of 1 sufficient hindrances were incorporated into the collagen material to 
delay the FITC dextran 70 release more significantly than the FITC dextran 20 
delivery. Incorporated FITC dextran did only affect the degradation behavior of 
bovine corium EDC cross-linked matrices fractionally for both cross-linked ratios 
(see Figure 4-46b).  
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Figure 4-46 Effect of the molecular weight of FITC dextran on drug release (a) and collagen 
degradation (b) of 10mm bovine corium EDC 0.25 and EDC 1 cross-linked minirods 
(0.1µg/ml enzyme was added after 0.25h; average ± SD; n=3) 
 
The influence of the molecular weight on drug release could be clearly shown 
for EDC cross-linked matrices. Pure swelling and diffusion controlled release 
from equine EDC 1 cross-linked extrudates decreased with an increase in 
molecular weight of FITC dextran. If 0.1µg/ml collagenase was added release 
was enhanced for FITC dextran 20 and 150, but not for FITC dextran 70. This 
indicated that the higher apparent density of FITC dextran 70 loaded equine 
EDC 1 cross-linked devices is responsible for the suppression of release by 
diffusion and not exclusively the molecular drug size. The investigation of 
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different EDC cross-linking degrees of bovine corium extrudates showed that 
delivery could only be controlled if sufficient new cross-links were introduced by 
an EDC cross-linking of 1.   
4.3.5.2 Variation in Drug Concentration  
Finally, the influence of total drug load on FITC dextran 70 release was 
investigated. Numerous studies on various delivery systems have shown that 
this parameter may substantially influence the release behavior, e.g. for 
collagen minipellets (Sano et al.; 2003), collagen discs (Gilbert; 1988b), 
poly(orthoester) discs (Sparer et al.; 1984), EVAc matrices (Saltzman; 2001) 
and tristearin implants (Mohl; 2004).  
Maeda et al. investigated the incorporation of HSA into minipellets (Maeda et 
al.; 1999). HSA was found as fine particulated clusters inside the matrices 
which were homogeneously distributed throughout the complete collagen 
extrudate. After water contact, these clusters dissolve and the drug could be 
released. As a result, small cavities remained inside the matrix at the areas 
where HSA was located before dissolution (Maeda et al.; 1999; Sano et al.; 
2003). Although Gilbert et al. postulated that drug loads higher than 10% inulin 
were necessary to create additional cavities (Gilbert et al.; 1990), Maeda et al. 
could demonstrate that even 1% HSA was sufficient to observe small pores in 
the surface of collagen extrudates during release (Maeda et al.; 1999). Since 
the structure of our minirods resembled more Maeda’s extrudates and because 
model drugs with higher molecular weights were used, it was assumed that new 
pores could be built during FITC dextran release as well. A 2% FITC dextran 70 
concentration was used as highest model drug concentration. FITC dextran 
solutions with higher concentrations show markedly increased viscosity which 
may lead to inhomogeneous drug distribution. Furthermore, the intense 
fluorescence may cause trouble in fluorescent investigations. As was also 
observed for HSA, interferon alpha and G-CSF release from collagen 
minipellets (Sano et al.; 2003), an increase in drug concentration resulted in a 
relative increase in drug liberation (for FITC dextran 70 see Figure 4-47a), 
because more cavities could be built. The density of the FITC dextran 70 loaded 
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devices (see Table 4-1; 1%: 1.109g/cm³, 2%: 0.829g/cm³) and consequently the 
thickness of the diffusion barrier decreased and a faster release took place 
(Sano et al.; 2003). This observation was made with highly water soluble 
compounds which are readily released by diffusion. Besides “normal” diffusion 
through water filled pores, diffusion through the swollen matrix itself could take 
place. This was observed for the release of hGH from air dried 2% collagen 
films (Maeda et al.; 2001). A 3% drug load resulted in Fickian diffusion, whereas 
release of 30% hGH was accelerated and became dependent on diffusion 
through water filled pores as well as the swollen matrix itself. If the drug is less 
soluble under physiological conditions or if interactions between drug and 
collagen occur, drug loading and diffusion controlled release becomes less 
important. This effect was observed for rh-BMP 2 (recombinant human bone 
morphogenetic protein 2) release from minipellets (Maeda et al.; 2004b). For rh-
BMP 2, diffusion controlled delivery could be amplified if glutamic acid was 
added which lowers the pH value inside the collagen matrix and increases the 
solubility of collagen and rh-BMP 2 (Maeda et al.; 2004a).  
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Figure 4-47 Effect of the FITC dextran 70 concentration on drug release (a) and collagen 
degradation (b) of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h; average ± SD; n=3) 
 
Since degradation of 1% and 2% minirods was identically the assumption of 
pore formation and additional diffusion controlled release through these new 
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cavities could be accepted for our minirods. This resulted in a higher initial 
release for the 2% devices (see Figure 4-47). 
4.3.6 Summary  
The objective of this chapter was to investigate the in vitro release of FITC 
dextrans from collagen minirods. Since drug release from collagen devices is 
mainly governed by diffusion dependent liberation (Radu et al.; 2002), diffusion 
equations had to be implemented into the mathematical model (see 4.5). 
Therefore, the diffusion coefficients in water of FITC dextran 20, 70 and 150 
were determined by FCS. According to their molecular weights, the diffusion 
coefficient decreased from 3*10-3cm²/h for FITC dextran 20 to 1.8*10-3cm²/h for 
FITC dextran 150. The observed diffusion coefficient of FITC dextran 70 
(2.4*10-3cm²/h) corresponded well with the diffusion coefficient of collagenase, 
described in the literature, and was consequently used for the enzyme in the 
mathematical model as well. 
Drug release was investigated with respect to the used collagen matrix quality, 
the incorporated drug and the added enzyme. If higher amounts of collagenase 
were added, FITC dextran 70 release and collagen degradation became faster 
(24h release: 0µg/ml collagenase: 35%, 0.1µg/ml collagenase: 50%, 6.7µg/ml 
collagenase: 85%, 24h degradation: 0.1µg/ml collagenase: 15%, 6.7µg/ml 
collagenase: 55%) and less drug was entrapped inside the collagen matrix, 
suggesting that a distinct drug portion could only be released by matrix erosion. 
It was demonstrated that the addition of collagenase to a fully swollen matrix 
resulted in faster collagen digestion, because more enzyme binding and 
cleavage sites became accessible.  
Using different collagen materials for minirod preparation gave a tool to control 
drug release. A fast release (and degradation) was observed for pulverized 
equine non cross-linked collagen and bovine tendon non cross-linked minirods. 
Delivery could be delayed by using lyophilized equine material. Further 
retardation in drug liberation was achieved by cross-linking. DHT treatment 
resulted in lower enzymatic resistance than EDC cross-linking (Pieper et al.; 
1999) and in consequence release was not as suppressed as from chemically 
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cross-linked matrices. Different ratios of EDC cross-linking were examined. 
Both investigated types of collagen, equine and bovine corium, showed the 
most promising results for EDC 1 cross-linked materials. 
With changing the dimensions of the extrudates, drug release could also be 
controlled. Increasing the length or diameter of the cylindrical rods resulted in a 
decrease of FITC dextran 70 delivery. This was attributed on the one hand to an 
increase of the smooth lateral surface area, if minirods were elongated, which 
exhibit a more hindered release pattern than the porous cross-section. On the 
other hand, if extrudates were thickened, diffusion ways increased and the 
specific surface area decreased which resulted in a lower particle release by 
diffusion. 
The last parameters which can influence drug release derive from the 
incorporated drug itself. In general, it is assumed that increasing the molecular 
weight lead to slower release by diffusion. However, the theoretical order FITC 
dextran 20 - 70 - 150 could only be detected for the diffusion based release 
from equine EDC 1 cross-linked minirods. The other collagen matrices met 
another order: FITC dextran 70 was always released slowest followed by FITC 
dextran 150 and 20. This change in sequence was attributed to the higher 
apparent density of FITC dextran 70 extrudates resulting in a lower degradation 
behavior. Since the other two FITC dextran loads exhibited almost identical 
matrix densities, the liberation of FITC dextran 150 was delayed due to more 
pronounced interactions with the collagen mesh. This indicated that the 
influence of the matrix structure on the release and degradation pattern was 
more pronounced than the effect of the molecular size of the incorporated 
drugs. If the incorporated drug portion was increased, faster release occurred. It 
was assumed that the faster release from 2% matrices derive from diffusion 
controlled release through newly formed cavities built at positions formerly filled 
by drug, because 1% and 2% minirods were degraded identically.   
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4.4 In vitro and in vivo Release of PCA-BSA 
After characterization of the in vitro release of FITC dextrans, the in vitro and in 
vivo release of bovine serum albumin (BSA) from collagen minirods was 
investigated. BSA was chosen as a model protein compound, because no 
interactions with collagen, which could affect the release profile, are known 
(Maeda et al.; 1999). Furthermore, spin labeling of BSA, necessary for ESR 
investigations, is fast and simple (Katzhendler et al.; 2000a) and due to its 
molecular weight (MW (BSA): 66kDa), comparison with the in vitro release data 
of FITC dextran 70 is possible.  
4.4.1 Introduction to Electron Spin Resonance (ESR) Spectroscopy 
Release of BSA was observed using ESR spectroscopy. In literature, synonyms 
for this method are “electron paramagnetic resonance” (EPR) and “electron 
magnetic resonance” (EMR). This technique is closely related to the better 
known nuclear magnetic resonance (NMR), because in both methods magnetic 
dipoles interact with an externally applied magnetic field (Swartz et al.; 1972). 
The main difference is the detected particle species: with ESR, unpaired 
electron spins are quantified, whereas in NMR measurements the behavior of 
protons in the applied magnetic field is monitored (Mäder; 1998).  
4.4.1.1 Physical Principles 
Electrons can be regarded as small bar magnets with north and south poles, 
because they have own magnetic moments arising to 99% from their quantum-
mechanical “spin” (called spin magnetic moment) (Lurie et al.; 2005; Swartz et 
al.; 1972). In general, stable chemical bonds consist of paired electrons with 
opposite spins, according to the Pauli exclusion principle (Swartz et al.; 1972). 
This is imperative in order to coexist in such close vicinity. The magnetic 
moment of paired electrons is erased (Lurie et al.; 2005). In contrast, unpaired 
electrons have a magnetic moment which can interact with the externally 
applied magnetic field 0B  during ESR measurements. 
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Figure 4-48 Electron spins without (left) and with externally applied magnetic field (right) 
(modified from (Mäder; 1998)) 
 
Two orientations of the electron spins in the presence of an externally applied 
magnetic field are possible (see Figure 4-48). Spins can either be aligned along 
the externally applied magnetic field or against it. This effect, known as the 
Zeeman splitting, results in two different energy states for the electron spins, a 
low energy state (m=-1/2) and a high energy state (m=+1/2) (see Figure 4-49). 
The energetic difference E∆  between these two states is dependent on the 
strength of the applied magnetic field 0B  and the molecular weight of the 
excited species. Due to the lower mass of electrons, the Bohr magneton is 
larger than that of protons and a higher energetic difference E∆  between the 
two states results which increase the sensitivity of ESR compared to NMR 
measurements (Mäder; 1998). In ESR investigations, electromagnetic radiation 
with frequencies between 0.3 - 10GHz are used to excite unpaired electrons 
(Lurie et al.; 2005). At the resonance conditions, the photon energy of the 
electromagnetic radiation matches the difference between the two energy states 
E∆  (see Figure 4-49). Electrons can now adsorb energy and jump from the low- 
to the high-energy state by flipping their electron spins by 180° (Lurie et al.; 
2005).  
 
 
B0 no B0 
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Figure 4-49 Electronic energy level diagram with resonance conditions (modified from (Mäder; 
1998)) 
 
Since all physical systems prefer the low-energy state, electrons fall back at this 
level within 0.1 – 1µs and simultaneously release electromagnetic radiation at 
the same frequency as the excitation frequency (Lurie et al.; 2005). If many 
electrons pass through this scenario at the same time, the resulting electron 
magnetism is strong enough to alter the externally applied magnetic field by 
reflecting parts of the applied microwaves. This change is detected during ESR 
measurements (Swartz et al.; 1972) and is monitored either as adsorption 
spectrum (amplitudes of the reflected microwaves versus magnetic field 
strength) or as first derivative spectrum (slope of the adsorption spectrum 
against magnetic field strength) (see Figure 4-50) (Lurie et al.; 2005).  
 
 
∆E:  energy difference between the two spin states 
h: Planck constant 
v: microwave frequency 
g: g-factor or Zeeman splitting factor (e-= 2.0023; H+= 5.5856) 
µ: Bohr magneton (e-= 9.274*10-24JT-1; H+= 5.051*10-27JT-1) 
B0:  applied magnetic field 
mS: quantum number 
E mS = + 1/2
mS = - 1/2
hvBgE ==∆ 0µ
B0
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Figure 4-50 Adsorption (top) and first derivative (bottom) ESR spectrum (modified from 
(Palmer; 1999)) 
 
In general, ESR spectra consist of more than one individual line, because 
unpaired electrons interact not only with the externally applied magnetic field, 
but also with the magnetic moments of nuclei (Katzhendler et al.; 2000b). The 
electron-nucleus interaction can take place between unpaired electrons and its 
own nucleus or a neighboring nucleus (Palmer; 1999). Since the nitrogen 
nucleus has a nuclear spin of 1, three orientations in the applied magnetic field 
are possible, resulting in three different magnetic moments (Katzhendler et al.; 
2000b). Unpaired electrons in nitroxides are exposed to a magnetic field 
composed of the strong externally applied magnetic field and a weaker local 
magnetic field of the nitrogen nucleus. The consequence is a “hyperfine 
splitting” of the ESR signal e.g. a three line spectrum for nitroxides, because the 
resonance condition is satisfied at three different values of the externally 
applied magnetic field (see Figure 4-51) (Swartz et al.; 1972). Hydrogen nuclei 
in vicinity of the nitrogen nucleus also influence the ESR spectrum. Their effect 
B0 
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is far less pronounced than that of the nitrogen nucleus, due to a greater 
distance to the unpaired electron, and results in line broadening instead of  
additional hyperfine splitting (Lurie et al.; 2005).  
Besides the permanent magnetic electron-nucleus interactions, orbital-orbital 
coupling effects occur as well, which depend on the symmetry of the electron 
orbital (Assenheim; 1966). This effect, known as the orbital magnetic moment, 
contributes the remaining 1% to the total magnetic moment of electrons (Swartz 
et al.; 1972) and is displayed in the ESR spectrum shape. If electrons of a 
spherical orbital (s-orbital) take part, isotropic interactions occur and the ESR 
spectrum is composed of identical lines. If a conical orbital (p-orbital) 
participates, the ESR signal is influenced by the three different planes (x, y and 
z). An anisotropic environment results, reflected by different, broadened line 
shapes which superpose to the finally observed spectra (see Figure 4-51 
bottom). These anisotropic effects can only be averaged out, if the detected 
electron can tumble very fast (see Figure 4-51 top) (Palmer; 1999).  
Summarizing the presented influences on electrons shows that the spectrum 
shape and width provide information about the molecule structure (Swartz et al.; 
1972).  
4.4.1.2 Samples 
A main advantage of ESR measurements is that a high variety of samples can 
be examined without any pre-treatment. All states of aggregation (liquid, solid or 
gaseous) can be studied. Furthermore, samples can be investigated without 
destruction and they must not be transparent or homogenous, as in other 
commonly used spectroscopic techniques. Due to the high sensitivity of this 
method, concentrations down to the nanomolar region can be detected (Mäder; 
1998). Samples for ESR measurements must have almost only one unique 
property: they must be paramagnetic, that means they must contain free 
electron spins arising from unpaired electrons. Otherwise they are ESR “silent” 
and no signal can be detected. In general, two kinds of paramagnetic samples 
are possible. On the one hand, samples which already contain unpaired 
electrons, e.g. oxygen, metals and transition metals or where radicals are 
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introduced by e.g. γ-irradiation (Mäder; 1998). Especially free radicals often 
exist only at a small number and have very short life times. Consequently, they 
can only be detected at low temperatures or with spin trapping techniques 
(Lurie et al.; 2005). On the other hand, stable free radicals can be incorporated 
into ESR silent diamagnetic samples as spin probes (physical incorporation) or 
spin labels (chemical incorporation) (Mäder; 1998). Due to their higher stability, 
measurement at room temperature is possible. Spin probes, like nitroxides can 
either be used directly, e.g. to simulate small model drugs, or can be used to 
label larger molecules, like polysaccharides or proteins (Lurie et al.; 2005). 
Pyrrolidine derivates, e.g. 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy 
(PCA), are more stable than piperidine radicals, e.g. 4-hydroxy-2,2,6,6-
tetramethyl-1-piperidinyloxy (TEMPOL) (Mäder; 1998; Yoshioka et al.; 1995). 
Limitations in sample selection are the size, restricted by the cavity dimensions, 
and the water content due to non-resonant dielectric loss (Lurie et al.; 2005). 
Samples of approximately 3mm in diameter and 10mm in length are normally 
used in X-band spectrometers. The water content is often the limiting factor if 
biological samples are examined. Water is electrically conductive, strongly 
interacts with the applied microwaves and limits the penetration depth to 
approximately 1mm for X-band spectrometers (Mäder et al.; 1996). 
Consequently, often only the outer surface of the sample can be investigated 
(Katzhendler et al.; 2000b). To overcome these limitations, low frequency 
spectrometers have been developed. The penetration depth is increased to e.g. 
16mm for L-band spectrometers (1GHz) (Mäder et al.; 1994) and direct in vivo 
studies of mice become possible (Lurie et al.; 2005; Saito et al.; 1997). A 
decrease in frequency goes along with a lower splitting of the energy levels 
which results in a remarkable decrease in sensitivity (Mäder et al.; 1994). 
4.4.1.3 Spectra Analysis 
In general, the first derivate spectrum is used for analysis. Different information 
can be drawn from ESR signals to characterize the homo- or heterogeneity of 
the investigated sample. Information about the molecule structure and its 
environment can be obtained. Using the phenomenon of hyperfine splitting, the 
microviscosity and the micropolarity can be determined. For this purpose, the 
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order parameter S and the hyperfine coupling constant an are used (see Figure 
4-51).  
To monitor the rotational freedom of the spin probe, the order parameter S is 
used. Values of 1 correspond to an entirely immobilized spin probe, whereas 
values approaching 0 indicate complete spin probe mobility (see Figure 4-51) 
(Katzhendler et al.; 2000b). Besides the change in S parameter, the value of an 
increases as well, when spin probes exhibit low mobility. 
 
 
Figure 4-51 PCA dissolved in water, 50/50 water/glycerol, 30/70 water/glycerol and in dry state 
(from top to bottom) with corresponding S parameters and hyperfine coupling 
constant an (modified from (Katzhendler et al.; 2000b)) 
 
The spectrum is a superposition of many individual spectra which arise from the 
slightly shifted orientation of electrons to the externally applied magnetic field. 
At low viscosities, effective averaging of the anisotropic spin-lattice interactions 
an 
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is possible due to a fast molecular tumbling of the radical. This results in three 
narrow lines, known as the Lorentzian line shape (Katzhendler et al.; 2000b). 
Increased viscosity is reflected by line broadening of the spectrum accompanied 
by a decrease in signal amplitude (see Figure 4-51 middle). Anisotropic effects 
can not be averaged as completely as in low viscosity systems (Capancioni et 
al.; 2003). This results in a Gaussian line shape. At this stage, the influence of 
nuclei becomes very important (Katzhendler et al.; 2000b). In the solid state, an 
asymmetric line shape is obtained, named “glass” or “powder” spectrum (see 
Figure 4-51 bottom).  
The absolute concentration of spin probes can be determined by the peak area 
of the adsorption spectra. Relative concentrations can be estimated by 
comparison of the spectra amplitudes of the first derivate spectra (see Figure 
4-50). In most cases, relative concentrations are determined, because for 
measuring absolute concentrations tremendous demands on experimental 
setup and analysis are necessary, including e.g. an internal standard (Mäder; 
1998). Determination of spin probe concentrations can be used e.g. to monitor 
drug release.  
Further insights into the mechanism of drug release can be gained by focusing 
on the changes in spectra intensity and shape during the observation period. 
Drug release controlled by surface erosion results in a decrease of spectra 
intensity with identical signal shape over the complete time, because the 
mobility of the radical remains constant. In contrast, spectra of drugs released 
by diffusion, swelling and/or bulk erosion change in intensity and shape due to a 
change in drug mobility (Lurie et al.; 2005). Spectra of dissolved and unsolved 
molecules superimpose. The S parameter changes over time, similar as 
observed for variation in viscosity (see Figure 4-51). Beyond this, degradation of 
the polymer and/or penetration of water are associated with a decrease in 
spectrum intensity because of reduction in the stabilizing environmental effects 
(Mäder; 1998).  
Due to adequate ESR spectrometers (see 4.4.1.2), in vivo investigations can be 
performed as well. Non-invasive in vivo drug release studies can be conducted 
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to correlate in vitro and in vivo data (Lurie et al.; 2005). Furthermore, all these 
investigations can be detected 2- or 3-dimensionally by simultaneously using 
different nitroxides (or different isotopes of the same nitroxide) or by applying 
imaging techniques (Lurie et al.; 2005). 
4.4.2 Labeling of BSA 
For ESR measurements, BSA was spin labeled with PCA. To verify that labeling 
had taken place, spectra of PCA-BSA were compared with spectra of pure 
PCA. PCA showed three identical narrow lines (see Figure 4-52), indicating 
high mobility of the small molecule in solution. If the spin label is bound to the 
protein, its mobility is reduced and lines in the spectra, especially in the high-
field, become broadened (Yoshioka et al.; 1995). This effect was observed for 
PCA-BSA, indicating that binding had taken place. 
B0
PCA-BSA
PCA
 
Figure 4-52 ESR spectra of PCA-BSA (top) and PCA (bottom) in water (determined by an L-
band ESR spectrometer) 
 
During spin labeling protein aggregation can take place. An increase in 
aggregate level would limit the in vivo application, because of potentially 
increased immunogenicity and formation of antibodies on the one hand 
(Hermeling et al.; 2004) and interferences in release kinetics on the other hand. 
As could be seen with SDS-PAGE (see Figure 4-53), the amount of monomers 
and aggregates were similar before and after labeling. This indicated that 
labeling did not induce aggregation and PCA-BSA could be used for in vivo 
studies. 
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Figure 4-53 Stability of BSA after labeling with PCA (lane 1: MW marker, lane 2: BSA, lane 3: 
PCA-BSA) 
 
 
 
Figure 4-54 Stability of PCA-BSA during incubation without (left) and with 0.1µg/ml collagenase 
(right) at 37°C (lane 1: MW marker, lane 2: non-incubated PCA-BSA, lane 3: PCA-
BSA incubated for 1h, lane 4: PCA-BSA incubated for 12h, lane 5: PCA-BSA 
incubated for 24h) 
4 Results and Discussion 158 
published by Verlag Dr. Hut, Munich, ISBN: 3-89963-253-2 
Before in vitro and in vivo drug release tests from collagen devices could be 
carried out, the possibility of enzymatic hydrolysis of BSA had to be considered. 
Collagenases are enzymes which only cleave collagen at specific amino acid 
sequences within its helical parts (Harrington; 1996). For in vitro studies we 
used a commercially available crude bacterial collagenase mixture which also 
exhibits caseinase activity (Sigma Aldrich; 1998). In vivo, proteinases which 
may cleave PCA-BSA are present as well. SDS-PAGE of labeled BSA 
incubated with and without crude bacterial collagenase indicated, that PCA-BSA 
was stable against enzymatic attack, because no enzymatic hydrolysis products 
could be observed in the presence of collagenase (see Figure 4-54).  
4.4.3 In vitro Release of BSA  
Since drug release from collagen devices is swelling, diffusion and erosion 
controlled (see 1.2.3.1), two different experimental setups were conducted. On 
the one hand, exclusively swelling and diffusion controlled release in the 
absence of collagenase was studied. On the other hand, bacterial collagenase 
was added to investigate the influence of matrix degradation on drug release. 
For measurements, minirods as a whole had to be transferred from the 
incubation buffer into the ESR spectrometer and the end of experiments was 
determined by the compactness of the minirods. Investigations were performed 
as long as it was possible to handle minirods properly. PCA-BSA release was 
estimated relatively by comparison of spectra amplitudes. Signal amplitudes 
decreased over time (see Figure 4-55, Figure 4-56 and Figure 4-57), indicating 
that the concentration of PCA-BSA decreased inside the minirods and that drug 
release occurred.  
Before contact to Tris buffer pH 7.5, a “powder” PCA-BSA spectrum was 
observed for all minirods (see Figure 4-55 and Figure 4-56). This indicated that 
the labeled BSA was immobilized inside the dry collagen matrices. After contact 
with the aqueous solution, water penetrated into the device and the ESR 
spectra changed to spectra of more mobile PCA-BSA, because the anisotropy 
of the hyperfine interaction was partially averaged and reorientation times 
decreased. However, the mobility was not as pronounced as that of PCA in 
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water (see Figure 4-52 top), because an was larger. In absence of collagenase, 
drug release was expected to be mainly diffusion controlled. This should result 
in a change in ESR spectra shape. With 0.1µg/ml collagenase, drug release 
might be dependent on matrix erosion as well. In case of pure erosion 
controlled release, no change in spectra shape should be observed (see 
4.4.1.3). 
 
Figure 4-55 ESR spectra of 10mm PCA-BSA loaded bovine tendon non cross-linked minirods 
incubated without (a) and with 0.1µg/ml collagenase (b) at 37°C 
 
Significant changes in spectra form and S parameter were observed for bovine 
tendon non cross-linked minirods with and without addition of collagenase (see 
Figure 4-55). Lines became broadened with longer observation time, as can be 
seen e.g. in the 4h spectra. A similar observation was made for bovine tendon 
EDC 1 cross-linked minirods in absence of collagenase (see Figure 4-56a). an 
increased from day 1 until the end of investigation. In the beginning, drugs 
which were not immobilized by the matrix could diffuse freely inside the matrix 
and spectra superimposed with the spectra of the less mobile drugs. 
Consequently, spectra of mobile PCA-BSA were observed with reorientation 
times between the time required in pure solution and in solid state. If the mobile 
PCA-BSA was released, the observed spectra were more and more dominated 
by the remaining immobilized drug fraction and the spectra shape changed. 
This indicated on the one hand that an environment with intermediate viscosity 
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was created and on the other hand that diffusion control was the dominating 
factor of PCA-BSA release.  
In contrast, for PCA-BSA signals of bovine tendon EDC 1 cross-linked matrices 
incubated with collagenase only a decrease in amplitude could be detected, but 
hardly no variation in spectra shape (see Figure 4-56b). This indicated that the 
environment inside the collagen minirods and in consequence the mobility of 
labeled BSA changed only marginally in these EDC cross-linked minirods over 
the complete observation period. Hence, besides swelling and diffusion 
phenomena, BSA delivery was also erosion controlled in bovine tendon EDC 1 
cross-linked minirods. This could be attributed to the higher number in 
hindrances compared to non cross-linked extrudates (see 4.1.1.2 and Table 
4-2). Reduced swelling and a more pronounced PCA-BSA immobilization was 
the result, and the immobilized drug fraction could only be released by erosion 
mechanism.  
Figure 4-56 ESR spectra of 10mm PCA-BSA loaded bovine tendon EDC 1 cross-linked bovine 
tendon minirods incubated without (a) and with 0.1µg/ml collagenase (b) at 37°C 
 
Diffusional drug release is dependent on the cross-linking degree of minirods, 
because a higher number of cross-links hampers diffusion of macromolecules 
(Frieß et al.; 1996b; Gilbert et al.; 1988a). As was already demonstrated by 
DSC measurements (see 4.1.1.2), the extent of cross-linking increased from 
bovine tendon non cross-linked over bovine corium EDC 1 cross-linked to 
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bovine tendon EDC 1 cross-linked collagen. The in vitro PCA-BSA release in 
pure Tris buffer pH 7.5 decreased in the same order (see Figure 4-57a), 
because a lower number of cross-links led to a more rapid swelling and more 
pronounced diffusion controlled release within the first day. This confirmed the 
assumption that a higher cross-linking degree delayed the PCA-BSA release.  
Figure 4-57 Signal amplitudes of ESR spectra of 10mm PCA-BSA loaded minirods incubated without 
(a) and with 0.1µg/ml collagenase (b) at 37°C (n=3) 
 
For all three types of minirods a change in spectra shape was observed, 
indicating that the major fraction of labeled BSA release was governed by 
diffusion of the mobile BSA. In the presence of collagenase, swelling, diffusion 
and erosion controlled drug release occurred simultaneously. Again, bovine 
tendon non cross-linked minirods showed the fastest release and bovine tendon 
EDC 1 cross-linked the slowest (see Figure 4-57b). Differences to the release 
without enzyme were observed. PCA-BSA delivery became faster, because 
minirods started earlier to disintegrate in the presence of collagenase (see 
4.1.2.1.2 and 4.3.2.1). More PCA-BSA could be released, because the PCA-
BSA fraction which was entrapped in the collagen matrix by cross-links could 
now be liberated by erosion. The extent of the erosion controlled delivery was 
lower for bovine tendon non cross-linked minirods than for EDC 1 cross-linked 
extrudates (10% versus 20%). By investigation of the spectra shape it became 
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evident that the release from EDC 1 cross-linked minirods is partly erosion 
controlled, because no change in spectra shape could be detected. At later 
incubation time points, measurements became impossible, because matrices 
were too instable to guarantee a complete transfer of the minirods into the ESR 
cavity. Consequently, only approximately 80-90% labeled BSA could be 
recovered, because PCA-BSA which remained inside the matrix until complete 
matrix disintegration could not be detected by this method. 
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Figure 4-58 In vitro drug release from 10mm bovine tendon EDC 1 cross-linked minirods 
incubated with 0.1µg/ml collagenase added after 0.25h (average ± SD; n=3) 
 
Good correlation was found for the first week between the PCA-BSA release 
and the in vitro release of FITC dextran 70 from bovine tendon EDC 1 cross-
linked minirods (see Figure 4-58). FITC dextran 70 delivery was followed until 
matrices were completely disintegrated and 100% of the incorporated FITC 
dextran 70 was recovered compared to 80-90% PCA-BSA.  
From this observation two conclusions could be drawn: FITC dextran 70 also 
shows only low interactions with collagen due to a congruent release profile with 
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labeled BSA during the first week, and the PCA-BSA fraction which was not 
recovered, remains inside the devices until the matrix disintegrates completely.  
4.4.4 In vivo Release of BSA 
The in vivo release of PCA-BSA was investigated in adult domestic pigs due to 
close resemblance to human histology (Burke et al.; 1983) and metabolism 
(Hönig et al.; 1993). Furthermore as a large animal, morphological and 
anatomical features are quite similar to humans. This is prerequisite for a good 
result transfer to humans (Thorwarth et al.; 2005). Implants can be injected 
subcutaneously by a trocar (Kissel et al.; 1991) to achieve a systemic effect or 
they can be administered directly in or nearby a superficial lesion, e.g. during 
surgery, for local treatment (Fujioka et al.; 1995). In the performed in vivo study, 
minirods were implanted subcutaneously into ears by surgery. After sacrificing 
the animals at designated time points, minirods were explanted and divided into 
two groups. Drug release was investigated by ESR measurements and in vivo 
compatibility by histology.  
In vivo ESR measurements are more challenging than in vitro experiments. The 
high water content of biological tissue reduces the penetration depth due to a 
high dielectric loss (Mäder; 1998). This dielectrical loss occurred by the 
measurement of the complete explanted tissues as well. Therefore, 
measurements were conducted in an X-band spectrometer (9.3GHz). 
Interference of water from the surrounding tissue was avoided and an overview 
of drug transportation was provided by introducing explants into TLC capillaries 
before ESR assessment. Distinction between the interior and the exterior of 
minirods, near (< 1mm) and distant (2-5mm) tissue and cartilage was made. As 
can be seen in Figure 4-59, the amplitudes of PCA-BSA signal decreased from 
the center to the minirods boundaries. This indicated that PCA-BSA was at first 
released near the matrix surface, before release occurred in the matrix interior. 
For tissue and cartilage only marginal ESR signals were observed with an 
additional change towards spectra of higher mobility. Hence, the labeled BSA 
was removed fast from the implantation site by diffusion phenomena after 
release from the collagen matrix. 
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Figure 4-59 ESR spectra of 10mm PCA-BSA loaded bovine tendon EDC 1 cross-linked minirod 7d 
post implanataion (i: center of the minirod, e: boundary of the minirod, n: tissue near 
the minirod, d: tissue distant from the minirod, c: cartilage) 
 
The in vivo release of PCA-BSA was monitored for 56d. The spectral shape of 
PCA-BSA loaded extrudates before implantation represented a so called 
“powder” ESR spectrum (see Figure 4-60; pre-implantation). It indicates a 
“frozen state” of the label, e.g. a very low degree of mobility. These spectral 
shapes are expected in dry and solid matrices. The spectral shape of the 
implants changed significantly within the first 5d after implantation for all 
collagen species (see Figure 4-60; 5d). The anisotropy of the hyperfine 
interaction was partially averaged and the nitroxide reorientation time was in the 
range of few nanoseconds. The mobility was significantly increased compared 
to day zero, but still much lower compared to an aqueous solution, where the 
molecule reorients in the order of several hundred picoseconds (see Figure 
4-52 top). It was concluded that water penetration into the implant occurred in 
vivo within 5d, going along with creation of an environment with intermediate 
viscosity. The resulting spectral changes of the first 5 days were comparable for 
all minirods. However, significant differences between the non cross-linked and 
EDC 1 cross-linked samples were found in the following days. 
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Figure 4-60 “Interior” ESR spectra of 10mm PCA-BSA loaded bovine tendon non cross-linked 
(a) and EDC 1 cross-linked (b) minirods and bovine corium EDC 1 cross-linked (c) 
minirods 
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The drug retention in the implant was determined by relative comparison of the 
signal amplitudes of the interior spectra. Signal amplitudes decreased over time 
for all three minirods until day 14. At day 28, only for bovine tendon EDC 1 
cross-linked minirods a signal in the magnitude of the detection noise was 
detectable and after 56d no signal could be measured for any minirods (see 
Figure 4-60). Besides the decrease in signal amplitudes, only the spectra shape 
of PCA-BSA in non cross-linked bovine tendon extrudates altered (see Figure 
4-60a). As was observed for the in vitro release (see 4.4.3), PCA-BSA mobility 
changed because release was mainly diffusion controlled. Almost no 
modifications in spectra shape were detected for PCA-BSA in EDC 1 cross-
linked minirods (see Figure 4-60b, c), indicating that the model protein was 
immobilized and delivery after 5d was also dependent on matrix erosion. This 
observation was consistent with the conclusion drawn from the in vitro drug 
release from EDC 1 cross-linked matrices in the presence of collagenase (see 
4.4.3).  
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Figure 4-61 Signal amplitudes of ESR spectra of 10mm PCA-BSA loaded minirods post 
implantation (n=3) 
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After 7d, approximately 90% PCA-BSA was liberated from bovine tendon non 
cross-linked and bovine corium EDC 1 cross-linked minirods and release was 
completed within 14d (see Figure 4-61). In contrast, 20% PCA-BSA was still 
present in bovine tendon EDC 1 cross-linked minirods after 5d and release was 
finished not until 28d. The same rank order of in vivo release rates was 
observed as in the in vitro studies (see Figure 4-57).  
Comparison of in vitro (see Figure 4-57) with in vivo data (see Figure 4-61) 
showed that besides the same release mechanism and the same order in 
release profiles, a similar magnitude in release time was observed. In general, 
in vivo release is often slower than in vitro, because water accessibility can be 
decreased and/or pH values can vary due to differences in buffer capacity 
(Lurie et al.; 2005). However, the main difference responsible for slower release 
in vivo is the implant encapsulation and consequently an additional diffusion 
barrier which hampers drug release (Anderson et al.; 1981). For our minirods 
only slight encapsulation was observed (see 4.4.5) and therefore the major 
reason for the slower in vivo release was the slightly restricted swelling and the 
slower degradation in pigs compared to the in vitro setups. Swelling was 
suppressed by surrounding tissue and the lower water content at the 
implantation site. Degradation was minimized because the restricted swelling 
hindered enzyme penetration and due to the lower in vivo enzyme 
concentrations. Analyzing all collected in vitro and in vivo data showed that in 
vitro and in vivo results were comparable. However, an in vitro - in vivo - 
correlation according to USP standards was not performed, because in vivo 
release data during the first 5d could not be collected. 
4.4.5 Biocompatibility 
In vivo performance of equine and bovine tendon non cross-linked and EDC 1 
cross-linked and bovine corium EDC 1 cross-linked minirods were analyzed 
macroscopically and microscopically. In macroscopic studies, implants could be 
observed over 28d. The implants could be differentiated well from the 
surrounding tissue, because minirods were darker and denser than the 
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surrounding tissue. Minirods were swollen, but their cylindrical shape was 
retained (see Figure 4-62). 
 
Figure 4-62 Sections of equine non cross-linked minirod 7d (cross-section), 14d (lateral section) 
and 28d (cross-section) post implantation (from left to right) 
 
To evaluate the biocompatibility of a material, in general two histological 
investigations are performed (Anderson; 1994). On the one hand the tissue 
response is evaluated with respect to degeneration of necrotic changes, 
inflammation, foreign body reactions and fibrosis. On the other hand, the cell 
types are characterized in more detail (Anderson; 1994). Histological 
evaluations of the minirods were more difficult than macroscopic examinations, 
because the collagen extrudates contain collagen type I with traces of collagen 
type III. Since these collagen types are also present in tissue, differentiation 
between implants and surrounding tissue was challenging, especially because 
pig dermal collagen appears denser than human collagen structures (Burke et 
al.; 1983). Minirods were identified by denser, more stained areas with atypical, 
non-native collagen bundle structures (Burke et al.; 1985). Additionally, 
especially at the later time points, cell accumulations gave hints where the 
minirods had been implanted.  
After surgical implantation acute and chronic inflammation reactions occur 
dependent on the implanted material, implantation site and the size, shape and 
motion of the device (Anderson et al.; 1981; Anderson; 1994). Usually antigenic 
reactions are detected during the first 72h post implantation (Soo et al.; 1993). 
1cm 1cm 1cm 
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The first response to an injury is the migration of leukocytes, predominantly 
neutrophiles, and the exudation of fluids and plasma proteins within minutes to 
days. This is followed by a chronic inflammation characterized by an increase in 
macrophages, monocytes and lymphocytes and proliferation of blood vessels 
and connective tissue. If normal wound healing takes place, the healing 
response is initiated by proliferation of macrophages and monocytes followed 
by appearance of fibroblasts and vascular endothelial cells and formation of 
granulation tissue. Subsequently, the foreign body reaction follows in which 
macrophages, fibroblasts and foreign body giant cells take part. This may lead 
finally to fibrosis or the formation of a fibrous capsule when particles with a size 
greater than 10µm were implanted (Medlicott et al.; 2004). If biomaterials are 
less biocompatible, body response ends at the stage of chronic inflammation 
and no further healing process is initiated (Anderson; 1994).  
Almost no inflammation could be detected by interferon 1β staining for all 
investigated insoluble collagen materials between day 5 and 56. Only 
superficial, slight inflammatory areas were observed, resulting from the 
administration of the solid, but rapidly swollen matrix (Hirasawa et al.; 1997) and 
the motion of the implant (Anderson et al.; 1981). Inflammatory reactions could 
be detected by TGFβ staining and cell accumulations, most likely leucocytes.  
 
Figure 4-63 Equine non cross-linked (a) and EDC 1 cross-linked (b) minirod 3d post implantation 
(TGFβ staining, solid arrows indicate boundaries of implant, dashed arrows: capsule) 
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TGFβ staining was performed between day 3 and 28. Positive TGFβ stained 
areas were detected near the implant boundaries up to day 14 (see Figure 
4-63). This observation corresponded to the interferon 1β staining studies. 
Differentiation between mono-, lympho- and granulocytes was difficult, because 
no cell specific staining was performed. However, it was assumed that the 
observed cells were mainly mono- or lymphocytes due to the short life time of 
granulocytes. The immunogenic response was slightly more pronounced for 
non cross-linked materials which could be due to less washing steps during raw 
material preparation (Park et al.; 2002) and a faster collagen degradation. Since 
gelatin and gelatin peptides are chemotactic for neutrophils, an acute 
inflammatory response can be elevated (Weadock et al.; 1984). No further 
increase in cell number was observed for EDC 1 cross-linked matrices, 
indicating that this cross-linking ratio was suitable for in vivo applications (van 
Wachem et al.; 1994a). In general, equal performance was observed for 
materials with and without PCA-BSA, indicating that the in vivo performance of 
minirods was mainly dependent on the matrix material and not on the 
incorporated labeled model compound.  
 
 
Figure 4-64 Remaining pocket of a bovine tendon non cross-linked minirod 5d post 
implantation (HE staining) 
100µm 
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At days 3 and 5 post implantation, difficulties in cutting of bovine tendon 
specimens occurred. The minirods were pressed out during this preparation 
step, resulting in a cavity with sharp, cell rich boundaries from the implantation 
procedure (see Figure 4-64). The increase in cell number gave evidence that 
cells were attracted by the collagen minirods. Both equine and bovine corium 
EDC 1 cross-linked minirods were attached firmly enough to the surrounding 
tissue, to remain at their position. At day 3, cells were already attracted by the 
equine and bovine corium EDC 1 cross-linked minirods. This resulted in 
formation of a cellular capsule around the implants (see Figure 4-65b), because 
the additionally cross-links hindered cells to penetrate into the matrix core. 
Equine non cross-linked extrudates were also attached well to the surrounding 
tissue. Cells already started to invade the devices and consequently no distinct 
capsule around the implants could be detected (see Figure 4-65a). 
 
Figure 4-65 Equine non cross-linked (a) and EDC 1 cross-linked (b) minirod 3d post implantation 
(HE staining, solid arrows indicate boundaries of implant, dashed arrows: capsule) 
 
After 7d, all materials were incorporated well and cells infiltrated the minirods 
(see Figure 4-66). Since minirods were swollen and fragmented, a mixed 
immune response could be observed. In the interior of the implant an acute 
inflammatory reaction, with a high number of presumably polymorphonuclear 
leukocytes, occurred. The cell number at the implant boundary decreased 
b a 
100µm 100µm 
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slightly compared to day 3 and a chronic immune reaction with monocytes and 
lymphocytes took place (Anderson; 1994), which resulted in the formation of a 
thin capsule around the minirods.  
 
Figure 4-66 Equine non cross-linked (a) and EDC 1 cross-linked (b) minirod 7d post implantation 
(HE staining, solid arrows indicate boundaries of implant, dashed arrows: capsule) 
 
Still a lower number of cells could be detected in the interior of equine EDC 1 
cross-linked minirods compared to equine non cross-linked matrices (see 
Figure 4-66). 
Looking closer at bovine tendon EDC 1 minirods, it was observed that the 
implant itself exhibited a porous structure which was surrounded by tissue with 
numerous cells (see Figure 4-67a). In spite of the different structure, 
incorporation had taken place, as can be seen by collagen I staining (see Figure 
4-67b). Extrudate fragments were stronger stained than tissue. Cells, 
presumable monocytes, infiltrated the minirods and the implants were 
degraded. An exact boundary could not be detected anymore. The remodeling 
process could also be observed with this sample. During wound healing 
processes, collagen type III is the prevalent collagen type (Burke et al.; 1985) 
and can already be detected between day 2 and 7 after injury. In later wound 
healing phases, collagen type III is replaced by collagen type I (Sedlarik; 2005).  
  
ba 
100µm 100µm 
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Figure 4-67 Bovine tendon EDC 1 minirod 7d post implantation (a) HE staining, (b) collagen I 
staining, (c) collagen III staining (arrows indicate boundaries of implant; in figure 
(b): solid arrows: inner implant, dashed arrows: transition, dotted arrows: tissue) 
a
b
c
100µm 
100µm 
100µm 
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Collagen III staining showed, that inside the original extrudate boundaries, 
collagen type III was present and it was concluded that new collagen structures 
had been built (see Figure 4-67c). 
After two weeks, the bovine corium EDC 1 minirods were degraded completely 
and at the site at which the sample had been implanted only a large cell 
accumulation could be detected (see Figure 4-68). This indicated that bovine 
corium EDC 1 extrudates stimulated a host response which caused fast implant 
degradation and replacement by newly formed collagen. A similar effect was 
observed by Burke et al. for a bovine dermal type I collagen (Zyderm®) 
suspension implanted in pigs (Burke et al.; 1983). 
 
 
Figure 4-68 Bovine corium EDC 1 minirod 14d post implantation (HE staining, arrow indicates 
cell accumulation) 
 
Bovine and equine tendon non cross-linked minirods were still present after two 
weeks and showed good incorporation into the surrounding tissue (see Figure 
4-69a).  
100µm 
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Figure 4-69 Equine non cross-linked (a) and EDC 1 cross-linked (b) minirod 14d post implantation 
(HE staining, arrows indicate boundaries of implant) 
 
Both tendon EDC 1 cross-linked extrudates were also incorporated well and 
retained their homogeneous structure even longer than non cross-linked 
matrices. Only at the boundaries small cavities were observed, whereas still a 
compact implant core with several invaded cells existed (see Figure 4-69b). 
After 28d, equine implants, independent of cross-linking, were infiltrated by 
many cells and extensive remodeling had taken place (see Figure 4-70). 
However, in contrast to bovine corium EDC 1 cross-linked extrudates after 14d 
(see Figure 4-68) shapes of minirods could still be detected.  
 
Figure 4-70 Equine non cross-linked (a) and EDC 1 cross-linked (b) minirod 28d post implantation 
(HE staining, arrows indicate boundaries of implant) 
a b
100µm 100µm 
a b
100µm 100µm 
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Collagen forms a swollen hydrogel after contact with physiological fluids. The 
swollen matrix is soft and elastic and minimizes mechanical and frictional 
irritation of the surrounding tissue (Anderson et al.; 1981). Consequently, a 
normal wound healing process was observed for collagen minirods. 
Additionally, protein adsorption can be prevented because of the hydrophilic 
mobile surface and the low adverse interaction between collagen and the 
aqueous biological environment (Park et al.; 1996). Taken these facts together, 
collagen has a good biocompatibility. Based on the histological data, the in vivo 
persistence of minirods was put in the following chronological order: bovine 
corium EDC 1 cross-linked minirods were taken up first (after 14d), followed by 
bovine tendon non cross-linked and EDC 1 cross-linked matrices and equine 
tendon non cross-linked extrudates. As was expected from DSC data (see 
4.1.1.2), swelling (see 4.1.2.1.1) and degradation studies (see 4.3.3), the 
slowest degradation was observed for equine EDC 1 cross-linked minirods. All 
materials were degraded in a comparable way. Digestion occurred 
simultaneously to formation of new collagen structures without abnormally high 
inflammatory reactions. This was in agreement with the common assumption 
that only low inflammation takes place after collagen implantation, because of 
almost similar amino acid sequences of collagen flavors extracted from different 
species (Gilbert; 1988b). Consistent observations were made for the in vivo 
digestion of minipellets (Hirasawa et al.; 1997).  
4.4.6 Summary 
In vitro and in vivo studies were performed with BSA loaded minirods. For drug 
release studies, BSA was labeled with PCA. During labeling no protein 
aggregation occurred and BSA was not hydrolyzed in the presence of a crude 
bacterial collagenase mixture. In vitro, 80% PCA-BSA was released from bovine 
tendon non cross-linked minirods within 48h in absence of collagenase and 
after 7h in the presence of 0.1µg/ml enzyme. Bovine corium EDC 1 cross-linked 
matrices released 80% drug within approximately 80h and 12h, respectively. 
From bovine tendon EDC 1 cross-linked devices 80% release occurred after 
168h without addition of collagenase and after 95h if 0.1µg/ml collagenase was 
present. The sequence of drug release was consistent for both experimental 
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setups. Hence, drug release and degradation were dependent on the used 
collagen material; more cross-links led to lower matrix degradation and 
decreased PCA-BSA release rates. In vitro drug release of FITC dextran 70 
was compared with the in vitro PCA-BSA delivery and good correlation was 
found. This indicated that FITC dextran 70 is suitable as a model “protein” drug 
and correlations based on the molecular weight can be made. In vivo PCA-BSA 
release was slightly more delayed than in vitro, because swelling of the 
minirods was more restricted and the devices were degraded more slowly in 
pigs compared to the in vitro setup. 80% PCA-BSA was delivered after 96h from 
bovine tendon non cross-linked and bovine corium EDC 1 cross-linked 
extrudates, whereas bovine tendon EDC 1 cross-linked minirods showed 80% 
release after 120h.  
Mechanistic studies, performed in vitro, showed that swelling and diffusion 
controls the drug release in pure Tris buffer pH 7.5 for minirods, irrespective of 
cross-linking degree. For bovine tendon non cross-linked matrices this was also 
the dominating mechanism if collagenase was present. In contrast, EDC 1 
cross-linked devices exhibited a release which was also dependent on matrix 
erosion. In the in vivo studies, similar release mechanisms as in the in vitro 
investigations with 0.1µg/ml collagenase were detected for all three collagen 
materials. Since it was possible to investigate different parts of the minirods in 
the in vivo experiments, it could further be demonstrated that the PCA-BSA 
release started at the matrix surface before release occured inside the minirods. 
In vitro - in vivo – comparison demonstrated that minirods behave equally in 
vitro and in vivo and that the period of release was in the same magnitude of 
time. 
Histological investigations of seven different minirods were performed (bovine 
tendon non cross-linked and EDC 1 cross-linked, bovine corium EDC 1 cross-
linked and equine tendon non cross-linked and EDC 1 cross-linked collagen 
matrices with incorporated PCA-BSA and drug free equine and bovine tendon 
non cross-linked collagen minirods). All devices were tolerated well, because no 
severe foreign body reaction was detected. The time course of the observed 
host digestion, resembling normal tissue turnover, was dependent on the 
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collagen material. Bovine corium EDC 1 cross-linked minirods were taken up 
fastest, followed by the bovine tendon non cross-linked, the bovine tendon EDC 
1 cross-linked and the equine non cross-linked matrices. The slowest 
adsorption was observed for equine EDC 1 cross-linked minirods. This order 
was consistent with the increase in cross-links from bovine to equine collagen 
materials. Since this remodeling process is required to avoid a surgical implant 
removal after drug depletion, prospects for in vivo application were promising. 
4.5 Mathematical Model of the Erosion Controlled Drug 
Release from Collagen Devices 
Since therapy with higher molecular weight drugs, e.g. proteins, attains more 
and more attraction, a mechanistic model for the release of macromolecules 
was developed. Swelling and diffusion controlled drug release of indomethacin 
and gentamicin from dense collagen devices were modeled by Radu et al. 
(Radu et al.; 2002). Fickian diffusion and concentration dependent diffusion 
coefficients of water and drug were assumed. If collagenous matrices are 
implanted parenterally, several processes occur simultaneously. Besides drug 
release by swelling and diffusion, delivery dependent on matrix erosion takes 
places (see 1.2.3.2). To adapt the model of Radu et al. to in vivo circumstances 
the influence of device erosion on drug release has to be incorporated into the 
mathematical model. A model dealing exclusively with drug release controlled 
by matrix erosion was developed, using experimental results obtained in the 
previous chapters. Subsequently, both models could be combined to achieve a 
model which describes the entire drug delivery properly.  
4.5.1 Model Development  
The model is designed for a matrix of cylindrical geometry with length l and 
diameter d, which consists of a homogeneous polymer (= collagen) with 
uniformly dispersed drug. Collagen is a hydrogel and swells after contact with 
aqueous solutions and a collagen fiber mesh with aqueous (drug) solution is 
assumed during the drug release (see Figure 4-71). Due to the assumed 
uniform collagen and drug distribution inside the collagen minirods, only the 
radial degradation and release was simulated. 
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Figure 4-71  Schematic illustration of a cylindrical drug device with diameter d and length l 
(bright mesh symbolizes collagen network, dark areas drug solution) 
 
In the model dealing exclusively with drug release controlled by matrix erosion a 
fully swollen matrix is assumed to eliminate the effect of swelling on the drug 
release. To describe the interaction between collagenase and collagen properly, 
three steps have to be considered: diffusion of collagenase towards the 
collagen substrate, adsorption onto the collagen surface and subsequently 
collagen degradation (see Figure 4-72). 
 
Figure 4-72  Schematic illustration of degradation of collagen minirods (  free collagenase,    
 adsorbed collagenase) 
 
The common reaction scheme for an enzymatically catalyzed degradation 
process was proposed by Michaelis and Menten (Cornish-Bowden; 1999) and 
can be summarized by:  
 
diffusion of collagenase adsorption of collagenase collagen 
d 
l 
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enzyme E + substrate S             enzyme-substrate complex ES ( 4-1 ) 
 
enzyme-substrate complex ES         enzyme E + product P ( 4-2 ) 
211 ,, kkk −  are rate parameters: 1k  describes the adsorption of collagenase onto 
the collagen fiber, 1−k  the dissociation of the ES complex without degradation 
(in general zero (Tzafriri et al.; 2002)) and 2k  the degradation process. The 
degradation was assumed to be the rate-limiting step, because equilibrium in 
adsorption was already obtained within 1h (see 4.2.3), whereas degradation last 
longer (see 4.3). This was in agreement with Tzafriri et al., who modeled the 
degradation of sparsely fibrillar collagen gels by human skin fibroblast 
collagenase (Tzafriri et al.; 2002). Hydrolytic erosion of a solid polymer matrix 
can occur by two extreme mechanisms (see 1.2.3.1). Heterogeneous erosion is 
restricted to the surface of the device and the undegraded carrier remains 
chemically intact during degradation. Homogeneous erosion, such as erosion of 
non cross-linked collagen matrices, involves random cleavage at a uniform rate 
throughout the complete matrix. While the molecular weight of the polymer 
decreases steadily, the matrix can remain essentially mechanically intact until 
90% of the polymer is degraded. Then mass loss and disintegration of the 
device starts. In the model for the release of chlorhexidine gluconate from a 
cross-linked gelatin chip, Tzafriri assumed solely matrix bulk erosion (Tzafriri; 
2000). For our dense collagen matrices a combination of surface and bulk 
erosion is assumed (see 4.3.2.2). Due to enzyme binding at its reaction sites 
and the dense matrix structure, which hinders diffusion of enzymes and 
degradation products, it would be incorrect to consider pure bulk erosion. A 
pure surface erosion, as was proposed by Tzafriri et al. for the degradation of 
dense collagen fibers (Tzafriri et al.; 2002), would also not reflect the complete 
digestion process properly, because it was demonstrated that a fully swollen 
matrix showed a higher degradation rate than a still swelling device (see 
k2 
k1 
k-1 
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4.3.2.2). From these observations it was concluded that a limited collagenase 
penetration into the collagen matrix is possible and that both processes must be 
combined. On the one hand tropocollagens can only be eroded at their surface 
(Steven; 1976), whereas on the other hand the complete collagen extrudate 
undergoes bulk erosion. Further basic assumptions in the model are that the 
diffusion of collagenase towards the collagen surface is assumed to be Fickian 
and that the Michaelis-Menten scheme does not describe the degradation in 
sufficient detail. The degradation rate 2k  is dependent on the concentration of 
collagen and collagenase and increased with higher concentration of 
collagenase (see 4.5.2.1). Because the enzymatic reaction of an insoluble 
substrate is modeled, degradation is limited by the enzyme reaction sites on the 
surface of collagen (see 1.3.1.2). These effects are taken into account by 
equation ( 4-3 ).  
γ
ESC
n
EEactECEEt CkCCkCkCCDC 21 )())(( +−=+∇⋅∇−∂   in Ω×J  ( 4-3 ) 
γ
ESC
n
EESt CkCCkC 21 )( −=∂         in Ω×J  ( 4-4 ) 
ext
EE CC =           in Γ×J  ( 4-5 ) 
0=EC          on Ω×0  ( 4-6 ) 
0=ESC          on Ω×0  ( 4-7 ) 
C
n
ECt CCkC )(1−=∂         in Ω×J  ( 4-8 ) 
0
CC CC =          on Ω×0  ( 4-9 ) 
CESE CCC ,,  denote the concentrations, expressed in mole per volume, of free 
enzyme E , enzyme-collagen complex ES  and collagen C , respectively. Ω  is a 
bounded domain in IR2 with a sufficiently smooth boundary Ω∂=Γ . ],0( TJ =  
denotes a finite interval with final time T. In ( 4-3 ) actk  represents a constant 
rate modeling the loss in enzymatic activity over time in the incubation medium 
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which was determined in 4.2.1. In contrast to Tzafriri et al. (Tzafriri et al.; 2002), 
a Freundlich isotherm is implemented (see ( 4-8 )). Based on experimental 
results (see 4.2.3), it was demonstrated that the Langmuir adsorption isotherm 
does not describe the adsorption process adequately. n  represents the index of 
the adsorption reaction, which is often set as a positive number (e.g. 2/3 
(McLaren et al.; 1970)). γ  describes the dependency of the degradation rate on 
the concentration of the ES complex. This relationship was investigated in 
4.5.2.1. The initial concentration of the enzyme and of the ES complex in the 
matrix is zero and at the boundary extEE CC =  is prescribed, where extEC  denotes 
the enzymatic concentration in the ambient medium. For the diffusion coefficient 
of the enzyme in the matrix ( ED ) a Fujita like dependence on the concentration 
of collagen CC  is assumed (free volume theory (Fujita; 1961)), i.e. 
)exp( 0
0
C
C
EEE C
C
DD β−= , where 0ED  is the diffusion coefficient of the enzyme in 
water, 0CC  the initial concentration of collagen and Eβ  a dimensionless 
parameter (Thombre et al.; 1985). An almost free diffusion of enzyme inside the 
completely swollen matrix was assumed (Siepmann et al.; 1999a; Tzafriri; 
2000). 
After matrix digestion, degraded collagen fragments P  and drug molecules A  
are released by diffusion. Diffusion is instantaneously compared to the time 
scale of degradation (Tzafriri et al.; 2002). 
γ
ESPPPt CkCDC 2)( =∇⋅∇−∂         in Ω×J  ( 4-10 ) 
0=PC           in Γ×J  ( 4-11 ) 
0=PC          on Ω×0  ( 4-12 ) 
PC  denotes the concentration of the hydrolyzed collagen fragments which can 
diffuse out of the matrix. A constant diffusion coefficient of the collagen 
fragments is assumed and the initial concentration of the product in the matrix is 
zero.  
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According to Tzafriri (Tzafriri; 2000), the drug load is composed of two pools: 
one part which can diffuse freely inside the swollen matrix and the other part 
which is immobilized by the polymer due to physical or chemical entrapment 
and can only diffuse after matrix degradation. Weadock drew a similar 
conclusion from adsorption studies (Weadock; 1986) and assumed that drugs in 
collagen membranes exhibit a dual sorption behavior; one drug fraction can 
diffuse freely inside the collagen membrane, whereas the diffusion of the other 
part is restricted because of reversible interactions with the collagen device. 
Since for FITC dextrans and BSA no chemical interactions with collagen could 
be detected (see 4.4.3), it was assumed that the drugs were only immobilized 
physically and drug liberation is proportional to the number of cross-links. Drug 
delivery is governed by a diffusion equation with a source term due to liberation 
of the immobilized drug by matrix degradation. Thus, writing a mass balance the 
following equation is obtained.  
AitACAAt CCCDC −∂=∇∇−∂ ))((   ( 4-13 ) 
AiA CC ,  denote the concentrations of free ( A ) and immobilized drug ( iA ), 
respectively. The incorporated drug is released by a diffusion mechanism 
influenced by a concentration gradient. The diffusion is restricted because of the 
physical entrapment. This effect is represented by the source term AitC∂ . Due 
to matrix degradation occurring simultaneously, the matrix phase through which 
the diffusion takes place, changes continuously as a function of the extent of 
collagen hydrolysis. The diffusion coefficient of the drug within the matrix can 
not be considered as constant, but as a function of the fluid and/or collagen 
concentration. According to the free volume theory (Fujita; 1961) the diffusion 
coefficient is given by  )exp( 0
0
C
C
AAA C
C
DD β−= , where 0AD  denotes the diffusion 
coefficient of the drug in water and Aβ  a dimensionless constant (Thombre et 
al.; 1985).  
To complete the model, a relation between the concentrations of free and 
immobilized drug is needed (see Figure 4-73). A general functional dependency 
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Θ= CAi CC σ  is assumed. σ  is a dimensionless constant, which was determined 
in 4.3, denoting the immobilizing capacity of the polymer which is equal to the 
number of hindering cross-links or entanglements per mole of the fully swollen 
substrate and θ  is a correlation factor, determined in 4.5.2.2. In contrast to 
Tzafriri (Tzafriri; 2000), a non-linear relationship between the immobilized drug 
and substrate concentration is valid.  
 
Figure 4-73  Schematic illustration of the mobile  and immobile  drug pool; hindrances are 
reduced after matrix degradation and the immobilized drug fraction becomes 
mobile  
 
The model is completed by implementing Dirichlet boundaries. Calculations 
were performed with the software package “UG”.  
In summary, a mathematical model was developed which describes the drug 
release controlled by matrix erosion from dense collagen extrudates. In some 
parts, similar assumptions were made as in the models proposed by Tzafriri 
(Tzafriri; 2000; Tzafriri et al.; 2002). With our model additional applications are 
possible, because equations for higher molecular weight drugs are implemented 
and the erosion of a dense collagen matrix is modeled. 
4.5.2 Additional Parameters Needed for the Model  
4.5.2.1 Dependency of 2k  on the Enzyme Concentration 
In general, a linear relationship between enzyme concentration and degradation 
rate is observed, which levels off at very high enzyme concentrations (Gilbert; 
1988b). In literature, several studies investigated this dependency. Mallya et al. 
collagen degradation  
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established a quantitative assay for the hydrolysis of different soluble collagen 
types by collagenase. A linear relationship between the initial reaction velocities 
and the collagenase concentrations was found and it was concluded that the 
reaction follows a first-order kinetic with respect to the enzyme concentration 
(Mallya et al.; 1986). Huang et al. investigated the degradation of insoluble 
bovine tendon collagen tapes and a first-order dependency with respect to the 
collagenase concentration was also detected (Huang et al.; 1977). Gilbert also 
assumed a linear relationship between the initial degradation rate of cross-
linked atelocollagen matrices and collagenase concentrations between 0 and 
200 units (Gilbert; 1988b). If a non-linear function would be fitted, even the 
complete range from 0 to 500 units is included (see Figure 4-74).  
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Figure 4-74 Initial degradation rate of GTA cross-linked random fibril collagen discs (45% ε-
blocked amino groups) versus collagenase concentration (adapted from Figure 38 
from (Gilbert; 1988b))   
 
Rubingh differentiated between a soluble substrate (N-succinyl-alanine-proline-
phenylalanine-p-nitroanilide) and an insoluble substrate (Azocoll) (Rubingh et 
al.; 1992). A linear dependency on the enzyme concentration was found for the 
degradation of the soluble substrate, whereas the relationship between enzyme 
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concentration and degradation rate was more complex for the insoluble Azocoll. 
For two enzymes a linear correlation was found, but for one protease an 
adsorption isotherm like function was observed. The adsorption isotherm type 
was assumed to describe the circumstances more precisely, because the 
degradation of insoluble substrates is dependent on the adsorption of the 
enzyme and on the substrate surface  ((Rubingh et al.; 1992) and 4.2.4). This 
hypothesis was manifested by Rubingh et al., because a linear plot of the 
degradation rate versus the enzyme surface concentration was obtained 
(Rubingh et al.; 1992).   
For our mathematical model, a function which describes the relationship 
between the turnover number k2 and very low enzyme concentrations is 
needed. Since the ES complexes could not be measured directly, the 
dependency on the enzyme concentration was investigated. The degradation of 
equine non cross-linked minirods was investigated. A non-linear dependency on 
the enzyme concentration, which resembled the results obtained by Gilbert 
(Gilbert; 1988b) and Rubingh et al. (Rubingh et al.; 1992), was detected (see 
Figure 4-75).  
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Figure 4-75 Dependency of the degradation rate of equine non cross-linked minirods on the 
concentration of collagenase  
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It was concluded that the degradation rate is also not linearly dependent on the 
concentration of ES complexes. This manifested indirectly the assumption that 
the Michaelis-Menten equation without consideration of adsorption phenomena 
would not describe the degradation of insoluble collagen properly. Therefore, a 
factor γ  was introduced into equations ( 4-3 ) and ( 4-10 ) to describe the 
degradation process more precisely. 
4.5.2.2 Correlation Between Immobile Drug and Degraded Collagen 
Tzafriri proposed a correlation between the immobilized drug fraction and the 
hindering properties of the drug matrix (Tzafriri; 2000). It was demonstrated that 
both model compounds, FITC dextrans and BSA, showed no chemical 
interactions with the collagen matrix (see 4.4.3). Therefore, the immobilizing 
capacity σ  of the dense collagen extrudates was attributed completely to 
physical interactions arising from the dense matrix structure and in particular 
from cross-linkages between the collagen bundles. A non-linear relationship 
between the immobilized drug fraction and the degraded collagen amount was 
found (see Figure 4-76 and Table 4-6). 
0 20 40 60 80 100
0
20
40
60
80
100
y = 2.14*x0.84
R2 = 0.9903
 
 
im
m
ob
ile
 F
IT
C
 d
ex
tra
n 
70
 [%
]
degraded collagen [%]
 
Figure 4-76 Determination of θ  of bovine corium EDC 1 cross-linked minirods containing FITC 
dextran 70 (incubated with 0.1µg/ml collagenase) 
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Since values of σ  and θ  were dependent on the used collagen material and 
the incorporated FITC dextran, the proposal that the degradation is independent 
of the incorporated drug (Tzafriri; 2000) could not be confirmed. In contrast, as 
was already assumed in 4.3.5, the degradation of our minirods was dependent 
on the incorporated drug, presumably due to the different apparent matrix 
densities (see Table 4-1).  
  
Table 4-6 Immobilization constants of Figure 4-76 (average ± SD; n=3) 
Sample 1% FITC dextran 
load 
Function  
Θ= CAi CC σ  
R2 
FITC dextran 20 θ =0.84 0.9839
FITC dextran 70 θ =1.97 0.9756
equine non cross-linked minirod 
FITC dextran 150 θ =1.36 0.9584
FITC dextran 20 θ =1.97 0.9660
FITC dextran 70 θ =1.51 0.9629
equine EDC 1 cross-linked minirod 
FITC dextran 150 θ =0.69 0.9332
bovine corium EDC 1 cross-linked 
minirod 
FITC dextran 70 θ =0.84 0.9903
 
 
Based on the values of σ , determined in 4.3, the exact value of σ  was 
calculated during the simulation according to AiC CC /
Θ=σ  for each time point.  
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4.5.3 Data used for Fitting the Model  
The following assumptions and parameters are used in the model. 
Table 4-7 Fundamental assumptions of the model  
Reaction Assumption 
Diffusion Fick’s second diffusion law with Fuijita like diffusion coefficients 
Adsorption Freundlich adsorption isotherm 
Degradation Michaelis-Menten kinetic with adsorption dependencies 
Release two drug pools:  
? mobile drug released by diffusion (and swelling) 
? immobile drug released by matrix erosion and subsequent 
diffusion 
 
 
Table 4-8 Experimentally determined parameter used in the model  
Parameter Value 
Ω  matrix dimensions (length and diameter of the extrudate) 
J  time interval during which the matrix is degraded 
ext
EC  enzyme concentration in the ambient medium  
0
CC  collagen concentration of the fully swollen matrix  
AC  drug concentration which can be released in absence of collagenase = 
mobile drug fraction (determined in 4.3) 
AiC  drug concentration which is entrapped inside the matrix if no collagenase 
is added = immobile drug fraction (determined in 4.3) 
actk  rate of loss in enzymatic activity (determined in 4.2.1)  
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0
ED  diffusion coefficient of collagenase in water (determined in 4.3.1) 
0
PD  diffusion coefficient of collagen fragments in water (determined in 4.3.1) 
0
AD  diffusion coefficient of FITC dextran 70 in water (determined in 4.3.1)) 
2k  degradation rate (determined in 4.2.4) 
θ  immobilization dependency (determined in 4.5.2.2) 
 
 
4.5.4 Elaboration of the Implemented Parameters  
To test the developed mathematical model, sensitivity analyses were 
performed. Based on an optimal parameter set for the release of FITC dextran 
70 from bovine corium EDC 1 cross-linked minirods (see 4.5.5.2), the influence 
of individual parameters was simulated. 
4.5.4.1 Sorption Parameters 
The adsorption process was implemented in equations ( 4-3 ) and ( 4-8 ). 
4.5.4.1.1 Type of Sorption Isotherm 
In literature, three different types of enzyme adsorption isotherms on insoluble 
substrates were proposed (see 1.3.1.1). Therefore, the Freundlich sorption 
isotherm was compared with the Langmuir isotherm and a combination of 
Langmuir and Freundlich (see Figure 4-77). The Langmuir isotherm approached 
a maximum in adsorption, because only an enzyme monolayer can be 
adsorbed. This resulted in very slow collagen degradation. Implementing the 
Freundlich isotherm led to a faster digestion, because more enzyme molecules 
can be adsorbed and consequently more ES complexes can be built. A 
combination of both isotherms resulted in a collagen degradation between the 
individual sorption isotherms, because effects were combined.  
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Figure 4-77 Variation in the sorption isotherm of collagenase on insoluble bovine corium EDC 1 
cross-linked collagen minirods (dots represent experimental data) 
 
On the basis of the experimental results (see 4.2.3) and the modeled adsorption 
variations (see Figure 4-77), a Freundlich sorption isotherm was implemented 
into the model. This isotherm contains two parameters which were tested for 
their influence: the Freundlich sorption exponent n  and the sorption rate k1. 
4.5.4.1.2 Freundlich Sorption Exponent n   
If enzyme adsorption follows the Freundlich isotherm more than a monolayer of 
enzymes can be adsorbed on the collagen surface, resulting in different surface 
covering states. Consequently, Gyani defined four extremes of n  (Gyani; 1945). 
The adsorption between two immiscible liquids yields n =1. Values lower than 1 
are valid, when adsorption between a solid and a liquid is investigated. 
Complete surface coverage of a smooth solid is presented by n =2/3. When 
n =1/3 is observed, only adsorption on edges and cracks of the solid takes 
place and only distinct points are covered when n =0 (Gyani; 1945). If n  is 
between 1/3 and 2/3, adsorption on edges and cracks and surface adsorption 
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occur simultaneously. If n >2/3 is valid, penetration of the solute into the solid 
can take place (McLaren; 1963).  
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Figure 4-78 Variation in the sorption constant n : theoretical values and optimal fitted value for 
the degradation of bovine corium EDC 1 cross-linked minirods (dots represent 
experimental data) 
 
For a theoretical evaluation, sorption constants of different levels were 
compared (see Figure 4-78). Based on the wrong assumption that the substrate 
is also soluble, n =1 resulted in almost no degradation. Digestion increased by 
reducing the value of n . The most promising results were obtained close to 
n =2/3. Further reduction, e.g. to n =0.44, led to a more pronounced 
degradation, which did not reflect the circumstances of the in vitro collagen 
minirod degradation. Experimental data indicated that n  is in the range of 
2/3< n <1 (see Figure 4-28), and that collagenase can penetrate into the 
collagen minirods. This range was investigated in more detail and best results 
were found for n  near 2/3 (most promising value 0.681). Hence, the enzyme 
solution covered the complete collagen minirod surface and not only elevations 
which arise from the extrusion process. Furthermore, this observation 
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manifested the assumption that not only surface erosion took place, but that 
collagenase could also penetrate into the collagen device and could degrade 
collagen molecules inside the matrices.  
4.5.4.1.3 Sorption Rate k1 
Variation in the sorption rate k1 was based on the experimentally determined k2-
value (k2 (bovine corium EDC 1 cross-linked minirods) = 51.4h-1, see Table 
4-5). If adsorption is fast (k1 > k2), the influence of adsorption is diminished and 
the overall reaction rate is determined by the degradation itself. The adsorption 
process becomes the rate limiting step, if a lower value is used (k1 < k2). This 
indicated that adsorption had a strong influence on the degradation of collagen 
(see Figure 4-79). Based on the experimental results, degradation was 
assumed to be the rate limiting process, because adsorption already reached 
equilibrium within 1h (see 4.2.3).  
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Figure 4-79 Variation in the sorption rate k1: calculated value (k1 4015 l/(h*mol)) and fitted 
values for the degradation of bovine corium EDC 1 cross-linked minirods (dots 
represent experimental data) 
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Since the development of the intermediate ES complex could not be measured 
directly, k1 was fitted. Two approaches were followed. In the first simulations, a 
typical Michael-Menten reaction is assumed and k1 was determined by 
MK
kk 21 = , similar as was done by Tzafriri (Tzafriri et al.; 2002). However, this 
approach must be handled with care, because the hydrolysis of insoluble 
collagen by bacterial collagenase did not follow the original Michael-Menten 
kinetics. Therefore, the next approaches were made by a direct fitting of k1. 
If the k1-value was increased, collagen was degraded faster, because of an 
excess of adsorbed enzymes. k1=4015 l/(h*mol) was determined by 
MK
kk 21 =  
(Tzafriri et al.; 2002). This value did not reflect the in vitro collagen degradation 
properly, because digestion was too fast. In addition, the assumption that the 
Michaelis-Menten kinetic did not describe the degradation of insoluble collagen 
properly could be confirmed. The most promising value for k1 was obtained for 
65 l/(h*mol). Higher values resulted in a high degradational turnover, because 
enzyme adsorption is very fast and many enzyme molecules are adsorbed at 
the collagen surface and can build ES complexes. Lowering the k1-value 
decreased the digestion rate, because not enough ES complexes can be built to 
maintain the digestion rate and the degradation becomes adsorption 
dependent. k1=65 l/(h*mol) was implemented into the model, because this fitted 
value simulated the experimental observations best. 
In summary, it was demonstrated that all parameters connected with the 
collagenase adsorption have a strong influence on the simulated collagen 
degradation. 
4.5.4.2 Degradation Parameters 
The degradation of collagen was modeled in equations ( 4-3 ) and ( 4-10 ). 
4.5.4.2.1 Degradation Rate k2 
The turnover number k2 (=kcat) was determined experimentally for every 
collagen material (see Table 4-5) and this value was used in the simulations.   
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4.5.4.2.2 Dependency of the Degradation Rate on the ES Complex 
Concentration (γ ) 
For the determination of the turnover number k2 higher enzyme concentrations 
(2µg/ml) were used than in the degradation and release studies (0.1µg/ml). The 
dependency of k2 on the concentration of collagenase was investigated 
exemplarily for equine non cross-linked minirods (see 4.5.2.1). A non-linear 
correlation was found and it was assumed that k2 is also a non-linear function of 
the ES complex concentration.  
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Figure 4-80 Variation in dependency of k2 on the concentration of ES (γ ): fitted values for the 
degradation of bovine corium EDC 1 cross-linked minirods (dots represent 
experimental data) 
For soluble substrates, a linear relationship between enzyme concentration and 
degradation rate was observed in literature (Gilbert; 1988b; Huang et al.; 1977; 
Mallya et al.; 1986; Rubingh et al.; 1992), indicating that a correlation of γ =1 is 
correct. Due to the influence of the adsorption process, different dependencies 
were postulated for the digestion of insoluble substrates (Gilbert; 1988b; 
Rubingh et al.; 1992). For values of γ <1 digestion became more enhanced 
(see Figure 4-80). Since a high initial degradation was observed in the 
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experimental studies (see 4.5.5.2), this indicated that a non-linear relation 
between k2 and the concentration of ES complexes, i.e. γ <1, describes the 
digestion of insoluble collagen better than a linear function. If a non-linear 
function was fitted to the data of Gilbert, γ =0.45 was obtained (see Figure 
4-74). A similar value (γ =0.44) was also assumed to be the optimal value for 
the simulation of degradation of minirods.  
Summarizing the effects of parameters concerning the degradation, it became 
evident that these constants did not influence the modeled collagen digestion as 
pronounced as the adsorption parameters.    
4.5.4.3 Parameters of the Drug Release 
The drug delivery was incorporated by equation ( 4-13 ) and the dependency 
Θ= CAi CC σ  into the mathematical model. 
4.5.4.3.1 FITC Dextran 70 Immobilization Inside the Collagen Minirods  
An important parameter for erosion controlled drug release is the immobilization 
of the drug load. Two parameters have to be considered. On the one hand the 
immobilization capacity of the matrix restricts the drug release when a high drug 
fraction is embedded. On the other hand, the exponent θ , which provides 
information about the relationship between degraded collagen and still 
immobilized drug fraction, affects the delivery rate. A non-linear correlation 
between the immobilized drug fraction and the degraded collagen matrix was 
found for all matrices (see 4.5.2.2). Increasing the immobile drug fraction 
reduces the initial release rates (see Figure 4-81). Based on the in vitro release 
data obtained by the “two interval” experimental setup (addition of 0.1µg/ml 
collagenase after 6d), 25% FITC dextran 70 was detected to be immobilized 
inside the fully swollen bovine corium EDC 1 cross-linked minirods. Since the 
simulated data was compared with an in vitro release study in which 
collagenase was added already after 0.25h, the matrices were not swollen 
completely in the beginning. In this state the immobilized drug fraction could not 
be determined and it was assumed that the amount was higher than 25% FITC 
dextran 70 due to more physical entanglements in the non-swollen device. This 
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could be manifested by simulations. The best fit was obtained with 35% 
immobilized drug. 
0 72 144 216 288 360
0
10
20
30
40
50
60
70
80
90
100
110
*
 
 
re
le
as
ed
 F
IT
C
 d
ex
tra
n 
70
 [%
]
time [h]
σ 15% 
σ 25%  
σ 35%  
σ 45%   
*
 
Figure 4-81 Variation in the immobilization capacity: experimentally determined value (25%) 
and fitted values for the FITC dextran 70 release from bovine corium EDC 1 cross-
linked minirods (dots represent experimental data) 
 
The dependency of immobilized drug on degraded collagen was implemented 
by Θ= CAi CC σ . An increase in θ  enhanced drug release (see Figure 4-82). 
Depending on the used collagen matrix and the incorporated drug different 
exponents θ  were obtained (see 4.5.2.2). For the release of FITC dextran 70 
from bovine corium EDC 1 cross-linked minirods θ <1 was assumed and best 
correlation was found for θ =0.6. 
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Figure 4-82 Variation in θ  for the FITC dextran 70 release from bovine corium EDC 1 cross-
linked minirods (dots represent experimental data) 
 
4.5.4.3.2 Diffusion Coefficients of FITC Dextran 70 and Collagenase 
Diffusion coefficients based on the free volume theory were assumed, because 
the diffusion coefficients are dependent on the degree of matrix degradation 
and the water content. The dimensionless constants Eβ  (for collagenase) and 
Aβ  (for FITC dextran 70) were fitted in order to get a correlation between the 
diffusion coefficient in the matrix and in solution. Siepmann et al. modeled the 
diffusion controlled drug release from hydroxypropyl methylcellulose tablets 
(Siepmann et al.; 1999b). A Fujita-type diffusion coefficient was assumed and it 
was emphasized that the value of the dimensionless constant is dependent on 
the molecular size of the diffusing agent and the water content. In our model, 
relations between the diffusion coefficient in solution and within the device were 
made. A fully swollen matrix and free diffusion inside the matrix were assumed. 
Best plots were obtained with Aβ  = 3.5 for FITC dextran 70 (see Figure 4-83a) 
and Eβ  = 1 for collagenase (see Figure 4-83b). 
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Figure 4-83 Variation in the fitted dimensionless constants of the diffusion coefficients:         
(a) Aβ  for the FITC dextran 70 release from bovine corium EDC 1 cross-linked 
minirods (dots represent experimental data) 
(b) Eβ  for the degradation of bovine corium EDC 1 cross-linked minirods (dots 
represent experimental data) 
 
Increasing the values of Eβ  and Aβ  diminished the diffusion coefficients of 
collagenase and FITC dextran 70, respectively, which resulted in an initial lag 
time in drug release (see Figure 4-83a) and degradation (see Figure 4-83b) 
which did not reflect the observed in vitro circumstances (see 4.5.5.2). Despite 
molecular weights in the same range, a lower value Eβ  was chosen, because 
of adsorption phenomena which limit enzyme diffusion.   
4.5.4.3.3 Matrix Dimensions  
In order to extent the model to other geometries, simulations were performed for 
variations in the cylinder diameter. Because only 2D-simulations were modeled, 
variation in the length was not tested. However, this can be done if 3-
dimensionally simulations would be performed.   
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Figure 4-84 Variation in the minirod diameter for the FITC dextran 70 release (a) and the 
degradation (b) of bovine corium EDC 1 cross-linked minirods  
 
As was already detected in the experimental studies (see 4.3.4.2), variation in 
the diameter of minirods did only affect the drug release behavior, but not the 
degradation profile (see Figure 4-84). With smaller diameters, release became 
enhanced because a higher specific surface area is available through which 
release can occur and diffusion pathways of water and drug are decreased (see 
Figure 4-84a). Consequently, the minirods swell faster and the collagen mesh 
untightens earlier. This resulted in increased drug liberation. Due to similar 
polymer properties, no variation in degradation profile could be detected. 
4.5.5 Comparison of Modeled and Experimental Data 
The development of an optimized simulation was performed in two steps. In the 
first stage (see 4.5.5.1), preliminary assumptions were made to get the 
possibility for fitting the values of n  and γ . In the second dataset, optimized 
assumptions were implemented and the fitted parameters were tested (see 
4.5.5.2). 
4.5.5.1 FITC Dextran 70 Release from Equine Non Cross-linked Minirods 
The first dataset was collected with the “two interval” setup to eliminate the 
contribution of drug release by diffusion and swelling and to guarantee a fully 
swollen matrix. Only the second part of this experiment was simulated, in order 
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to plot exclusively the drug release of the immobilized drug fraction. Simulated 
data were compared with results of FITC dextran 70 release from equine non 
cross-linked minirods (see Figure 4-85). Numerous simulations were performed 
and the best fit was obtained for the parameter set listed in Table 4-9. 
In this set, k1 was calculated by applying the assumption from Tzafriri (
MK
kk 21 = ; 
(Tzafriri et al.; 2002)). n  and γ  were fitted and validated by the second 
experimental comparison (see 4.5.5.2). Good correlation was found for the first 
3d (see Figure 4-85). Subsequently, simulated degradation and release were 
lower than the observed experimental results. This could be attributed to the 
used diffusion coefficients (used values were determined at room temperature) 
and the simplified boundaries of the enzyme concentration. In the simulation it 
was prescribed that the enzyme activity vanished within 7.5min after addition of 
collagenase which resulted in a restricted degradation behavior, especially 
during longer replacement intervals. 
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Figure 4-85 Simulation of (immobilized) FITC dextran 70 release (a) and collagen degradation (b) 
of 10mm equine non cross-linked minirods (0.1µg/ml enzyme was added after 6d; 
dots represent experimental data) 
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Table 4-9 Parameter set of FITC dextran 70 release from 10mm equine non cross-linked 
minirods  
Parameter  Value 
Ω  diameter: 0.278cm, length: 1.386cm  
J  (0h, 164h] 
ext
EC  t=0: 0.1µg/ml 
t=between replacement of incubation medium: linear 
decrease to 0µg/ml within 0.125h 
t=replacement of incubation medium: 0.1µg/ml  
0
CC  1.12*10
-6 mol/cm³ 
0
AC = AiC  1.36*10
-8 mol/cm³ 
actk  0 
0
ED = 
0
PD  = 
0
AD  1.7*10
-3cm²/h  
sorption isotherm Freundlich 
1k  4579 l/(h*mol)
 
n  0.681 
2k  174h
-1 
γ  0.44 
Eβ  1.0 
Aβ  1.0 
θ  1.5 
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4.5.5.2 FITC Dextran 70 Release from Bovine Corium EDC 1 Cross-linked 
Minirods 
FITC dextran 70 release and degradation of bovine corium EDC 1 cross-linked 
minirods were investigated in the presence of 0.1µg/ml collagenase added after 
0.25h. Consequently, the release of the mobile and the immobile FITC dextran 
70 fractions were modeled simultaneously. The basic experimental setup was 
compared with a special experimental setup in which collagenase was changed 
and samples were drawn in regular intervals (every 2h during the first 100h, 
every 12h between 100h and 250h and every 24h until the end of the study, see 
Figure 4-86). This setup was conducted to verify whether a limit in degraded 
collagen fragments and liberated FITC dextran 70 was reached during the 
reaction intervals.  
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Figure 4-86 Effect of sample drawing on FITC dextran 70 release (a) and collagen degradation 
(b) of 10mm bovine corium EDC 1 cross-linked minirods (0.1µg/ml enzyme was 
added after 0.25h; average ± SD; n=3) 
 
Almost similar release profiles were observed for both experimental setups, 
irrespectively of the investigation intervals (see Figure 4-86a). The slightly lower 
drug delivery in the regular setup during the first 144h could be explained by the 
slower degradation (see Figure 4-86b). Since in the “irregular interval” setup the 
enzyme was replaced every hour during the first 6h, more collagenase was 
available in the beginning of the experiment and more collagen molecules could 
be degraded. After 40% and 60% collagen degradation in the irregular and the 
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regular experiment, respectively, almost similar degradation rates were reached 
for both setups. This indicated that a similar reaction occurred during a longer 
time interval between enzyme changes and a more often replacement.   
Since it was assumed that the water soluble FITC dextran 70 was released by 
diffusion, the release data were plotted versus t0.45. This exponent was used 
instead of the usually square root of time according to the Higuchi law, because 
circumstances in cylindrical matrices are better represented by 0.45 (Wise et 
al.; 2000). Comparison of the release profiles indicated that approximately 55% 
FITC dextran 70 was released in both experimental setups by diffusion (see 
Figure 4-87a). This drug fraction is composed of drug initially located at the 
device surface and the drug amount which is free to diffuse inside the collagen 
matrix. Subsequently, the release rate became dependent on matrix swelling 
(see Figure 4-87b). Due to water penetration, the mobility of collagen chains 
increases, the glassy barrier changes to a rubbery state and release can occur 
(Gilbert; 1988b). The release becomes strongly dependent on the diffusion 
coefficient in this phase, because the diffusion coefficients change as a function 
of water content. Since minirods were highly cross-linked, this phase should 
follow a Fickian dependency as well (Gilbert; 1988b). This assumption could be 
manifested by the linear dependency when the release was plotted against the 
time t0.45 (see Figure 4-87b). After approximately 80% delivery, another 
reduction in release rate was observed (see Figure 4-87c). The remaining drug 
fraction corresponded to the drug fraction which is immobilized inside the matrix 
and can only be released by erosion processes.   
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Figure 4-87 FITC dextran 70 release from 10mm bovine corium EDC 1 cross-linked minirods 
plotted against t0.45: differentiation between diffusion (a), swelling (b) and erosion 
(c) control (0.1µg/ml enzyme was added after 0.25h; average ± SD; n=3; similar 
legend for all graphs) 
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Exemplarily, the regular setup was simulated (parameter set see Table 4-10). 
Several assumptions were improved compared to the simulation of equine non 
cross-linked minirods (see 4.5.5.1). The adsorption rate k1 was fitted, and not 
calculated according to Tzafriri (Tzafriri et al.; 2002), the enzyme concentration 
in the ambient medium remained constant and diffusion coefficients referred to 
37°C were implemented. The parameters n  and γ  from 4.5.5.1 were used to 
validate their values. 
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Figure 4-88 Simulation of FITC dextran 70 release (a) and collagen degradation (b) of 10mm 
bovine corium EDC 1 cross-linked minirods (0.1µg/ml enzyme was added after 
0.25h; similar legend for release and degradation; dots represent experimental data) 
 
Comparison to experimental data showed that good correlation was obtained 
for the matrix degradation (see Figure 4-88b) and the diffusion and erosion 
controlled release phase (see Figure 4-88a). The part of swelling controlled 
release was not plotted satisfactorily. This was not surprising, because swelling 
controlled release was not considered in the applied mathematical model. If the 
mathematical model would be combined with the model of swelling controlled 
release presented by Radu et al. (Radu et al.; 2002), good correlation for the 
complete drug release profile can be expected.    
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Table 4-10 Parameter set of FITC dextran 70 release from 10mm bovine corium EDC 1 cross-
linked minirods  
Parameter  Value 
Ω  diameter: 0.159cm, length: 1.135cm 
J  (0h, 456h] 
ext
EC  0.1µg/ml (constant during complete observation) 
0
CC  2.18*10
-6 mol/cm³ 
0
AC  8.17*10
-8 mol/cm³ 
AiC  2.86*10
-8 mol/cm³ 
actk  0 
0
ED = 
0
PD  = 
0
AD  2.4*10
-3cm²/h  
sorption isotherm Freundlich 
1k  65.0 l/(h*mol)
 
n  0.681 
2k  51.4h
-1 
γ  0.44 
Eβ  1.0 
Aβ  3.5 
θ  0.6 
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4.5.6 Summary 
In this chapter a mathematical model was presented which describes the drug 
release from dense collagen devices controlled by enzymatic matrix erosion. 
The challenging part within this model was to describe the degradation of an 
insoluble substrate properly. Based on experimental observations, a Freundlich 
sorption isotherm was incorporated into the Michaelis-Menten equation to 
describe the dependency of the degradation rate on the concentration of ES 
complexes correctly. It was assumed that the degradation reaction itself is the 
rate limiting step. A mixture of experimentally determined and fitted parameters 
was implemented and the model was tested. Since adsorption is the 
prerequisite step for the enzymatic reaction, a high influence of parameters 
related to the sorption process (i.e. k1 and n ) was observed. The degradation 
rate k2, which limits the value of k1, and the matrix dimensions did affect the 
degradation of collagen minirods only marginally. The simulated data were 
compared with experimentally performed degradation and release studies. 
Some parameters were fitted in the first experimental setup and validated in the 
second setup. Good correlation was found for the degradation studies. In the 
release studies good correlation was obtained for the diffusion and erosion 
dependent drug liberation, but the swelling controlled drug delivery was not 
plotted satisfactorily. This highlighted that the model is appropriate to simulate 
the release by erosion, but shows deficits in description of the release by 
swelling. A combination with the model for swelling controlled drug delivery 
presented by Radu et al. (Radu et al.; 2002) would be a promising attempt to 
model the drug release from dense collagen devices more precisely. Figure 
4-89 summarizes such a combined mathematical modeling approach:  
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Figure 4-89 Schematic illustration of a  combined mathematical model of dense collagen minirods           
(  drug release,  free collagenase,  adsorbed collagenase) 
 
This model would provide further insights into the release mechanism of erosion 
controlled drug delivery from dense collagen matrices. Using the combined 
mechanistic model, its application can be extended to other collagen materials 
or drugs and expensive experimentally investigations for the development of 
new drug devices can be reduced. However, one has to keep in mind that the 
developed model is a rather simplified assumption of the reactions occurring 
during drug release and matrix erosion, which nevertheless describes the 
processes adequately. Further improvement could be obtained e.g. by 
implementation of a distinction between lateral and cross-section surface area 
which behave differently with respect to their liberation properties. 
swelling of the matrix and 
diffusion controlled drug 
release 
collagen degradation and 
erosion controlled drug 
release 
adsorption of collagenase 
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5 Final Summary  
The aim of this thesis had been to develop collagen drug devices for higher 
molecular weight drugs, e.g. proteins, from which drug release is controlled by 
diffusion, swelling and matrix erosion. Besides this, the degradation of insoluble 
collagen type I by bacterial collagenase was studied in more detail to gain 
further insight into the enzymatic hydrolysis of collagen. Based on the obtained 
in vitro results a mathematical model was to be developed to describe drug 
release from collagen matrices undergoing enzymatic degradation. To achieve 
a matrix form, suitable for parenteral applications, cylindrical rods were 
prepared by extrusion. Since it was desired to obtain a delivery system which 
controls release mainly by erosion, insoluble collagen type I materials were 
used to enhance the resistance against enzymatic attack. Consequently, the 
developed implants, named “minirods”, combine the advantage of restricted 
drug diffusion and enzyme penetration, due to the chosen collagen and the high 
apparent matrix density with optimal dimensions for parenteral application. 
Finally, in vivo drug release, degradation and biocompatibility of the developed 
minirods were evaluated to provide further basis for future applications. 
The physicochemical properties of collagen materials and matrices were 
investigated in chapter 4.1. A compact, parallel orientated surface pattern was 
observed by scanning electron microscopy which corresponded to the direction 
of extrusion. The apparent matrix density was lower than the apparent density 
of collagen reported in the literature (Weadock et al.; 1984).It was demonstrated 
that collagen materials extracted from equine sources showed higher melting 
temperatures (Tm) than bovine collagen qualities. Moreover, collagen materials 
which were extracted from tendon exhibited higher melting temperatures than 
corium collagen material. The lowest melting temperature was observed for 
bovine corium non cross-linked collagen (Tm = 39.4 ± 1.2°C; Tonset = 32.1 ± 
0.5°C) which leads to rapid disintegration at 37°C. An increase in melting 
temperature was detected for increasing EDC (1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide) cross-linking ratios which leveled off between 62°C 
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and 68°C. Since collagen is a hydrogel, water interacts with the collagen 
structures during swelling. The self-diffusion coefficient (D) of water inside the 
collagen matrices, determined by pulsed field gradient nuclear magnetic 
resonance, was decreased (5.76*10-2cm²/h) compared to the diffusion 
coefficient of pure water (D(solution)/D(minirod)=0.67). The swelling behavior of 
minirods during the first 3d was not affected by the presence of collagenase. 
Results obtained by differential scanning calorimetry, concerning the matrix 
stability, were confirmed by swelling studies and equine tendon collagen was 
chosen as most promising material for device manufacturing.  
After finding the standard matrices, the degradation of insoluble collagen was 
characterized in chapter 4.2. A fundamental investigation of the degradation 
pattern was necessary, because this information is very important to describe 
the drug release by a mechanistic mathematical model properly. Collagenase 
can only form an enzyme-substrate complex with insoluble collagen after 
adsorption onto the substrate surface. Hence, besides the degradation, the 
adsorption profile and isotherm were examined. An adequate experimental 
setup to analyze the binding of bacterial collagenase and human gelatinases (A 
and B) was developed. The adsorption of bacterial collagenase reached 
equilibrium between 0.5h to 1h and followed a Freundlich sorption isotherm. 
The subsequent degradation was highly influenced by this adsorption process. 
The highest degradational turnover was detected for equine non cross-linked 
collagen powder (kcat=750h-1) and the lowest for equine EDC 1 cross-linked 
minirods (kcat=33.4h-1). 
In chapter 4.3, the in vitro drug release of FITC (fluorescein isothiocyanate) 
dextrans, representing model “protein” drug compounds, was investigated. The 
diffusion coefficients of FITC dextrans in solution were determined by 
fluorescence correlation spectroscopy. The obtained value of 2.4*10-3cm²/h for 
FITC dextran 70 was also used for the diffusion equations of collagenase in the 
mathematical model, because of a good correlation with coefficients reported in 
the literature (Gaspers et al.; 1994; Seifter et al.; 1959). Several processes, i.e. 
diffusion, swelling and erosion, contribute to the overall release profile from 
collagen minirods. Therefore, different experimental setups were conducted to 
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separate swelling and erosion controlled drug release. The required release 
profile could be adapted by a change in collagen matrix material, e.g. animal 
source or cross-linking degree, or by variation of the matrix dimensions, either 
length or diameter of the minirods. Using these parameters, 80% FITC dextran 
70 liberation could be extended from approximately 13h for bovine tendon non 
cross-linked minirods to approximately 3d for equine non cross-linked matrices 
and approximately 5d for equine EDC 1 cross-linked extrudates. A change in 
matrix dimensions of equine non cross-linked minirods resulted in an increase 
in retardation from approximately 8h (diameter: 0.5mm; length: 10mm) to 5d 
(diameter: 2mm; length: 20mm). Besides this, the drug load also influenced the 
release profile. Increasing the molecular weight of FITC dextrans led to 
retardation in release from equine non cross-linked minirods (e.g. after 24h 99% 
FITC dextran 20 delivery and 48% FITC dextran 70 liberation, respectively), 
because of a restricted diffusion. As a consequence, a higher drug fraction was 
entrapped inside the collagen matrix, which could only be released by matrix 
erosion. However, this effect was not valid for all minirods, because the matrix 
degradation was influenced by the apparent minirod density as well (e.g. after 
24h 67% FITC dextran 150 versus 48% FITC dextran 70 liberation from equine 
non cross-linked minirods). Increasing the concentration of FITC dextran 70 
resulted in a faster release. Equine non cross-linked matrices loaded with 2% 
(w/w) FITC dextran 70 showed 80% delivery already after approximately 7h, 
whereas 80% of a 1% (w/w) load was released within approximately 3d.   
The in vitro release of PCA-BSA (bovine serum albumin labeled with 3-carboxy-
2,2,5,5-tetramethyl-1-pyrrolidinyloxy) was investigated in chapter 4.4.3. 
Differentiation between swelling controlled release and delivery dependent on 
enzymatic erosion was made. Similar release profiles were obtained for FITC 
dextran 70 and PCA-BSA, manifesting the assumption that FITC dextrans could 
be used to model protein drug release from collagen devices and that previous 
results could be transferred. PCA-BSA release was monitored by electron spin 
resonance (ESR) spectroscopy. Besides the release profiles, insights into the 
release mechanism were obtained. It was demonstrated that water penetrated 
into the collagen devices within 0.25h. In absence of bacterial collagenase, 
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PCA-BSA release from minirods was mainly diffusion controlled. Addition of 
0.1µg/ml collagenase led to a differentiation between the investigated minirod 
variations. Non cross-linked extrudates still released PCA-BSA diffusion 
controlled, but EDC 1 cross-linked devices showed also an erosion dependent 
delivery. This confirmed the assumption that a mobile and an immobile drug 
pool was created inside dense collagen minirods and that a higher number in 
cross-linkages could immobilize drugs inside the device. The mobile drug 
fraction was released by diffusion and swelling, whereas the immobilized 
fraction could only be released by diffusion after matrix erosion.    
In chapter 4.4.4 and 4.4.5, the in vivo release of PCA-BSA and the 
biocompatibility of minirods were monitored in adult domestic pigs. Results of 
protein delivery were comparable to the in vitro investigations. However, release 
was slightly delayed due to a lower swelling and degradation in vivo. Release 
started at the matrix surface, before a change in drug concentration occurred in 
the minirod interior. After PCA-BSA liberation fast diffusional remove from the 
implantation site took place. Mechanistic studies showed again that EDC 1 
cross-linked minirods released PCA-BSA by diffusion, swelling and erosion 
phenomena, whereas the delivery from non cross-linked matrices was mostly 
independent of the erosion process. To achieve an even deeper insight into the 
mechanistic properties of the drug release from collagen devices, further ESR 
studies would have to be performed with spin labeled collagen matrix material.  
Histological evaluations demonstrated that all minirods were tolerated well and 
that only minor inflammation reactions occurred, which were detectable by 
TGFβ-staining and cell accumulations. Cell penetration into non cross-linked 
minirods was facilitated, because of a slightly lower apparent matrix density and 
a lower number of cross-links. In vivo persistence was similar to the order of the 
in vitro degradation in the presence of 0.1µg/ml bacterial collagenase. Cross-
linked matrices were more stable than non cross-linked devices and the 
minirods prepared from equine collagen showed the highest resistance. Tissue 
remodeling, which resembled normal wound healing, took place and 
emphasized the assumption that collagen minirods can be used in vivo without 
surgical removal after drug depletion. 
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The presented experimental in vitro studies were used to develop a 
mathematical model in chapter 4.5, which describes the drug release by erosion 
from dense collagen minirods. Equations for the collagen degradation and the 
drug release were implemented. Adsorption and diffusion phenomena were 
incorporated and a mixture of experimentally determined and fitted parameters 
was used to feed the model. Parameters related to adsorption (i.e. k1 and n ) 
had a high influence on the digestion of the collagen matrix, whereas the 
degradation rate k2, which limits the value of k1, and the matrix dimensions did 
affect the degradation of collagen minirods only marginally. Good correlation 
was found for the collagen degradation. Simulated release of FITC dextran 70 
reflected the diffusion and erosion controlled delivery phases well. The swelling 
dependent drug release was not modeled sufficiently, because this influence 
was not yet implemented into the model. To describe the in vivo drug release 
from dense collagen matrices completely, the developed mathematical model 
for erosion controlled drug release has to be combined with the model for 
swelling controlled release presented by Radu et al. (Radu et al.; 2002).  
 
In conclusion, a promising dense collagen implant was developed which can be 
easily manufactured by extrusion at room temperature without the need of 
organic solvents. It was shown that high molecular weight drugs can be 
incorporated and that their release can be controlled by e.g. using different 
collagen variations. Besides the enhanced degradation and release properties 
compared to collagen devices prepared from soluble collagen, e.g. 
atelocollagen, the mechanism of release can be changed towards erosion 
control by the degree of matrix cross-linking. Furthermore, the developed 
minirods showed good biocompatibility, which provides the basis for potential 
applications in vivo. 
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